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Psoriasis
History of the Disease
Psoriasis is probably as old as mankind. It was first described by the founding father of 
western medicine, the Greek physician Hippocrates, who lived between 460 and 377 BC. 
He separated diseases from divine influences and religion and used the word psora, 
meaning itch for the itchy lesions patients were suffering from. In the first century, psoriasis 
was described as the fourth variant of impetigo by Cornelius Celsus, a Roman author. 
Joseph Jacob Plenck (Vienna, 1776) wrote of psoriasis as being amongst the group of scaly 
or scale-like diseases. The English dermatologist Robert Willan (1757-1812) was the first 
to further differentiate psoriasis from other dermatological conditions and recognized it 
as an independent disease. For almost a century, psoriasis was known as Willan’s lepra 
divided into two categories. Leprosa Graecorum was the term referring to the condition 
when the skin had scales. Psora Leprosa was used to describe the condition when it 
became eruptive. In 1841 the Viennese dermatologist Ferdinand Hebra worked on Willan’s 
notes and was the first to ascribe the name ‘psoriasis’ to the clinical picture of psoriasis as 
it is used today.1-3 
Epidemiology 
Psoriasis is one of the most common chronic inflammatory skin disorders, affecting 
approximately 2-3% of the Caucasian population worldwide.4, 5 Both men and women are 
affected equally.5 Psoriasis may become apparent at any age, but there is a bimodal 
distribution of age at onset with a large peak at young adulthood between 20 and 30 
years and a smaller peak at late middle age between 50 and 69 years.5-7 
Clinical Features
Psoriasis is a disease with many faces and can clinically present itself in many different 
ways (Fig. 1). The most common type is chronic plaque psoriasis or psoriasis vulgaris, 
which accounts for approximately 90% of all psoriasis patients (Fig. 1a-b). All investigations 
described throughout this thesis are about chronic plaque psoriasis. Sharply demarcated, 
erythematous plaques, covered with silvery white scaling hallmark psoriasis. When 
scratching a plaque, a characteristic coherence of the scales can be seen as if one scratches 
a wax candle (‘signe de la tache de bougie’). Another finding typical for psoriasis is the 
‘Auspitz sign’, in which the removal of scales lead to pinpoint bleedings.3, 8 Lesions are 
often symmetrically distributed over the body with a predilection for the extensor sites of 
the elbows and knees, scalp, the umbilical region and the sacral region. 
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Besides chronic plaque psoriasis, there are other forms in which the disease can manifest 
itself. Other frequently seen subtypes of psoriasis are:
· Inverse psoriasis; referring to a presentation involving the intertriginous areas were scaling 
is minimal. Therefore, this variant may be easily misdiagnosed as a fungal or bacterial 
infection.
· Guttate psoriasis; develops suddenly and is characterized by the eruption of numerous 
small round droplet-like red papules (0.5 - 1 centimeter) (Fig. 1c). It is usually seen in 
children and adolescents, sometimes in response to a streptococcal throat infection. 
Generally, this subtype of psoriasis clears in a few weeks, although a substantial 
proportion of patients develops plaque-type psoriasis at a later time in life. 
· Erythrodermic psoriasis: is an uncommon manifestation that presents itself as erythema 
covering most of the body surface (Fig. 1f). Scaling is less prominent than with plaque 
psoriasis and patients are at high risk for complications related to loss of adequate 
barrier protection and electrolyte abnormalities.10 
Figure 1  Clinical types of psoriasis
( a ) Chronic plaque psoriasis with ( b ) involvement of the scalp; ( c ) psoriasis guttata; ( d ) involvement of the rima 
ani; ( e ) involvement of the genitals; ( f ) psoriatic erythrodermia; ( g ), nail psoriasis with pitted nail and incipient 
oil spot. (Adapted from Mrowietz et al.9)
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· Pustular psoriasis; pustular forms of psoriasis are quite rare and various forms of this 
subtype have been described, including generalized pustular psoriasis (von Zumbusch). 
Like its name is suggesting, this disease is characterized by erythematous areas and 
pustules. Genetic studies have indicated that this variant is etiologically distinct from 
psoriasis vulgaris, rather than a variant of the same disease.11-15 
Psoriasis may not only affect patients’ skin and is associated with extracutaneous 
manifestations. Disfiguring nail changes (Fig. 1g), which are refractory to most topical 
treatments, may occur in 10 to 81 percent of patients with a lifetime incidence of 80 to 90 
percent.16, 17 Typical signs of nail psoriasis may affect both the nail matrix and the nail bed 
and include nail pitting, distal onycholysis, subungual hyperkeratosis, splinter hemorrhages 
and discoloration (oil drop phenomenon). In 7 to 48 percent of cases,18-22 psoriasis is 
complicated by psoriatic arthritis, an inflammatory reaction of the joints. In general, psoriatic 
arthritis consists of asymmetric oligoarthritis, distal interphalangeal joint involvement, 
dactylitis and enthesitis.16, 18, 23-28 In addition, psoriasis is also associated with multiple 
comorbidities, like obesity and the metabolic syndrome, including abdominal obesity, 
dyslipidaemia and insulin resistance and multiple cardiovascular risk factors, like hyper- 
tension and diabetes.29-33
Histopathology 
Active psoriatic lesions have several histological features deviating from the normal skin. 
An abnormal increase in keratinocyte turnover leads to thickening of the epidermis 
(acanthosis), the presence of remnants of nuclei within the stratum corneum (parakeratosis) 
and scaling due to premature maturation and incomplete cornification of keratinocytes 
(hyperkeratosis). At the same time, the hyperproliferation leads to the formation of 
elongated rete ridges that form fingerlike protrusions into the dermis. The granular layer, 
the starting site of terminal differentiation of keratinocytes, is absent. The psoriatic skin is 
infiltrated by multiple immune cells, like neutrophils, T-lymphocytes, and macrophages. 
Neutrophils accumulate within the stratum spinosum and stratum corneum forming 
micropustules of Kogoj and microabscesses of Munro, respectively.26, 34
 In active psoriatic lesions, elongated and dilated, slightly tortuous blood vessels 
within the dermal papillae are seen. The increased dilatation, tortuosity and permeability 
of the dermal papillary capillaries precede visual epidermal hyperplasia and disappear 
with disease clearance.35-37
Pathogenesis
The evolving knowledge on players in the field of psoriasis has had a significant impact on 
our insights in the pathogenesis of this disease. For years, psoriasis was considered to be 
a primary epidermal disorder with epidermal hyperplasia as the most prominent clinical 
and histological feature.38 During the 1970s, a role for the immune system in its patho - 
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genesis was suggested, based on the presence of large numbers of immune cells within 
psoriatic lesions.39-41 This was supported by the beneficial therapeutic effect of systemic 
drugs targeting the immune system.42, 43 Further exploration of the role of the immune 
system revealed an important assignment for T cells, important components of the 
adaptive immune system. At first, psoriasis was thought to be a T helper 1 (Th1) cell mediated 
process, due to a disturbed balance between Th1 and Th2 cells.26 However, a few years 
ago a novel T cell subset was discovered; the T helper 17 cells.44, 45 Since their discovery, 
researchers have found that Th17 cells play an important role in several inflammatory 
diseases including psoriasis (Fig. 2).
 The occurrence of triggering environmental factors, like streptococcal infections, 
cutaneous injury, and lithium can result in disease development in genetically predisposed 
individuals. Genome-wide association studies have identified multiple susceptibility loci 
of psoriasis-associated genes, like PSORS1 on chromosome 6p21 (HLA-Cw6) and the LCE 
cluster on chromosome 1q21.46-49 
 A common hypothesis on the pathogenesis of psoriasis is that as a reaction to a 
stressor, keratinocytes can release self-DNA which activates plasmacytoid dendritic cells,50 
which are increased in number in early lesions of psoriasis.51 These cells produce interferon 
alpha (IFN-α) which in turn activate dermal dendritic cells.50, 52 The activated dermal 
dendritic cells migrate to the skin-draining lymph nodes and promote the attraction, 
activation and differentiation of naive T cells into Th1 and Th17 cells by producing cytokines 
such as IL-23 and IL-12.53 Subsequently, these activated cells migrate via lymphatic and 
blood vessels into the dermis, attracted by the keratinocyte-derived chemokines and 
signaling molecules, such as IL-1, IL-6, IL-8 and tumor necrosis factor alpha (TNF-α). 
Apart from the dermal dendritic cells, macrophages and neutrophils are also important 
representatives of the innate immune system. The exact role of these cells in the patho- 
genesis remains uncertain, however, it is thought that they contribute through antigen 
presentation to T cells as well as cytokine production (Fig. 2). 
 The differentiation of Th1 cells is promoted by IL-12, produced by dermal dendritic 
cells. Recruited Th1 cells release interferon gamma (IFN-y) and TNF-α, which amplify the 
inflammatory cascade, acting on keratinocytes and dermal dendritic cells. The activation 
of Th17 cells by IL-23 stimulates the production of IL-17 and IL-22, which stimulates 
keratinocyte activation and proliferation and the release of antimicrobial peptides, 
cytokines and the neutrophil recruiting chemokines. The neutrophil chemoattractant IL-8 
is highly elevated in psoriatic lesions,54, 55 and these cells infiltrate the stratum corneum 
and are found in collections either in spongiform pustules of Kogoj or in microabscesses 
of Munro. These collections are a typical histological feature of the psoriatic skin. They 
produce reactive oxygen species and alpha defensin with antimicrobial activity as well as 
IL-8 and IL-6. In addition, there is increasing evidence that neutrophils are important 
sources of IL-17.56, 57 
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 Keratinocytes also release vascular endothelial growth factor (VEGF) and angiopoietins, 
thereby promoting angiogenesis. The endothelial cells within psoriatic lesions express 
elevated levels of VEGFs which contribute to the leaky and tortuous vessels that are 
characteristic in psoriatic lesions and promotes the attraction and transmigration of 
immune cells.59 
 Cytokines produced by immune cells and keratinocytes effect the inflammatory 
process via participation in positive feedback loops.58
Figure 2   Schematic suggested overview of the pathogenesis of psoriasis
(Adapted from Nestle et al.58)
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Treatment Options
Over the years, numerous therapies have been developed for the treatment for psoriasis. 
A short overview of the treatment modalities for psoriasis is described below. 
Topical Treatment Options
· Keratolytics, such as salicylic acid or urea, have a keratolytic effect on the skin causing the 
loosening of the stratum corneum. It is mostly described in combination with other 
topical therapies to enhance the penetration. It also works slightly anti-inflammatory, 
anti-mycotic and anti-bacterial. Skin irritation is most frequently seen as adverse 
reaction.60
· Coal tar is one of the oldest treatments for inflammatory skin diseases like psoriasis. 
For a long time the exact mechanism of action was not fully understood, but a recent 
study in atopic dermatitis showed that the aryl hydrocarbon receptor (AHR) is activated 
by coal tar, resulting in the induction of epidermal differentiation.61 It also has an anti- 
inflammatory and anti-pruritic effect and causes vasoconstriction. Most frequently seen 
adverse reactions are folliculitis, irritation and discoloration of the skin.62
· Dithranol or anthralin also accounts as one of the topical treatments used for many years 
in dermatology. The mode of action of dithranol is not completely understood. It has a 
direct inhibitory effect on keratinocyte proliferation, it inhibits the function of neutrophils, 
and modulates surface receptors of epidermal cells. Common adverse events are 
discoloration of skin, nails and hair, and local irritation, itch and erythema around the 
treated lesions.63
· The mode of action of topical vitamin D analogues is still not completely understood. 
It is thought that its antipsoriatic effect is conducted due to the inhibition of proliferation 
and modulation of epidermal keratinocytes. Moreover, it is thought to inhibit the 
proliferation of T-cells and other inflammatory cells in the skin. Important side effects 
are local irritation of the skin, especially when it is used on the sensitive facial skin, 
together with erythema and itch.64, 65
· Topical corticosteroids conduct an anti-inflammatory, vasocontrictive and anti-mitotic 
effect. Adverse reactions of the skin are skin atrophy, striae atrophicae and the skin 
tends to bleed more easily.66
· Calcineurin inhibitors inhibit the calcium dependent signaling within T-cells, interfering 
with the transcription and synthesis of cytokines. Adverse reactions which are often 
reported are itch and a transient burning sensation of the skin.67
· Topical retinoids have a modest effect on psoriatic plaques. Tazarotene down-regulates 
markers of keratinocyte proliferation, keratinocyte differentiation, and inflammation 
and mediates an antiproliferative effect. Most common side effects are skin irritation, 
erythema and scaling of the skin.68
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Phototherapy
· There are different forms of phototherapy; there is phototherapy with ultraviolet B (UVB) 
and photochemotherapy with ingestion or topical application of psoralen followed by 
ultraviolet A (UVA). UV light conducts a locally immunosuppressive effect, which may 
lead to a switch from a Th1 phenotype into a Th2 phenotype.69 
Systemic Treatment Options
· Methotrexate is a folic acid antagonist, prohibiting the reduction of dihydrofolic acid into 
tetrahydrofolic acid, which is essential for the division of cells. Most common adverse 
reactions are nausea, abdominal discomfort, leucopenia and hepatotoxicity. To reduce 
abdominal discomfort, oral administration can be replaced by subcutaneous administration. 
· Cyclosporin is a calcineurin inhibitor which inhibits T-cell function, leading to a restrained 
production of various cytokines. Dose dependent renal impairment is the most common 
cause of treatment withdrawal. Patients should be monitored for nephrotoxicity, 
hypertension, malignancies and infections.70 
· Acitretin is a vitamin A analogue and belongs to the retinoid family. The mode of action 
is not completely understood, but acitretin normalizes the epidermal cell proliferation 
and differentiation. Acitretin is teratogenic and important adverse reactions are dose 
dependent and include mucocutaneous problems, e.g. dryness of the eyes, nasal and 
oral mucosa, epistaxis and xerosis.71 
· Fumarates, with dimethyl fumarate considered as the active component, are used off 
label and are not registered in the Netherlands.72 Apoptosis is induced, particularly in 
activated T cells and maturation of dendritic cells is inhibited. Frequently seen side effects are 
flushing and gastrointestinal complaints, particularly in the first weeks of treatment.72 
· Biologics are the newest agents used to treat moderate to severe forms of psoriasis. 
Different biologic treatments have become available with different modes of action. 
The biologic agents currently available in Europe for the treatment of psoriasis are 
etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®) and ustekinumab 
(Stelara®). Adalimumab was used in one of the investigations contributing to this thesis. 
It is a recombinant human immunoglobulin (IgG1) monoclonal antibody targeting 
soluble TNF-α which neutralizes the biological function of this cytokine by blocking its 
interaction with the cell surface TNF-α receptors.73
Niches in Clinical Evidence
Psoriasis is a chronic condition causing a serious burden of disease for patients suffering 
from it. Over the years many therapies, both topical and systemic, have been developed 
with varying efficacy and safety profiles. However, psoriasis is still considered a chronic 
disease without a cure, dedicating patients to a lifelong treatment. The vast majority of 
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patients suffers from mild to moderate psoriasis and can be treated with one of the many 
available topicals. In daily clinical practice, patients are often treated with a combination of 
topicals, as combining different products with different mechanisms of action can be very 
promising. 
 Extensive literature searches focusing on the use of topical monotherapies have been 
done and let to the formulation of useful guidelines.74, 75 However, an overview of the 
available evidence regarding the use of combinations of different topicals is lacking, while 
there is a need for this analyses as most patients will receive a combination of topical 
therapies at some point during the treatment of their disease. 
Niches in Pathomechanistic Insights
The pathogenesis of psoriasis is a complex unsolved riddle involving components of the 
innate and adaptive immune system, the endothelium, genetics and environment. 
Insights in the pathophysiology have changed over the years as more and more players in 
the field of psoriasis were discovered. And by each newly identified player, the pathogenesis 
becomes more complex to understand. 
 To get hold of isolated cell types or isolated events within the complexity of a full 
blown psoriatic lesion can be very challenging. In vivo models provide the opportunity to 
study isolated cells in a simplified environment and as initiation is inflicted in a controlled 
manner we are able to investigate the early and all consecutive events in an inflammatory 
process. During the past decades, two established in vivo models have been used to study 
transient psoriasis-like inflammatory patterns of the skin of normal subjects. However, 
newly discovered drivers in the field of psoriasis have not been studied within these 
models.
 
Among all important players in the pathogenesis of psoriasis, angiogenesis is thought to 
be a key phenomenon, with an important role for the increased blood flow in particular 
in the development and maintenance of psoriatic lesions. An increase in the superficial 
cutaneous blood flow is one of the earliest detectable changes exceeding the characteristic 
clinical psoriasis features.37, 76-78 Numerous studies have been done to investigate the 
superficial perfusion because a greater insight into these early changes may harbor new 
information about the (early) development of new psoriatic lesions and maintenance of 
this disease.35, 77-79 However, an overview of the superficial microcirculation in a whole 
field is lacking as the techniques used before had a small radius of only a few millimeters 
or slow scanning speed. 
 In addition, changes in the dilatation and permeability of the dermal papillary 
capillaries seem to outrun clinical changes and disappear with disease remission.35-37 
Therefore it is attractive to speculate that an increased superficial perfusion within the 
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unaffected skin may predicted the development of newly formed psoriatic lesions and 
that perfusion intensity also correlates with disease severity. 
 It is not known whether the perfusion intensity influences the composition of 
important cytokines and cellular components of the innate and acquired immune system 
within lesions and within uninvolved skin. It remains to be studied whether the 
participation of key components in pathogenesis such as innate immunity, acquired 
immunity, epidermal proliferation and abnormal differentiation may vary related to the 
degree of perfusion, within treated and untreated psoriatic lesions. 
Aims and Outline of this Thesis
Aims of this Thesis
The main objective of this thesis was to investigate the above mentioned niches in clinical 
evidence and in pathomechanistic insights regarding patients with psoriasis patients. 
The following aims are formulated:
Niches in Clinical Evidence
Aim 1:   To obtain an overview of efficacy and safety of combinations of topical therapies in psoriasis 
Aim 2:  To formulate recommendations on topical combination therapies
Niches in Pathomechanistic Insights
Aim 3:   To further elucidate the dynamics of the early and consecutive stages of skin inflammation in 
two established in vivo models (i.e. the application of LTB4 and the removal of the stratum 
corneum by tape stripping) with respect to newly discovered drivers in the pathogenesis 
of psoriasis 
Aim 4:   To explore the usability of a new whole field Laser Doppler Imager in studying the superficial 
cutaneous perfusion within psoriatic lesions
Aim 5:   To investigate the relation between the cutaneous perfusion intensity and newly discovered 
drivers in the pathogenesis of psoriasis 
Aim 6:   To further explore the effects of a combination of topical corticosteroids and vitamin D 
analogues, and of anti-TNF-α on the newly discovered drivers in the pathogenesis of 
psoriasis
22
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Outline of this Thesis
Chapter 2 comprises two systematic reviews on the efficacy and safety of combinations of 
topical treatments, contributing to the clinical evidence of treating patients with mild to 
moderate plaque psoriasis with a combination of topicals. Part one describes the results 
of the combinations of classical topical therapies like coal tar, dithranol and salicylic acid. 
Part two comprises the results on the combinations of first-line topicals, like cortico-
steroids, vitamin D analogues, calcineurin inhibitors and retinoids. 
 In chapter 3 we present the results of two studies investigating the involvement and 
course of different newly discovered drivers in the pathogenesis of psoriasis within two 
different well established in vivo models (i.e. the application of LTB4 and the removal of the 
stratum corneum by tape stripping).
 In the first part of chapter 4 we report on the results of a pilot study exploring the 
usability of a novel laser Doppler imager (TOPCam) in studying the vascularisation of 
psoriatic lesions in a whole field. As an increased blood flow is thought to play an important 
role in the development and maintenance of psoriasis, we speculated that the perfusion 
intensity may learn us more about the development of newly formed plaques as well as 
about the cytokine and cell composition of a mature lesion. In the second part of this 
chapter, the results of our study on the composition of several spots within and outside a 
psoriatic lesion with different grades of perfusion intensity on psoriasis related genes and 
proteins are described.
 Chapter 5 comprises the results of two studies on the effect of topical treatment and 
systemic treatment on important players in the field of psoriasis. As the results of the 
systematic literature searches showed that most clinical evidence is gathered to advice 
the use of a combination of corticosteroids and vitamin D analogues, we investigated the 
effect of this combination of topicals on important drivers of the pathogenesis of psoriasis. 
The results of this immunohistochemical study are reported in the first part of this chapter. 
Besides the important role topical therapies fulfill in the treatment of psoriasis, there is a 
growing offer of biological treatments for severe forms of psoriasis. In the second part of 
this chapter the results of a study on the effects of adalimumab, targeting TNF-α, on the 
same pathogenetic drivers are reported. 
 To conclude this thesis, the main results of our studies are summarized and the aims 
of this thesis are discussed within chapter 6.
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Abstract
Background Despite the availability of newer topical treatments, classical topical 
treatments for chronic plaque psoriasis still have an important position for selected patient 
populations. The vast majority of patients are treated with a combination of topicals. The 
question arises: what is the evidence behind these approaches? 
Objectives To systematically review all available literature on efficacy and safety of 
combinations of classical topical treatments in chronic plaque psoriasis, including all 
combinations with dithranol, coal tar and penetration enhancers, and ultimately, to 
propose recommendations for combination treatment. 
Methods Standardized literature searches in PubMed, EMBASE and the Cochrane 
Controlled Clinical Trial Register, and allocation of the degree of evidence was carried out.
Results In total 2918 publications on topical combination therapy were revealed, of which 
48 articles on combinations of classical treatments. In this article, the results concerning 
the 19 included publications are stated. The majority of combination regimens is at least 
as effective as monotherapies, and is generally well tolerated. 
Conclusions Methods of classical treatments are not standardized and different protocols 
in different treatment settings are used. Therefore the interpretation of study results 
cannot be generalized. Most evidence was found to recommend the use of a combination 
regimen of topical corticosteroids and salicylic acid, above monotherapy with either 
component. Also, the combinations of dithranol with superpotent corticosteroids or with 
coal tar may be preferred above both monotherapies. In case first-line treatments and 
systemic therapies are not effective or contraindicated, combinations of classical topicals 
may provide an important opportunity. 
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Introduction
Most patients with psoriasis are treated with a combination of topical treatments. Classical 
therapies, such as coal tar and dithranol, some decades ago first-line in the treatment, now 
have a restricted use. However, in case first-line treatments are not effective or contra-
indicated, or patients are unsuitable for systemic therapies, classical topicals in a combination 
schedule at specialized units can provide an important solution as ultimum refugium.
 Classical topicals are not ‘user friendly’. To make the treatment even more complex 
with a combination regimen can be a real challenge. Therefore classical topicals in 
combination with other topicals are restricted to day-care units and are either carried out 
by nurses or by patients after an instruction programme. It is questionable whether all the 
effort is always worthwhile. On the other hand the principle of combination therapies can 
be promising. Combining two drugs with different and possibly synergistic mechanisms 
of action may lead to a superior effectiveness and helps preventing abundant use of the 
individual components and thereby to prevent adverse events. 
 In 2009 an extensive Cochrane review on the topical treatment of psoriasis was 
published with a literature search up to 2008.1 Updates have been carried out but lack 
systematic approach or do not comprise critical analysis of topical combination therapy. 
The aim of this communication was to systematically review all available literature 
concerning efficacy and safety of the combinations of classical topicals for chronic plaque 
psoriasis, to find out which combination regimens have an added value to the corresponding 
monotherapies and to formulate treatment recommendations. The analyses on combinations 
of first-line topicals, including topical corticosteroids, vitamin D analogues, retinoids and 
calcineurin inhibitors, will be published separately. 
Methods
An extensive literature search was conducted in three computerized bibliographical 
databases for articles published from January 1985 to April 2012: PubMed, EMBASE, and 
the Cochrane Controlled Clinical Trial Register. Main key words used were ‘psoriasis’, 
‘topical’ and ‘treatment’, including all possible synonyms and all combinations of 
antipsoriatic treatments (generic names and brand names). The search was limited to 
publications written in English, German or Dutch. Full details on the search strategy are 
available from the corresponding author on request. Articles present in more than one 
database were included once. Descriptions of demographic data and an outcome 
measure were mandatory. Outcome measures included Psoriasis Area and Severity Index 
(PASI); Physician Global Assessment; total severity score for erythema, scaling, and 
thickness; and more subjective parameters such as percentage of clearance. Psoriasis of 
the scalp was considered a variant of plaque psoriasis. Excluded were studies concerning 
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other subtypes of psoriasis, nail psoriasis only or psoriatic arthritis. If the treatment regimen 
was unclear, the study was not included. Articles on childhood psoriasis were excluded, 
because an extensive literature search has already been done by our group.2 Penetration 
enhancers like salicylic acid are used principally as a stabilizer for dithranol to prevent 
oxidation; therefore we choose to not take this combination into account. After all articles 
were identified, reference lists were checked for additional relevant articles that were not 
identified in the database search (Fig. 1). 
Figure 1  Selection process for relevant citations
Cochrane: 588Embase: 2197PubMed: 1450
Citations identified from 
electronic database search: 
n=4235 
Duplicate articles excluded:
n=1317
Potentially relevant citations 
for first screening: 
n=2918 
Citations excluded after 
screening titles and abstracts: 
n=2649 
Full text articles for full text 
screening: 
n=269 
Citations excluded because full 
text were not reached: 
n=4  
Citations excluded after full 
text screening: 
n=137
Full text articles for detailed 
evaluation: 
n=128 
Articles obtained via 
reference lists:
n=0
Full text articles for detailed 
evaluation on first-line 
combinations: 
n=80 Full text articles for detailed 
evaluation on combinations of 
classical therapies: 
n=48 
Citations on combinations of  
classical therapies excluded  
after detailed examination: 
n=29 
Full text articles included on 
combinations of classical  
therapies: 
n=19 
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 After the initial search was performed a two-stage selection process was obtained. 
First, titles and abstracts of all identified citations were screened for inclusion and exclusion 
by one reviewer (A.H.), using a checklist. Of the 2918 articles found, 2649 were excluded 
because titles and/or abstracts showed that the studies were not eligible for inclusion. 
Subsequently, full-texts were obtained from the remaining 269 articles and were screened 
using the same checklist; four articles were not reached. After the full-text screening 128 
articles were identified and were independently and critically assessed for inclusion or 
exclusion by two reviewers (A.H. and R.K.). Differences among reviewers were resolved 
by consulting a third investigator (P.v.d.K.). A pre-designed data extraction form was used 
by the same two reviewers (A.H. and R.K.) to extract and record the data on study 
 characteristics (both methodological and clinical) from each full-text article. Study 
 characteristics included study design, study population, number of participants, duration 
of treatment, primary outcome, side effects, and level of evidence (LoE). LoEs (Table 1) and 
grading recommendations (A–D) (Table 2) were determined according to the Oxford 
Centre for Evidence-based Medicine Levels of Evidence.3 To compare different efficacy 
measures the percentages change from baseline in clinical parameters as used in the 
evaluation, were used. In addition, when percentages were not stated, they were calculated 
by the reviewers whenever possible. Definitions of the safety parameters seemed to be 
poorly standardized. In order to structure these outcome measures, we tried to use the 
occurrence of local adverse events such as lesional and perilesional reactions and adverse 
drug reactions to compare incidence rates. 
Table 1  Level of evidence
1a
1b
2a
2b
3a
3b
4
5
Systematic review of RCTs
Individual RCT
Systematic review of cohort studies
Individual cohort study (including low-quality RCT)
Systematic review of case-control studies
Individual case-control study
Case series
Case reports, expert opinion 
RCT, Randomized controlled trial.
Data from the Oxford Centre for Evidence-based Medicine Levels of Evidence.3
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Results
Screening Results
Full-text screening revealed that 128 articles were eligible for detailed evaluation, of which 
48 articles concerned combinations of classical topicals. All these articles are presented in 
the results, as are the reasons for exclusion of 29 articles. The data from the remaining 
articles are summarized in Table 3. In this analysis, literature with all grades of evidence 
on the different combinations of treatments will be provided in order to present a 
comprehensive report on all combinations of classical topical treatments.
Penetration Enhancers Combined with Topical Corticosteroids 
The literature search revealed 11 papers on corticosteroids combined with the use of 
penetration enhancers.4-14 Three papers were excluded because the treatment regimen 
or the outcome measure was unclear,9, 10, 14 one paper because the study population was 
not clear,13 and one paper because it was a brief overview of an article which already had 
been included.8 
 Table 4 summarizes the overall efficacy and safety of the combination of topical 
steroids with penetration enhancers, as are the data on both monotherapies. It can be 
seen that combination treatment of only 7 days already leads to an improvement in 
clinical parameters of at least 44%.4 When treatment was prolonged to 21 days, the 
percentage of improvement was enhanced to at least 60.8%.7 
 Ilknur et al. (LoE 2b) compared the treatment with the superpotent steroid clobetasol 
propionate plus salicylic acid, to the treatment with pulsed dye laser (PDL) therapy with 
and without a penetration enhancer within one patient.5 After 15 weeks a mean reduction of 
83.4% was found for modified PASI scores concerning the sites treated with steroids and 
salicylic acid. The improvement was significantly greater in these sites compared to the 
sites treated with PDL, with and without salicylic acid. 
Table 2  Grades of recommendation
A
B
C
D
Studies with consistent LoE 1a and/or 1b (Table 1)
Studies with consistent LoE 2a, 2b, 3a, or 3b; or extrapolations from studies with LOE 1a or 1b
Studies with LoE 4 or extrapolations from studies with LoE 2a, 2b, 3a, or 3b
Studies with LoE 5 or troublingly inconsistent or inconclusive studies of any level 
LoE, Level of Evidence.
Data from the Oxford Centre for Evidence-based Medicine Levels of Evidence.3
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 In three of the papers included,6, 11, 12 the 21 days combination regimen of the potent 
steroid mometasone furoate with 5% salicylic acid was investigated. All study groups 
reported a statistically significant reduction in psoriasis severity favourable for the combination 
therapy when compared to both monotherapies. 
Overall, the different treatment regimes were well tolerated. Mild to moderate application- 
site reactions were the most commonly reported treatment-related adverse events. 
Incidence rates of side effects were comparable between different therapies. No signs or 
symptoms of systemic toxicity have been reported. 
Conclusion Grade B The results indicate that treatment with corticosteroids given in 
combination with penetration enhancers is more efficacious than monotherapy with 
either component, especially when combination therapy is compared to monotherapy 
with a penetration enhancer. Combination therapy is well tolerated with only mild to 
minor side effects. 
Penetration Enhancers and other Topical Treatments
Twelve papers were found on the combination of penetration enhancers and topical 
treatments other than corticosteroids.15-26 Seven papers were excluded because they 
were on the combination with dithranol.15-21
 Two papers on the combination of topical tacrolimus ointment with a penetration 
enhancer were identified.22, 23 Carroll et al.22 conducted a study comparing the efficacy of 
tacrolimus combined with the use of 6% salicylic acid to the efficacy of salicylic acid 
monotherapy. Combination therapy seemed to be more efficacious with a significantly 
greater reduction in psoriasis severity compared to salicylic acid monotherapy. In the study by 
Remitz et al.,23 diisopropyl adipate was used as enhancer. With this penetration enhancer no 
improvement in therapeutic efficacy was reported. Both combinations were well tolerated.
 On the combination of penetration enhancers with coal tar, three studies were 
found.24-26 One study was excluded because the treatment regimen was unclear.24 Both 
included studies were on scalp psoriasis. In a randomized open-label study Klaber et al.25 
(LoE 2b) concluded that the combination was inferior to the treatment with calcipotriol 
scalp solution. Wright et al.26 compared this combination to dithranol treatment, and 
found no statistically significant differences between treatment groups regarding 
therapeutic efficacy. In both studies, side effects were reported less frequently by patients 
treated with the combination regimen.
Conclusion Grade D According to the studies included, tacrolimus treatment with salicylic 
acid should be preferred above salicylic acid monotherapy. However, no literature for 
superiority of the combination was found comparing the efficacy to tacrolimus mono- 
therapy. Regarding the combination of coal tar with salicylic acid, no recommendations 
could be made. 
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Table 3  Summary of included articles
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Penetration enhancers and corticosteroids 
Tiplica, 20091 ROL 360 (184-176) 2b Gr1: twice daily mometasone furoate 0.1% plus 
salicylic acid 5% for 7 days, followed by 
mometasone monotherapy. Gr2: mometasone 
monotherapy.
7 days At day 7 mean reduction in PASI score was significantly greater in Gr1 (44% vs. 37%). DLQI 
scores indicated significant lower values in Gr1. Only one treatment-related adverse event  
(i.e. skin irritation) was reported in Gr1. No adverse events were reported in Gr2.
Ilknur, 20062 CT 19 (19-19-19) 2b Sites 1: PDL 3 times at 3 weeks interval. 
2: twice daily salicylic acid for 7 days before PDL.  
3: twice daily salicylic acid for 7 days, and thereafter 
when the plaque had scales, followed by clobetasol 
propionate.
15 weeks mPASI reduction at  week 15: 52.3% vs. 64.9% vs. 83.4%*. Reduction at site 3 was significantly 
greater than at 2 and 1 (p = 0.013 and p = 0.001, respectively). Reduction at site 2 was 
significantly greater than at site 1 (p = 0.024). Side effects were only reported at the PDL treated 
sites (i.e. hyperpigmentation, purpura and pain).
Koo, 19983 RCT 408 (203-205) 1b Gr1: twice daily mometasone furoate 0.1% plus 
salicylic acid 5% ointment. Gr2: twice daily 
mometasone furoate alone.
21 days Mean % improvement TSS at day 22 was 68.9% vs. 60.9% (p < 0.01). According to the IGA of the 
overall clinical response, treatment was statistically significantly more effective in Gr1 (p < 0.01). 
Application-site reactions were reported in 9% vs. 8%in Gr1 and 2, respectively.
Katz, 19984 RCT 341 (136-136-69) 1b All patients applied twice daily mometasone 
furoate 0.1%/salicylic acid 5% (Gr1), mometasone 
furoate 0.1% (Gr2) or salicylic acid 5% (Gr3) 
ointment.
21 days Mean % improvement TSS at day 22 was 75% vs. 68% vs. 39%; improvement in Gr1 and 2 was 
significantly higher than in Gr3 (p < 0.01), whereas improvement in Gr1 was significantly greater 
compared to Gr2 (p < 0.01). Global evaluation of overall change in disease: ‘good, excellent’ or 
‘cleared’: 86% vs. 77% vs. 32%. AEs, mainly ASRs like burning, occurred in 20% vs. 13% vs. 18%.
Crosti, 19975 ROL 160 (80-80) 2b Patients applied twice daily calcipotriol 50µg/g 
ointment (Gr1) or betamethasone dipropionate 
0.05% plus salicylic acid 3% (Gr2).
6 weeks, 
4 weeks 
follow-up
At EOT reductions in the scores of erythema, infiltration, and exfoliation from baseline were 
significant, but not between groups. PASI had dropped 66.8% vs. 60.8%. IGA: ‘improved’ or 
‘healed’: 79% vs. 89.4%. Patients found calcipotriol more acceptable. Local adverse reactions, 
mainly burning, itching and erythema, were reported in 7 vs. zero patients. 
Medansky, 19976 RCT 40 (40-40) 2b All patients applied twice daily mometasone 
furoate 0.1%/salicylic acid 5% ointment on one side 
of the body and fluocinonide 0.05% ointment on 
the other.
21 days Mean % improvement TSS at day 22 was 65.1%* vs. 55.3% (p < 0.01). At day 22 ≥ 70% overall 
improvement was seen in 55% vs. 20%. No AEs were observed or reported.
Penetration enhancers and other topicals
Carroll, 20057 RCT 30 (30-30) 2b Twice daily application 6% salicylic acid gel followed 
by 0.1% tacrolimus ointment (site 1) or by its vehicle 
(site 2) on each half of their body.
8 weeks, 
4 weeks 
follow-up
Mean % reduction in the summed score of erythema, scale and thickness scores at week 8: 
51.2% vs. 32.4%*. Improvement in erythema, scaling, and pruritus was significantly greater at 
site1 (p = 0.02, 0.04, and 0.04, respectively). After 12 weeks no differences were seen in the 
summed score. Local AEs, like stinging, were minor, and could not be localized to one side.
Klaber, 20008 ROL 475 (328-237) 2b Gr1: twice daily calcipotriol 50µg/ml scalp solution. 
Gr2: once daily 1% coal tar / 1% coconut oil / 0.5% 
salicylic acid shampoo.
8 weeks Mean % reduction in TSS from baseline to the end of the comparative treatment phase: 39.2% 
vs. 26%*. Mean difference being significant favorable for Gr1 (p < 0.001). Moderate 
improvement or better was seen in 57% vs. 37% (p < 0.001). AEs (most frequent cutaneous AEs) 
were recorded in 59.6% vs. 35.8%. Severe AEs were reported in 9.6% vs. 7.4%.
Remitz, 19999 RCT 16 (6 sites per 
patient)
2b Sites 1. Tacrolimus ointment with diisopropyl 
adipate. 2. Tacrolimus ointment. 3. 0.1% 
betamethasone 17 valerate ointment. 4. 0.005% 
calcipotriol ointment, ointment bases for tacrolimus 
(5) and betamethasone (6). Ointments were 
reapplied and the area was sealed every 2-3 days.
14 days At EOT median % reduction in summed score for erythema and infiltration: 66.7% vs. 66.7% vs. 
85.7% vs. 47.2% vs. 29.2% vs. 21.4%. No difference was found between tacrolimus with or 
without enhancer. Nothing on side effects was reported.
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Table 3  Summary of included articles
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Penetration enhancers and corticosteroids 
Tiplica, 20091 ROL 360 (184-176) 2b Gr1: twice daily mometasone furoate 0.1% plus 
salicylic acid 5% for 7 days, followed by 
mometasone monotherapy. Gr2: mometasone 
monotherapy.
7 days At day 7 mean reduction in PASI score was significantly greater in Gr1 (44% vs. 37%). DLQI 
scores indicated significant lower values in Gr1. Only one treatment-related adverse event  
(i.e. skin irritation) was reported in Gr1. No adverse events were reported in Gr2.
Ilknur, 20062 CT 19 (19-19-19) 2b Sites 1: PDL 3 times at 3 weeks interval. 
2: twice daily salicylic acid for 7 days before PDL.  
3: twice daily salicylic acid for 7 days, and thereafter 
when the plaque had scales, followed by clobetasol 
propionate.
15 weeks mPASI reduction at  week 15: 52.3% vs. 64.9% vs. 83.4%*. Reduction at site 3 was significantly 
greater than at 2 and 1 (p = 0.013 and p = 0.001, respectively). Reduction at site 2 was 
significantly greater than at site 1 (p = 0.024). Side effects were only reported at the PDL treated 
sites (i.e. hyperpigmentation, purpura and pain).
Koo, 19983 RCT 408 (203-205) 1b Gr1: twice daily mometasone furoate 0.1% plus 
salicylic acid 5% ointment. Gr2: twice daily 
mometasone furoate alone.
21 days Mean % improvement TSS at day 22 was 68.9% vs. 60.9% (p < 0.01). According to the IGA of the 
overall clinical response, treatment was statistically significantly more effective in Gr1 (p < 0.01). 
Application-site reactions were reported in 9% vs. 8%in Gr1 and 2, respectively.
Katz, 19984 RCT 341 (136-136-69) 1b All patients applied twice daily mometasone 
furoate 0.1%/salicylic acid 5% (Gr1), mometasone 
furoate 0.1% (Gr2) or salicylic acid 5% (Gr3) 
ointment.
21 days Mean % improvement TSS at day 22 was 75% vs. 68% vs. 39%; improvement in Gr1 and 2 was 
significantly higher than in Gr3 (p < 0.01), whereas improvement in Gr1 was significantly greater 
compared to Gr2 (p < 0.01). Global evaluation of overall change in disease: ‘good, excellent’ or 
‘cleared’: 86% vs. 77% vs. 32%. AEs, mainly ASRs like burning, occurred in 20% vs. 13% vs. 18%.
Crosti, 19975 ROL 160 (80-80) 2b Patients applied twice daily calcipotriol 50µg/g 
ointment (Gr1) or betamethasone dipropionate 
0.05% plus salicylic acid 3% (Gr2).
6 weeks, 
4 weeks 
follow-up
At EOT reductions in the scores of erythema, infiltration, and exfoliation from baseline were 
significant, but not between groups. PASI had dropped 66.8% vs. 60.8%. IGA: ‘improved’ or 
‘healed’: 79% vs. 89.4%. Patients found calcipotriol more acceptable. Local adverse reactions, 
mainly burning, itching and erythema, were reported in 7 vs. zero patients. 
Medansky, 19976 RCT 40 (40-40) 2b All patients applied twice daily mometasone 
furoate 0.1%/salicylic acid 5% ointment on one side 
of the body and fluocinonide 0.05% ointment on 
the other.
21 days Mean % improvement TSS at day 22 was 65.1%* vs. 55.3% (p < 0.01). At day 22 ≥ 70% overall 
improvement was seen in 55% vs. 20%. No AEs were observed or reported.
Penetration enhancers and other topicals
Carroll, 20057 RCT 30 (30-30) 2b Twice daily application 6% salicylic acid gel followed 
by 0.1% tacrolimus ointment (site 1) or by its vehicle 
(site 2) on each half of their body.
8 weeks, 
4 weeks 
follow-up
Mean % reduction in the summed score of erythema, scale and thickness scores at week 8: 
51.2% vs. 32.4%*. Improvement in erythema, scaling, and pruritus was significantly greater at 
site1 (p = 0.02, 0.04, and 0.04, respectively). After 12 weeks no differences were seen in the 
summed score. Local AEs, like stinging, were minor, and could not be localized to one side.
Klaber, 20008 ROL 475 (328-237) 2b Gr1: twice daily calcipotriol 50µg/ml scalp solution. 
Gr2: once daily 1% coal tar / 1% coconut oil / 0.5% 
salicylic acid shampoo.
8 weeks Mean % reduction in TSS from baseline to the end of the comparative treatment phase: 39.2% 
vs. 26%*. Mean difference being significant favorable for Gr1 (p < 0.001). Moderate 
improvement or better was seen in 57% vs. 37% (p < 0.001). AEs (most frequent cutaneous AEs) 
were recorded in 59.6% vs. 35.8%. Severe AEs were reported in 9.6% vs. 7.4%.
Remitz, 19999 RCT 16 (6 sites per 
patient)
2b Sites 1. Tacrolimus ointment with diisopropyl 
adipate. 2. Tacrolimus ointment. 3. 0.1% 
betamethasone 17 valerate ointment. 4. 0.005% 
calcipotriol ointment, ointment bases for tacrolimus 
(5) and betamethasone (6). Ointments were 
reapplied and the area was sealed every 2-3 days.
14 days At EOT median % reduction in summed score for erythema and infiltration: 66.7% vs. 66.7% vs. 
85.7% vs. 47.2% vs. 29.2% vs. 21.4%. No difference was found between tacrolimus with or 
without enhancer. Nothing on side effects was reported.
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Table 3  Continued
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Penetration enhancers and other topicals
Wright, 198510 RCT 38 (18-20) 2b Gr1: once daily 0.1% dithranol in 17% urea base.  
Gr2: once daily coal tar solution 6%, salicylic acid 
2%, Tween 20 1% in emulsifying ointment. Both 
regimens following a 17.5% cetrimide shampoo.
3 weeks After 14 days clearance occurred in 94% vs. 85% of patients (NS). Time taken to clearance was 
10.7 days vs. 13.2 days (NS). Side effects, particularly stinging and burning, were reported 
significantly more in Gr1 (15 patients vs. 1 patient).
Coal tar plus corticosteroids 
Pinheiro, 199711 ROL 122 (65-57) 2b Patients applied twice daily calcipotriol 50µg/g 
ointment (Gr1) or 5% coal tar/2% allantoin/0.5% 
hydrocortisone cream (Gr2).
8 weeks IGA: ‘cleared’ or ‘marked improvement’ at week 8: 72.3% vs. 49.1% (p < 0.02). Reduction of TSS, 
scaliness and thickness was significantly greater in Gr1, but not in redness. Patients assessed the 
efficacy and acceptability of calcipotriol treatment as better than with coal tar combination  
(p < 0.02 and p = 0.08, respectively). AEs were reported in 23.1% vs. 17.5% (NS), most of which 
were application related (i.e. pruritus, itch, irritation, etc) and mild to moderate. 
Coal tar plus dithranol
Saraswat, 200712 RCT 20 (20-10-10) 2b Dithranol lipogel was applied on one arm, on the 
other arm patients applied 0.5% liposomal base 
(Gr1) or Derobin ointment (1.15% dithranol, 1.15% 
salicylic acid, 5.3% coal tar in cream base) (Gr2).
6 weeks Mean % reduction in TSS from baseline to 2 weeks/4 weeks/6 weeks for the dithranol lipogel 
treated sites: 37.7%/59.0%/73.8%*; for the Derobin treated sites: 41.3%/63.5%/76.2%*; for the 
liposomal base treated sites vs. 14.5%/24.2%/33.9%*. Perilesional erythema was observed more 
frequently in the Deborin-treated sides compared to the lipogel- and liposomal base-treated 
sites.
Harrington, 198913 ROL 23 (23-23) 2b Gr1: twice daily dithranol 0.11%/coal tar 1% /
salicylic acid 1.6% (Psorin) on the left side of the 
body and alcoholic extract coal tar 5% /allantoin 2% 
(Alphosyl) on the right. Gr2: used them in the 
alternate way. 
6 weeks Reductions in the scores of overall disease severity, erythema and scaling were all significant 
superior for Psorin (p <0.001). AEs, confined to itch, soreness or burning, were reported similar 
for both treatments. Most patients preferred Psorin above Alphosyl (p < 0.001).
Dithranol plus corticosteroids or vitamin D analogues 
Swinkels, 200214 ROL 12 (3 sites per 
patient)
2b Pretreatment with salicylic acid 10%. Site 1: 
dithranol cream plus clobetasol-17-propionate 
ointment. Site 2: dithranol cream + vehicle. Site 3: 
clobetasol. All applied 5 days/week. 
(3-day short contact dithranol application scheme 
varying in time and concentration).
39 days, 
23 weeks 
follow-up
Combination treatment showed the fastest decrease in sum score (p < 0.001). These lesions also 
showed a slower relapse rate (p < 0.001). No perilesional erythema was observed.
Monastirli, 200215 RCT 46 (23-23) 2b Once daily application of dithranol 2% ointment 
(containing salicylic acid) for 30 min and twice daily 
(Gr1) vehicle or (Gr2) calcipotriol 50µg/g.
6 weeks PASI reduction from baseline at week 6: 84.9% vs. 100%* (p = 0.0001). All patients revealed 
irritation, burning and discoloration, but no significant differences were found between groups.
Sander, 199816 ROL 30 (10-10-10) 2b Gr1: twice daily dithranol (1/32%-1%). Gr2: 
calcipotriol 0.005% ointment in the morning and 
dithranol in the evening. Gr3: mometasone 0.1% 
cream in the morning and dithranol in the evening.
4 weeks, 
6 weeks 
follow-up
After week 1 and 2, Gr2 revealed a significantly faster reduction in PASI score than Gr1 (p ≤ 0.01). 
Gr3 showed a NS faster reduction. After 4 weeks of treatment and 6 weeks of follow-up there 
were no differences between PASI scores. Fewer side effects (i.e. perilesional toxic dermatitis) 
were observed in Gr2 compared to the other groups.
Grattan, 198817 RCT 30 (30-30) 2b Patients applied twice daily dithranol in Lassar’s 
paste on one side of the body and dithranol  
and fluocinonide 0.01% in Lassar’s paste on the 
other side.
28 days, 
3 months 
follow-up
Severity score showed a significantly greater reduction after week 1 and 2 on the side treated 
with the combination (p < 0.01 and p < 0.05, respectively), but was NS after week 3 and 4.  
Skin staining was more marked on the side treated with combination therapy (p = 0.002).  
Earlier relapse was seen on the side treated with the combination therapy (p = 0.011).
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year (ref)
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Penetration enhancers and other topicals
Wright, 198510 RCT 38 (18-20) 2b Gr1: once daily 0.1% dithranol in 17% urea base.  
Gr2: once daily coal tar solution 6%, salicylic acid 
2%, Tween 20 1% in emulsifying ointment. Both 
regimens following a 17.5% cetrimide shampoo.
3 weeks After 14 days clearance occurred in 94% vs. 85% of patients (NS). Time taken to clearance was 
10.7 days vs. 13.2 days (NS). Side effects, particularly stinging and burning, were reported 
significantly more in Gr1 (15 patients vs. 1 patient).
Coal tar plus corticosteroids 
Pinheiro, 199711 ROL 122 (65-57) 2b Patients applied twice daily calcipotriol 50µg/g 
ointment (Gr1) or 5% coal tar/2% allantoin/0.5% 
hydrocortisone cream (Gr2).
8 weeks IGA: ‘cleared’ or ‘marked improvement’ at week 8: 72.3% vs. 49.1% (p < 0.02). Reduction of TSS, 
scaliness and thickness was significantly greater in Gr1, but not in redness. Patients assessed the 
efficacy and acceptability of calcipotriol treatment as better than with coal tar combination  
(p < 0.02 and p = 0.08, respectively). AEs were reported in 23.1% vs. 17.5% (NS), most of which 
were application related (i.e. pruritus, itch, irritation, etc) and mild to moderate. 
Coal tar plus dithranol
Saraswat, 200712 RCT 20 (20-10-10) 2b Dithranol lipogel was applied on one arm, on the 
other arm patients applied 0.5% liposomal base 
(Gr1) or Derobin ointment (1.15% dithranol, 1.15% 
salicylic acid, 5.3% coal tar in cream base) (Gr2).
6 weeks Mean % reduction in TSS from baseline to 2 weeks/4 weeks/6 weeks for the dithranol lipogel 
treated sites: 37.7%/59.0%/73.8%*; for the Derobin treated sites: 41.3%/63.5%/76.2%*; for the 
liposomal base treated sites vs. 14.5%/24.2%/33.9%*. Perilesional erythema was observed more 
frequently in the Deborin-treated sides compared to the lipogel- and liposomal base-treated 
sites.
Harrington, 198913 ROL 23 (23-23) 2b Gr1: twice daily dithranol 0.11%/coal tar 1% /
salicylic acid 1.6% (Psorin) on the left side of the 
body and alcoholic extract coal tar 5% /allantoin 2% 
(Alphosyl) on the right. Gr2: used them in the 
alternate way. 
6 weeks Reductions in the scores of overall disease severity, erythema and scaling were all significant 
superior for Psorin (p <0.001). AEs, confined to itch, soreness or burning, were reported similar 
for both treatments. Most patients preferred Psorin above Alphosyl (p < 0.001).
Dithranol plus corticosteroids or vitamin D analogues 
Swinkels, 200214 ROL 12 (3 sites per 
patient)
2b Pretreatment with salicylic acid 10%. Site 1: 
dithranol cream plus clobetasol-17-propionate 
ointment. Site 2: dithranol cream + vehicle. Site 3: 
clobetasol. All applied 5 days/week. 
(3-day short contact dithranol application scheme 
varying in time and concentration).
39 days, 
23 weeks 
follow-up
Combination treatment showed the fastest decrease in sum score (p < 0.001). These lesions also 
showed a slower relapse rate (p < 0.001). No perilesional erythema was observed.
Monastirli, 200215 RCT 46 (23-23) 2b Once daily application of dithranol 2% ointment 
(containing salicylic acid) for 30 min and twice daily 
(Gr1) vehicle or (Gr2) calcipotriol 50µg/g.
6 weeks PASI reduction from baseline at week 6: 84.9% vs. 100%* (p = 0.0001). All patients revealed 
irritation, burning and discoloration, but no significant differences were found between groups.
Sander, 199816 ROL 30 (10-10-10) 2b Gr1: twice daily dithranol (1/32%-1%). Gr2: 
calcipotriol 0.005% ointment in the morning and 
dithranol in the evening. Gr3: mometasone 0.1% 
cream in the morning and dithranol in the evening.
4 weeks, 
6 weeks 
follow-up
After week 1 and 2, Gr2 revealed a significantly faster reduction in PASI score than Gr1 (p ≤ 0.01). 
Gr3 showed a NS faster reduction. After 4 weeks of treatment and 6 weeks of follow-up there 
were no differences between PASI scores. Fewer side effects (i.e. perilesional toxic dermatitis) 
were observed in Gr2 compared to the other groups.
Grattan, 198817 RCT 30 (30-30) 2b Patients applied twice daily dithranol in Lassar’s 
paste on one side of the body and dithranol  
and fluocinonide 0.01% in Lassar’s paste on the 
other side.
28 days, 
3 months 
follow-up
Severity score showed a significantly greater reduction after week 1 and 2 on the side treated 
with the combination (p < 0.01 and p < 0.05, respectively), but was NS after week 3 and 4.  
Skin staining was more marked on the side treated with combination therapy (p = 0.002).  
Earlier relapse was seen on the side treated with the combination therapy (p = 0.011).
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Coal Tar in Combination with Topical Corticosteroids or Vitamin D Analogues
Five publications on coal tar combined with topical corticosteroids were identified27-31; 
four studies were excluded because no clear outcome measure was described, the treatment 
regimen was unclear or the publication was not on plaque psoriasis.27-29, 31 On the 
combination with vitamin D analogues only one publication was revealed,32 which was 
excluded because neither the number of participants nor demographic data were stated. 
 Only one randomized open comparison study was included, comparing the 
therapeutic effects of coal tar/allantoin/hydrocortisone cream to calcipotriol ointment.30 
After 8 weeks the investigators found that the proportion of patients ‘cleared’ or ‘markedly 
improved’ treated with vitamin D to be significantly higher than patients treated with the 
coal tar combination (72.3% and 49.1%, respectively), whereas application related adverse 
events were not significantly different. 
Conclusion Grade D No data were available to compare the combination of coal tar and 
corticosteroids to either monotherapy. However, the evidence that we found suggests 
that the combination regimen of coal tar and corticosteroids seems to be less effective 
than vitamin D monotherapy, whereas the safety seems to be equal. Therefore, this 
combination therapy cannot be recommended. 
Table 3  Continued
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Other combinations 
Sander, 200118 ROL 30 (10-10-10) 2b All patients were treated with dithranol in increasing 
concentrations at noon and with tazarotene 0,025% 
in the evening and mometasone (Gr1), urea (Gr2) or 
calcipotriol (Gr3) in the morning.
4 weeks PASI improvement 89.4% vs 82.9% vs 89.9%*. Gr1 and 3 revealed a significant faster reduction of 
the PASI compared to Gr2. Local irritations in Gr1 and 3 occurred less often than in Gr2.
Sander, 199919 ROL 50 (10 patients 
per group)
2b Gr1: twice daily dithranol (1/32%-1%) plus 2% 
 salicylic acid. Gr2: dithranol plus 2% salicylic acid/
Tazarotene 0.025% gel. Gr3: Dithranol plus 2% 
 salicylic acid/Tazarotene (0.005%-0.1%) gel. Gr4: 
twice daily tazarotene 0.025% gel. Gr5: Tazarotene 
0.05% gel/vehicle.
4 weeks PASI reduction Gr1 74.1% vs 83.7% in Gr2 (p < 0.05)*. The largest PASI reduction was seen within 
Gr2 (p < 0.05) and the smallest in Gr5. Between Gr1, 3 and 4 there was no significant difference. 
Skin irritation was most severe in Gr2.
ADR, adverse drug reaction; AE, adverse event; ASR, application-site reaction; CT, controlled trial; DLQI, 
Dermatology Life Quality Index; Gr, group; IGA, investigator global assessment; LoE, level of evidence; mPASI, 
modified Psoriasis Area and Severity Index; NS; not significant; ODS, overall disease severity; OL, open-label 
study; PASI, Psoriasis Area and Severity Index; PDL, pulsed dye laser; PGA, patient global assessment; RCT, 
randomized controlled trial; ROL, randomized open-label study; TSS, total sign score. 
* Numbers were calculated.
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Coal Tar in Combination with Dithranol 
Of the eight studies identified,33-40 three studies were excluded because no clear outcome 
measure was stated,37, 38, 40 two because demographic data were not described,36, 39 and 
one because the treatment regimen was not clear.34 
 Harrington et al.35 investigated the clinical efficacy of the combination regimen of 
coal tar and dithranol and compared it to alcoholic coal tar extract and allantoin. They 
showed that reduction in overall disease severity was significantly superior on the sites 
treated with coal tar combined with dithranol compared to the sites treated with alcoholic 
coal tar, whereas adverse effects were reported equally. The paper by Saraswat et al.33 
showed that the efficacy of dithranol lipogel monotherapy was comparable to the 
combination regimen coal tar with dithranol. Moreover, a marked reduction in the 
incidence of skin irritation and staining was seen in the dithranol lipogel treated sites. 
Conclusion Grade C The data available show that combination therapy of coal tar and 
dithranol is at least as effective as both dithranol monotherapy and tar monotherapy. 
Combination treatment of coal tar and dithranol could be preferred above coal tar 
monotherapy with a remarkable reduction in disease severity, whereas dithranol lipogel 
monotherapy seems to be favourable regarding its safety profile. 
Table 3  Continued
Author,  
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design
No. patients  
(per group)
LoE Treatment Duration Outcome
Other combinations 
Sander, 200118 ROL 30 (10-10-10) 2b All patients were treated with dithranol in increasing 
concentrations at noon and with tazarotene 0,025% 
in the evening and mometasone (Gr1), urea (Gr2) or 
calcipotriol (Gr3) in the morning.
4 weeks PASI improvement 89.4% vs 82.9% vs 89.9%*. Gr1 and 3 revealed a significant faster reduction of 
the PASI compared to Gr2. Local irritations in Gr1 and 3 occurred less often than in Gr2.
Sander, 199919 ROL 50 (10 patients 
per group)
2b Gr1: twice daily dithranol (1/32%-1%) plus 2% 
 salicylic acid. Gr2: dithranol plus 2% salicylic acid/
Tazarotene 0.025% gel. Gr3: Dithranol plus 2% 
 salicylic acid/Tazarotene (0.005%-0.1%) gel. Gr4: 
twice daily tazarotene 0.025% gel. Gr5: Tazarotene 
0.05% gel/vehicle.
4 weeks PASI reduction Gr1 74.1% vs 83.7% in Gr2 (p < 0.05)*. The largest PASI reduction was seen within 
Gr2 (p < 0.05) and the smallest in Gr5. Between Gr1, 3 and 4 there was no significant difference. 
Skin irritation was most severe in Gr2.
ADR, adverse drug reaction; AE, adverse event; ASR, application-site reaction; CT, controlled trial; DLQI, 
Dermatology Life Quality Index; Gr, group; IGA, investigator global assessment; LoE, level of evidence; mPASI, 
modified Psoriasis Area and Severity Index; NS; not significant; ODS, overall disease severity; OL, open-label 
study; PASI, Psoriasis Area and Severity Index; PDL, pulsed dye laser; PGA, patient global assessment; RCT, 
randomized controlled trial; ROL, randomized open-label study; TSS, total sign score. 
* Numbers were calculated.
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Dithranol Combined with Topical Corticosteroids or Vitamin D Analogues 
Literature search revealed eight studies on the combination of dithranol and topical corti-
costeroids41-48 and two on dithranol combined with vitamin D analogues.46, 49 Three 
papers were excluded because results were on other types of psoriasis and other localized 
skin diseases,41, 44, 45 one because demographic data were lacking,48 and one paper was 
excluded because the treatment strategy was unclear.43 Results show that the added 
value of a topical corticosteroid to dithranol therapy is related to steroid-potency. 
 The study by Swinkels et al.42 showed that adding a superpotent corticosteroid to 
short-contact dithranol therapy led to a significantly faster reduction in psoriasis severity 
and a lower relapse rate. No perilesional erythema was reported. Two other papers 
concluded that the combination of dithranol with a mid-potent47 or with a potent 
corticosteroid46 respectively showed no significant differences compared to dithranol 
monotherapy. In the latter open clinical study46 dithranol monotherapy was compared to 
combination therapy of dithranol with mometasone and to a combination regimen with 
dithranol and calcipotriol ointment. Adding calcipotriol to conventional dithranol 
application resulted in an enhancement of the therapeutic efficacy. However, this 
augmentation of the antipsoriatic effects of dithranol was only seen in the initial phase of 
the treatment. After 6 weeks of treatment, no significant differences were found with 
regard to therapeutic efficacy. 
 In contrast to these results, Monastirli et al.49 concluded that the statistically significant 
greater improvement by the combination in clinical parameters which was seen already in 
the initial phase of the study remained until the end of treatment after 6 weeks. 
Conclusion Grade C Combining dithranol with topical corticosteroids seems only 
appropriate when using superpotent corticosteroids. Regarding to our literature search, it 
is conceivable that adding corticosteroids with a lower class of strength to dithranol 
monotherapy does not improve therapeutic efficacy. Therefore, only the combination 
with a superpotent corticosteroid may be preferred. However, combining dithranol to 
vitamin D analogues seem to enhance the therapeutic efficacy, at least within the first 
weeks of treatment, without an increase in the incidence or intensity of perilesional side 
effects.
Remaining Combination of Topicals 
The extensive literature search revealed also one study by Sander et al.,50 in which the 
authors investigated whether it was possible to increase the antipsoriatic effect by 
combining dithranol with tazarotene. They found that combination therapy showed a 
significantly faster improvement of clinical severity scores than dithranol monotherapy.
 Finally, one article was included on triple-therapy.51 All patients were treated with 
dithranol and tazarotene, and consecutively received mometasone, calcipotriol or urea. 
The combinations with mometasone and calcipotriol revealed a significantly faster 
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reduction in PASI scores, whereas local irritations occurred less often in these groups 
compared to the combination with urea on the same lesions. 
 Because no more evidence was found on these combinations, no recommendations 
could be made.
Discussion
The present systematic review on combinations of classical topicals reveals that study 
designs and outcome criteria are at variance and prohibit comparisons between different 
combinations. This arises, at least partially, from the lack of standardized utilization 
methods of classical treatments. Research approaches in the past decades were 
descriptions of experiences. Therefore, it is conceivable that there is older literature on 
these combinations which was excluded because we sought to include papers published 
ever since 1985. Furthermore, double blind studies on dithranol are not possible as efficacy 
is reached by gradual concentration increments until mild irritation. 
 With respect to classical treatments, the evidence for an improved efficacy and safety 
of the combination with other topicals as compared to monotherapy is limited. However, 
the combination of dithranol with tar and superpotent corticosteroids enhances efficacy 
whilst reducing side effects. The combination of dithranol with calcipotriol enhances the 
efficacy as compared to dithranol monotherapy. 
 A complexity with dithranol treatment is that actual efficacy with limited irritation is 
only achieved at daycare units and in patient departments with qualified nurses carrying 
out or instructing this treatment to patients with adequate management of dose 
increment or reduction. The relevance of the treatment setting is clearly expressed in the 
review by van de Kerkhof et al. on the older literature of dithranol and dithranol 
combinations.52 In daycare setting dithranol cream monotherapy was shown to be even 
more efficacious than treatment with calcipotriol ointment,53 whereas calcipotriol has 
become a first-line treatment for psoriasis. 
 Despite classical topicals being difficult to apply as a routine outpatient therapy, it is 
born out of clinical practice that these treatments have an important position for many 
patients. In children with psoriasis and in patients contraindicated for systemic treatments 
dithranol and tar-based treatment can be the ultimum refugium. The present systematic 
literature study suggests that penetration enhancers with corticosteroids, dithranol with 
corticosteroids and dithranol-tar combinations are worthwhile, and that combination 
treatment of classical treatments can be exploited to boost efficacy and enhance safety.
 The use of salicylic acid, as an adjunct treatment, is adored by some dermatologist 
and refuted by others. Evidence concerning the combination with corticosteroids 
suggests that this addition is worthwhile. This combination therapy is well tolerated with 
only mild to minor side effects. Therefore it can be recommended above monotherapy. 
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The addition of penetration enhancers, like salicylic acid, to dithranol is preventing 
dithranol oxidation and is therefore more rule than exception. Because of this, the 
combination of penetration enhancers and dithranol was not taken into account in this 
review. The combination of salicylic acid and other topicals cannot be supported by 
evidence from literature. We recommend carrying out descaling with salicylic acid before 
treatment in case thick scaling crusts prevent adequate application of topicals. 
 In conclusion, classical treatments still have an important position for selected patient 
populations. Of the combinations examined, the combination regimen of topical cortico-
steroids and salicylic acid is recommended above monotherapy with either component. 
Furthermore, the combinations of dithranol with superpotent corticosteroids as well as 
dithranol with coal tar may be preferred above corresponding monotherapies. However, 
for future research, it is important to develop a consensus between researchers on 
mandatory outcome measures in order to facilitate comparison of study data. High quality 
evidence-based data are limited. The efficacy and safety of classical treatments and their 
combinations has to be studied in controlled studies, reconciling the fact that quality of 
these treatments is dependent on the treatment protocol, the quality of the treatment 
units and the health care professionals carrying out these treatments. 
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Abstract
Background Most psoriasis patients suffering from mild to moderate disease are treated 
with first-line topical treatments, including corticosteroids, vitamin D analogues, topical 
retinoids and calcineurin inhibitors. Although evidence-based guidelines on combinations 
are lacking, the majority of patients will be treated with combinations of these popular 
topicals at some point during their life-long treatment.
Objectives We intended to systematically review all available literature on the efficacy and 
safety of combinations of first-line topicals in chronic plaque psoriasis, and ultimately, to 
propose recommendations for combined regimens concerning first-line treatments.
Methods Databases used as data sources were PubMed, EMBASE and the Cochrane 
Controlled Clinical Trial Register. According to standardized procedures, literature searches 
were performed and a level of evidence was determined.
Results In total 2918 publications on topical combination therapy were revealed, of which 
45 articles on first-line combinations were included. The combination of potent and 
superpotent corticosteroids with vitamin D analogues provides an improvement of 
psoriasis within 2 weeks, reaching a maximal improvement after 4 weeks in the majority 
of patients. The two-compound product permits once-daily treatment and therefore is a 
good solution for chronic plaque psoriasis including scalp psoriasis. Combinations of cor-
ticosteroids, with tazarotene or with calcineurin inhibitors do not provide an advantage 
above corticosteroid monotherapy.
Conclusions The combination of potent corticosteroids with calcipotriol has been studied 
most extensively and should be regarded as an efficacious and safe treatment option with 
the two-compound products as the most practical solution.
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Introduction
Topical treatments remain the first choice of treatment for psoriasis since the majority of 
patients suffer from mild to moderate disease.1 When phototherapy or systemic treatment 
is required, topical therapy can provide additional benefit and permit reduction of the 
required doses.2 
 From the broad range of topical therapies available, topical steroids have been the 
mainstay of treatment for many years. During the previous two decades, therapies such as 
vitamin D analogues, retinoids and calcineurin inhibitors became available. These treatments 
comprise the first-line topical therapies. 
 In daily practice, combination therapy is more rule than exception. The principle of 
combining two drugs can be promising, but not all combinations provide additive or 
synergistic effects. It is important to offer an appropriate, effective, and non-complex treatment 
regimen with minimal side effects to stimulate compliance. In this respect, healthcare 
professionals should simplify topical treatment to the most effective combinations, which 
are both practical and suitable for patients’ daily life.
 An extensive Cochrane review with a literature search up to 2008 on the topical 
treatment of psoriasis was published in 2009.3 Updates have been performed but lack 
systematic approach or do not comprise critical analysis of topical combination therapy. 
The aim of the present review was to find out which combinations of topical treatments 
have an added value to the corresponding monotherapies with respect to efficacy and 
safety, and to formulate treatment recommendations. In this publication, we restrict the 
analyses to first-line topical therapies. The analyses on combinations of classical topicals, 
such as dithranol and coal tar have been analyzed using the same methodology and are 
published separately.4 
Methods
An extensive literature search was conducted in three computerized bibliographical 
databases for articles published from January 1985 to April 2012: PubMed, EMBASE, and 
the Cochrane Controlled Clinical Trial Register. Main key words used were ‘psoriasis’, 
‘topical’ and ‘treatment’, including all possible synonyms and all combinations of 
antipsoriatic treatments (generic names and brand names). The search was limited to 
publications written in English, German or Dutch. Full details on the search strategy are 
available from the corresponding author on request. Articles present in more than one 
database were included once. Descriptions of demographic data and an outcome 
measure were mandatory. Outcome measures included Psoriasis Area and Severity Index 
(PASI); Physician Global Assessment; total severity score for erythema, scaling, and 
thickness; and more subjective parameters such as percentage of clearance. Psoriasis of 
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the scalp was considered a variant of plaque psoriasis. Excluded were studies concerning 
other subtypes of psoriasis, nail psoriasis only or psoriatic arthritis. If the treatment regimen 
was unclear, the study was not included. Articles on childhood psoriasis were excluded, 
because an extensive literature search has already been done by our group.5 After all 
articles were identified; reference lists were checked for additional relevant articles that 
were not identified in the database search (Fig. 1). 
Figure 1  Selection process for relevant citations
Cochrane: 588Embase: 2197PubMed: 1450
Citations identified from 
electronic database search: 
n=4235 
Duplicate articles excluded:
n=1317
Potentially relevant citations 
for first screening: 
n=2918 
Citations excluded after 
screening titles and abstracts: 
n=2649 
Full text articles for full text 
screening: 
n=269 
Citations excluded because full 
text were not reached: 
n=4  
Citations excluded after full 
text screening: 
n=137
Full text articles for detailed 
evaluation: 
n=128 
Articles obtained via 
reference lists:
n=0
Full text articles for detailed 
evaluation on classical 
topical combinations: 
n=48Full text articles for detailed 
evaluation on combinations of 
first-line topical therapies: 
n=80 
Citations on combinations of  
first-line therapies excluded  
after detailed examination: 
n=35 
Full text articles included on 
combinations of rst-line  
topical therapies: 
n=45
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 After the initial search was performed a two-stage selection process was obtained. 
First, titles and abstracts of all identified citations were screened for inclusion and exclusion 
by one reviewer (A.H.), using a checklist. Of the 2918 articles found, 2649 were excluded 
because titles and/or abstracts showed that the studies were not eligible for inclusion. 
Subsequently, full-texts were obtained from the remaining 269 articles and were screened 
using the same checklist; four articles were not reached. After the full-text screening, 128 
articles were identified and were independently and critically assessed for inclusion or 
exclusion by two reviewers (A.H. and R.K.). Differences among reviewers were resolved by 
consulting a third investigator (P.v.d.K.). A pre-designed data extraction form was used by 
the same two reviewers (A.H. and R.K.) to extract and record the data on study character-
istics (both methodological and clinical) from each full-text article. Study characteristics 
included study design, study population, number of participants, duration of treatment, 
primary outcome, side effects, and level of evidence (LoE). LoEs (Table 1) and grading 
recommendations (A–D) (Table 2) were determined according to the Oxford Centre for 
Evidence-based Medicine Levels of Evidence.6 To group and compare different efficacy 
measures the percentages change from baseline in clinical parameters as used in the 
evaluation by the authors, were used. In addition, when percentages were not stated, they 
were calculated by the reviewers whenever possible. Definitions of the safety parameters 
seemed to be poorly standardized. To structure these outcome measures, we tried to use 
the occurrence of local adverse events such as lesional and perilesional reactions and 
adverse drug reactions to compare the incidence rates. 
Table 1  Level of evidence
1a
1b
2a
2b
3a
3b
4
5
Systematic review of RCTs
Individual RCT
Systematic review of cohort studies
Individual cohort study (including low-quality RCT)
Systematic review of case-control studies
Individual case-control study
Case series
Case reports, expert opinion 
RCT, Randomized controlled trial.
Data from the Oxford Centre for Evidence-based Medicine Levels of Evidence.6 
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Results
Screening Results
In total, 128 articles on combinations of topical treatments in general were eligible for 
detailed evaluation according to full-text screening. Of these, 80 articles concerned 
combinations of first-line topicals which are all presented here, as well as the reasons 
for exclusion of 35 articles. Table 3 summarizes the data from the remaining 45 articles. 
To present a comprehensive report on all combinations of first-line topical treatments, 
no selection on study type was used and literature with all grades of evidence will be 
provided in this analysis.
Topical Corticosteroids in Combination with Vitamin D Analogues
Database research revealed 66 publications7-72 on the combined use of corticosteroids 
and vitamin D analogues in chronic plaque psoriasis. Thirty studies were excluded 
because of various reasons: 10 studies were excluded because outcome reports also 
included systemic treatments or involved other types of psoriasis,7-16 eight studies 
because outcome measures were not described or outcomes were not recorded as 
absolute numbers,17-24 five because the treatment regimen was unclear,25-29 four because 
the papers did not reveal original data,30-33 two because demographic data were not 
described,34, 35 and one study because of inconsistent data.36 Eight of the 36 included 
studies concern scalp psoriasis and will be discussed separately. 
 The overall efficacy of this combination has been analyzed for three classes of 
strength of corticosteroids: (i) superpotent, (ii) potent and (iii) low to mid potent cortico-
steroids.73 Furthermore, we made a classification according to the duration of intervention: 
short-term (up to 4 weeks), mid-term (up to 12 weeks), and long-term (> 12 weeks) 
treatment. 
Table 2  Grades of recommendation
A
B
C
D
Studies with consistent LoE 1a and/or 1b (Table 1)
Studies with consistent LoE 2a, 2b, 3a, or 3b; or extrapolations from studies with LOE 1a or 1b
Studies with LoE 4 or extrapolations from studies with LoE 2a, 2b, 3a, or 3b
Studies with LoE 5 or troublingly inconsistent or inconclusive studies of any level  
LoE, Level of Evidence.
Data from the Oxford Centre for Evidence-based Medicine Levels of Evidence.6
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Chronic Plaque Psoriasis 
Table 4 summarizes the overall efficacy of various combinations of vitamin D analogues 
with topical corticosteroids. During the first 2 weeks of treatment all LoE 1b studies included, 
reported an average improvement of ± 40% or more for the superpotent and potent 
corticosteroids combined with vitamin D as separate formulations, as for the two- 
compound formulation. Calcipotriol monotherapy resulted in a similar improvement in 
only half of these studies. This was reconfirmed by the studies with a lower LoE (Table 5). 
 After 4 weeks of treatment, the average improvement reported was above ± 60% in 
all LoE 1b studies for the combinations, except for two studies using gel as vehicle.37, 58 
This improvement was seen in only about half of the studies on monotherapy with potent 
corticosteroids. The studies with lower LoEs reconfirmed the superiority of the combination 
as compared with both monotherapies. 
 Our search only revealed four papers38-41 on the efficacy of long-term treatment. 
Regarding the treatment during more than 12 weeks, efficacy outcomes show a tendency 
towards a superiority of combination therapy compared to either active constituent used 
as a monotherapy. The addition of calcipotriol on weekdays improved the duration of 
remission in patients on pulse therapy with superpotent steroids during weekend days 
only.38, 39 Long-term treatment as needed up to 52 weeks with the two-compound 
formulation of calcipotriol and betamethasone resulted in the maintenance of the trend 
towards a benefit compared with 48 weeks of maintenance treatment with calcipotriol 
ointment following 4 weeks induction treatment with the two-compound product.40, 41 
Several head to head comparative studies have revealed important information:
1 A statistically significant superiority was shown for the combination of superpotent 
steroids and vitamin D analogues as compared to monotherapies.38, 42, 43
2 Both the combinations of clobetasol cream with either calcipotriol ointment or calcitriol 
ointment led to a reduction of clinical parameters, but no significant differences 
between both regimens were found.44 
3 The paper by Ruzicka et al. focusing on the sequential use of a potent steroid during 
weekend days and vitamin D during weekdays showed that this combination therapy 
was significantly more effective in reducing psoriatic symptoms than vitamin D 
monotherapy.45
4 A series of articles investigated the two-compound formulation; combining a potent 
corticosteroid with a vitamin D analogue.46-55, 72 Considering the short-term treatment, 
three randomized controlled trials (RCTs) (LoE 1b) compared the two-compound 
product with either active component alone, and concluded that treatment with the 
two-compound formulation had a significant superior efficacy with a more rapid 
onset of action than treatment with either monotherapy.50, 51, 54 Moreover, once-daily 
treatment was shown to be as effective as twice-daily application. 
5 In a multicentre, double-blind, parallel group study, Kragballe and colleagues56 showed 
that combination therapy of calcipotriol with a potent steroid was significantly more 
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Table 3  Summary of included articles
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Corticosteroids and Vitamin D Analogues
Calzavara-Pinton, 
201262
ROL 20 (20-20) 2b Plaque 1: once daily budesonide 0.25mg/g cream in 
the morning and tacalcitol 4µg/g in the evening 
(Gr1). Plaque 2: once daily calcipotriol 50µg/g 
betamethasone dipropionate 0.5mg/g ointment.
8 weeks,
8 weeks
follow-up
Mean decrease(%) in PSI scores from baseline to 4 weeks / 8 weeks / 12 weeks / 16 weeks:  
50% / 87.5% / 81.3% / 62.5%* vs. 50% / 75% / 75% / 62.5%*. A statistically significant  difference 
in favor of Gr1 was seen at week 4. Most common cutaneous side effects were mild to 
 moderate skin irritation, which occurred in 1/18 lesions in Gr1 and 3/18 lesions in Gr2 (p < 0.05). 
Out of the 20 treated patients, 10 preferred calcipotriol/betamethasone treatment, 6 preferred 
budesonide/tacalcitol treatment and 4 patients had no preferences. 
Hudson, 201171 OL 70 (70) 4 Calcipotriol ointment 3µg/g applied twice daily on 
weekdays. Clobetasol propionate spray 0.05% twice 
daily on weekends.
4 weeks ODS: ‘clear’, ‘almost clear’ or ‘mild’ at week 2 and 4: 69% and 79%. The treatment was well 
 tolerated. After 4 weeks, 51% had no pruritus, 93% had no teleangiectases, 79% had no 
 burning/stinging and 93% had no folliculitis. 
Patel, 201172 RCT 35 (35-35) 2b Patients applied calcipotriene 0.005% / 
betamethasone dipropionate 0.064% on two 
plaques qd. One lesion (plaque 1) was then 
occluded with a hydrogel patch for at least 6 to 8 
hours daily. 
4 weeks,
2 weeks
follow-up
Mean % decrease in mPASI from baseline to 4 weeks: 76.2%* vs. 64.5%* (P=0.008). After 2 weeks 
follow-up, at week 6, mPASI increased with 10.2%* vs. 26.0%* compared to week 4 (p = 0.1249). 
No adverse effects related to the study, including skin irritation, were observed or reported. 
Langley, 201158 RCT 458 (183-184-91) 1b Once daily application of calcipotriol 50µg/g 
betamethasone dipropionate 0.5mg/g gel (Gr1) or 
tacalcitol ointment 4µ/g (Gr2) or gel vehicle alone 
(Gr3).
8 weeks IGA: ‘clear or almost clear’: 39.9% vs. 17.9% vs. 5.5% (p < 0.001 in both comparisons). Mean % 
reduction in PASI at week 8: 57.0% vs. 41.9% vs. 17.9% (p < 0.001 for both). The proportion of 
patients with at least one AE was not significantly different between groups (39.6% vs. 45.1%  
vs. 38.5%). The proportion of patients with at least 1 ADR, mainly pruritus and skin irritation,  
was significantly lower in Gr1 compared to the other groups (8.8% vs. 15.8% vs. 17.6%). 
Fleming, 201037 RCT 364 (162-79-83- 
40)
1b Once daily application of calcipotriol 50µg/g 
betamethasone 0.5mg/g gel (Gr1), betamethasone 
0.5mg/g (Gr2), calcipotriol 50µg/g (Gr3) or gel 
vehicle (Gr4).
8 weeks IGA: ‘clear’ or ‘minimal disease’ at week 4: 16.0% vs. 9.6% vs. 3.8% vs. 2.5% (Gr1 significant better 
than Gr3+4). At week 8: 27.2% vs. 16.9% vs. 11.4% vs. 0.0% (Gr1 significantly better than all other 
groups). Mean % reduction in PASI at week 4/week 8: 48.1%/55.3% vs. 40.9%/49.8% vs. 
32.7%/41.2% vs. 16.9%/11.9%. Proportion pt with at least one AE: 42.5% vs. 48.2% 35.4% vs. 
55.0% (NS). Lesional/perilesional AEs occurred in 7.5% vs. 8.4% vs. 10.1% vs. 25.0%.
Ortonne, 201057 RCT 408 (98-104-104-
102)
1b Once daily treatment with ointment containing 
either calcipotriol 25mcg/g (Gr1), calcipotriol 
25mcg/g plus hydrocortisone 10mg/g (Gr2), 
calcipotriol 50mcg/g (Gr3) or calcipotriol 50mcg/g 
plus hydrocortisone 10mg/g (Gr4).
8 weeks Overall median % decrease in PASI from baseline to EoT: 63.8% vs. 65.4% vs. 59.2% vs. 69.9% 
(NS). The face alone: 78.2% vs. 91.7% vs. 80.0% vs. 91.7%: formulations with hydrocortisone were 
significantly more effective (p < 0.001). IGA overall: ‘absent or very mild disease’: 27.6% vs. 39.4% 
vs. 37.5% vs. 37.3% (NS). IGA face alone: 49.0% vs. 70.2% vs. 64.4% vs. 74.5%; formulations with 
hydrocortisone and the highest concentration calcipotriol were significantly more effective  
(p = 0.001 / 0.036). Proportion of patients ≥ 1 ADR (i.e. erythema, pruritus, and skin irritation) 
was significantly lower in combination groups: 30.9% vs. 18.4% vs. 32.0% vs. 20.8%.
Tyring, 201063 RCT 177 (135-42) 1b Once daily calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g scalp formulation (Gr1) vs. 
vehicle (Gr2). 
8 weeks IGA: ‘cleared’ or ‘minimal disease’: 71.9% vs. 40.5% (p < 0.001). PGA: ‘cleared’ or ‘very mild  disease’: 
62.2% vs. 35.7% (p = 0.004). TSS ≤ 1: 50.4% vs. 23.8% (p = 0.004). Thickness showed that 
 combination therapy was statistically significantly more effective. Redness and scaliness 
 approached statistical significance in favor or the combination therapy. ADRs were reported 
in 7.0% vs. 7.9% of patients (NS).
van der Velden, 
201059
RCT 18 (6-6-6) 2b All patients applied twice daily: calcipotriol 50µg/g 
and betamethasone dipropionate 0.5mg/g 
ointment (Gr1) or calcipotriol 50µg/g in vehicle 
(Gr2) or betamethasone 0.5mg/g (Gr3). 
6 weeks Mean % decrease in SUM score in target lesion at week 1: 56% vs. 18 vs. 21%. At week 4: 61% vs. 
32% vs. 41%. At week 6: 58% vs. 45% vs. 56%.
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Calzavara-Pinton, 
201262
ROL 20 (20-20) 2b Plaque 1: once daily budesonide 0.25mg/g cream in 
the morning and tacalcitol 4µg/g in the evening 
(Gr1). Plaque 2: once daily calcipotriol 50µg/g 
betamethasone dipropionate 0.5mg/g ointment.
8 weeks,
8 weeks
follow-up
Mean decrease(%) in PSI scores from baseline to 4 weeks / 8 weeks / 12 weeks / 16 weeks:  
50% / 87.5% / 81.3% / 62.5%* vs. 50% / 75% / 75% / 62.5%*. A statistically significant  difference 
in favor of Gr1 was seen at week 4. Most common cutaneous side effects were mild to 
 moderate skin irritation, which occurred in 1/18 lesions in Gr1 and 3/18 lesions in Gr2 (p < 0.05). 
Out of the 20 treated patients, 10 preferred calcipotriol/betamethasone treatment, 6 preferred 
budesonide/tacalcitol treatment and 4 patients had no preferences. 
Hudson, 201171 OL 70 (70) 4 Calcipotriol ointment 3µg/g applied twice daily on 
weekdays. Clobetasol propionate spray 0.05% twice 
daily on weekends.
4 weeks ODS: ‘clear’, ‘almost clear’ or ‘mild’ at week 2 and 4: 69% and 79%. The treatment was well 
 tolerated. After 4 weeks, 51% had no pruritus, 93% had no teleangiectases, 79% had no 
 burning/stinging and 93% had no folliculitis. 
Patel, 201172 RCT 35 (35-35) 2b Patients applied calcipotriene 0.005% / 
betamethasone dipropionate 0.064% on two 
plaques qd. One lesion (plaque 1) was then 
occluded with a hydrogel patch for at least 6 to 8 
hours daily. 
4 weeks,
2 weeks
follow-up
Mean % decrease in mPASI from baseline to 4 weeks: 76.2%* vs. 64.5%* (P=0.008). After 2 weeks 
follow-up, at week 6, mPASI increased with 10.2%* vs. 26.0%* compared to week 4 (p = 0.1249). 
No adverse effects related to the study, including skin irritation, were observed or reported. 
Langley, 201158 RCT 458 (183-184-91) 1b Once daily application of calcipotriol 50µg/g 
betamethasone dipropionate 0.5mg/g gel (Gr1) or 
tacalcitol ointment 4µ/g (Gr2) or gel vehicle alone 
(Gr3).
8 weeks IGA: ‘clear or almost clear’: 39.9% vs. 17.9% vs. 5.5% (p < 0.001 in both comparisons). Mean % 
reduction in PASI at week 8: 57.0% vs. 41.9% vs. 17.9% (p < 0.001 for both). The proportion of 
patients with at least one AE was not significantly different between groups (39.6% vs. 45.1%  
vs. 38.5%). The proportion of patients with at least 1 ADR, mainly pruritus and skin irritation,  
was significantly lower in Gr1 compared to the other groups (8.8% vs. 15.8% vs. 17.6%). 
Fleming, 201037 RCT 364 (162-79-83- 
40)
1b Once daily application of calcipotriol 50µg/g 
betamethasone 0.5mg/g gel (Gr1), betamethasone 
0.5mg/g (Gr2), calcipotriol 50µg/g (Gr3) or gel 
vehicle (Gr4).
8 weeks IGA: ‘clear’ or ‘minimal disease’ at week 4: 16.0% vs. 9.6% vs. 3.8% vs. 2.5% (Gr1 significant better 
than Gr3+4). At week 8: 27.2% vs. 16.9% vs. 11.4% vs. 0.0% (Gr1 significantly better than all other 
groups). Mean % reduction in PASI at week 4/week 8: 48.1%/55.3% vs. 40.9%/49.8% vs. 
32.7%/41.2% vs. 16.9%/11.9%. Proportion pt with at least one AE: 42.5% vs. 48.2% 35.4% vs. 
55.0% (NS). Lesional/perilesional AEs occurred in 7.5% vs. 8.4% vs. 10.1% vs. 25.0%.
Ortonne, 201057 RCT 408 (98-104-104-
102)
1b Once daily treatment with ointment containing 
either calcipotriol 25mcg/g (Gr1), calcipotriol 
25mcg/g plus hydrocortisone 10mg/g (Gr2), 
calcipotriol 50mcg/g (Gr3) or calcipotriol 50mcg/g 
plus hydrocortisone 10mg/g (Gr4).
8 weeks Overall median % decrease in PASI from baseline to EoT: 63.8% vs. 65.4% vs. 59.2% vs. 69.9% 
(NS). The face alone: 78.2% vs. 91.7% vs. 80.0% vs. 91.7%: formulations with hydrocortisone were 
significantly more effective (p < 0.001). IGA overall: ‘absent or very mild disease’: 27.6% vs. 39.4% 
vs. 37.5% vs. 37.3% (NS). IGA face alone: 49.0% vs. 70.2% vs. 64.4% vs. 74.5%; formulations with 
hydrocortisone and the highest concentration calcipotriol were significantly more effective  
(p = 0.001 / 0.036). Proportion of patients ≥ 1 ADR (i.e. erythema, pruritus, and skin irritation) 
was significantly lower in combination groups: 30.9% vs. 18.4% vs. 32.0% vs. 20.8%.
Tyring, 201063 RCT 177 (135-42) 1b Once daily calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g scalp formulation (Gr1) vs. 
vehicle (Gr2). 
8 weeks IGA: ‘cleared’ or ‘minimal disease’: 71.9% vs. 40.5% (p < 0.001). PGA: ‘cleared’ or ‘very mild  disease’: 
62.2% vs. 35.7% (p = 0.004). TSS ≤ 1: 50.4% vs. 23.8% (p = 0.004). Thickness showed that 
 combination therapy was statistically significantly more effective. Redness and scaliness 
 approached statistical significance in favor or the combination therapy. ADRs were reported 
in 7.0% vs. 7.9% of patients (NS).
van der Velden, 
201059
RCT 18 (6-6-6) 2b All patients applied twice daily: calcipotriol 50µg/g 
and betamethasone dipropionate 0.5mg/g 
ointment (Gr1) or calcipotriol 50µg/g in vehicle 
(Gr2) or betamethasone 0.5mg/g (Gr3). 
6 weeks Mean % decrease in SUM score in target lesion at week 1: 56% vs. 18 vs. 21%. At week 4: 61% vs. 
32% vs. 41%. At week 6: 58% vs. 45% vs. 56%.
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Menter, 200953 RCT 93 (44-49) 2b Gr1: clobetasol propionate 0.05% spray twice daily 
vs. Gr2: calcipotriene 0.005% betamethasone 
dipropionate 0.064% ointment once daily.
4 weeks,
4 weeks
follow-up
ODS: ‘clear’ or ‘almost clear’ at 4 weeks/8 weeks: 75%/14% vs. 45%/8% (P=0.003/NS). IGA: ‘clear’  
or ‘mild’ at weeks 4/weeks 8: 73%/41% vs. 65%/24%. The proportion of patients with at least  
1 adverse event was 31% vs. 33% (NS). Only 33% and 19% of reported AEs were considered 
possibly, probably or definitely related to treatment in Gr1 or 2, respectively. 
Kragballe,200964 RCT 312 (207-105) 1b Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g scalp formulation qd (Gr1) vs. calcipotriol 
50µg/g scalp formulation bid (Gr2).
8 weeks,
8 weeks
follow-up
IGA: ‘clear’ or ‘minimal disease’ at week 8: 68.6% vs. 31.4% (p < 0.001). PGA: ‘cleared’ or ‘very mild 
disease’ at week 8: 82.1% vs. 34.3% (p < 0.001). TSS ≤ 1 at week 8: 38.6% vs. 10.5% (p < 0.001). 
Proportion of patients with ≥ 1 ADR / ≥ 1 lesional/perilesional AE: 3.4%/3.4% vs. 26.9%/19.2%  
(p < 0.001 for both comparisons). ADRs included pruritus, skin irritation, burning and erythema. 
Relapse/rebound was seen in 54.1%/1.5% vs. 34.5%/0%. 
van de Kerkhof, 
200966
RCT 1417 (568-563- 
286) 
1b Calcipotriol 50µg/g betamethasone dipropionate 
0.5 mg/g scalp formulation qd (Gr1) or 
betamethasone 0.5 mg/g scalp formulation qd 
(Gr2) or calcipotriol 50µg/g scalp formulation qd 
(Gr3).
8 weeks IGA: ‘absence of disease’ or ‘very mild disease’ at week 8: 68.4% vs. 61.0% (p = 0.0079) vs. 43.4%  
(p < 0.0001). Mean % reduction in TSS: 74.4% vs. 67.9% (p = 0.0002) vs. 56.6% (p < 0.0001).  
PGA: ‘clear’ or ‘almost clear’: 69.6% vs. 59.9% (p = 0.0006) vs. 44.7% (p < 0.0001). The proportion 
of patients with at least one AE in Gr1 was similar to that in Gr2 (38.7% vs. 41.0%), while the 
proportion of patients in Gr3 was significantly higher than that in Gr1 (46.1%; p = 0.04). 
Lesional/perilesional AEs, mainly pruritus and skin irritation occurred in 6.2% vs. 5.8% vs. 12.8%.
Buckley, 200865 RCT 218 (108-110) 1b Once daily calcipotriol 50µg/g betamethasone 
0.5mg/g scalp formulation (Gr1) or betamethasone 
dipropionate 0.65 mg/g scalp formulation (Gr2). 
8 weeks The absolute change from baseline in total sign score was significantly greater in Gr1 (P=0.042). 
The percentage change from baseline in TSS was also in favor of Gr1 (NS). IGA: 8.8% more 
patients achieved controlled disease in Gr1. Skin-related drug reactions; mainly pruritus, were 
seen in 6.5% vs. 7.3% (NS).
Luger, 200868 RCT 869 (429-440) 1b Once daily application when required. Gr1: 
calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g scalp formulation vs. Gr2: calcipotriol 
50µg/g in the same vehicle.
52 weeks ADRs/specific AEs such as lesional/perilesional skin irritation reported in 17.2%/11.9% vs. 
29.5%/21.6% (p < 0.001 for both comparisons).  
AEs possibly associated with long-term corticosteroid use were seen in 2.6% vs. 3.0%. 
Satisfactorily controlled disease was reached in 92.3% vs. 80.0% of visits (p > 0.001). 
Jemec, 200867 RCT 1505 (541-556- 
272-136)
1b Once daily application of calcipotriene 50µg/g 
betamethasone dipropionate 0.5mg/g (Gr1), 
betamethasone dipropionate (Gr2), calcipotriene 
(Gr3) or vehicle (Gr4).
8 weeks IGA: ‘absence of disease’ or ‘very mild disease’ at week 8: 71.2% vs. 64.0% (p = 0.011) vs. 36.8%  
(p < 0.0001) vs. 22.8% (p < 0.0001). % reduction in TSS was 70.8% vs. 67.7% (p = 0.12) vs. 49.0%  
(p < 0.0001) vs. 35.6% (p < 0.0001). PGA ‘clear’ or ‘almost clear’: 68.6% vs. 62.5% (p = 0.2) vs. 38.3% 
(p < 0.0001) vs. 20.7% (p < 0.0001). The proportion of patients with at least one AE in Gr1 was 
similar to that in Gr2 (34.5% vs. 34.9%), significantly smaller than that in Gr3 (46.2%; p = 0.0014), 
and smaller than in Gr4 (40%; p = 0.24). Lesional/perilesional AEs, mainly pruritus and skin 
irritation, was seen in 4.7% vs. 5.3% vs. 13.2% vs. 13.3%. 
Cassano, 200769 OL 25 (25) 4 Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g ointment qd for 2 weeks. Calcipotriol 
50µg/g betamethasone dipropionate 0.5mg/g qd 
and calcipotriol 0.005% bid on alternate days for  
4 weeks.
2 weeks
and
4 weeks
Mean % reduction in total score from baseline to week 2 and week 6: 57.8% and 68.7%*  
(p < 0.05 for each evaluation). Proportion of patients that judged the efficacy / acceptability of 
the treatment as ‘good’ or ‘excellent’: 76% / 40%. 
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Menter, 200953 RCT 93 (44-49) 2b Gr1: clobetasol propionate 0.05% spray twice daily 
vs. Gr2: calcipotriene 0.005% betamethasone 
dipropionate 0.064% ointment once daily.
4 weeks,
4 weeks
follow-up
ODS: ‘clear’ or ‘almost clear’ at 4 weeks/8 weeks: 75%/14% vs. 45%/8% (P=0.003/NS). IGA: ‘clear’  
or ‘mild’ at weeks 4/weeks 8: 73%/41% vs. 65%/24%. The proportion of patients with at least  
1 adverse event was 31% vs. 33% (NS). Only 33% and 19% of reported AEs were considered 
possibly, probably or definitely related to treatment in Gr1 or 2, respectively. 
Kragballe,200964 RCT 312 (207-105) 1b Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g scalp formulation qd (Gr1) vs. calcipotriol 
50µg/g scalp formulation bid (Gr2).
8 weeks,
8 weeks
follow-up
IGA: ‘clear’ or ‘minimal disease’ at week 8: 68.6% vs. 31.4% (p < 0.001). PGA: ‘cleared’ or ‘very mild 
disease’ at week 8: 82.1% vs. 34.3% (p < 0.001). TSS ≤ 1 at week 8: 38.6% vs. 10.5% (p < 0.001). 
Proportion of patients with ≥ 1 ADR / ≥ 1 lesional/perilesional AE: 3.4%/3.4% vs. 26.9%/19.2%  
(p < 0.001 for both comparisons). ADRs included pruritus, skin irritation, burning and erythema. 
Relapse/rebound was seen in 54.1%/1.5% vs. 34.5%/0%. 
van de Kerkhof, 
200966
RCT 1417 (568-563- 
286) 
1b Calcipotriol 50µg/g betamethasone dipropionate 
0.5 mg/g scalp formulation qd (Gr1) or 
betamethasone 0.5 mg/g scalp formulation qd 
(Gr2) or calcipotriol 50µg/g scalp formulation qd 
(Gr3).
8 weeks IGA: ‘absence of disease’ or ‘very mild disease’ at week 8: 68.4% vs. 61.0% (p = 0.0079) vs. 43.4%  
(p < 0.0001). Mean % reduction in TSS: 74.4% vs. 67.9% (p = 0.0002) vs. 56.6% (p < 0.0001).  
PGA: ‘clear’ or ‘almost clear’: 69.6% vs. 59.9% (p = 0.0006) vs. 44.7% (p < 0.0001). The proportion 
of patients with at least one AE in Gr1 was similar to that in Gr2 (38.7% vs. 41.0%), while the 
proportion of patients in Gr3 was significantly higher than that in Gr1 (46.1%; p = 0.04). 
Lesional/perilesional AEs, mainly pruritus and skin irritation occurred in 6.2% vs. 5.8% vs. 12.8%.
Buckley, 200865 RCT 218 (108-110) 1b Once daily calcipotriol 50µg/g betamethasone 
0.5mg/g scalp formulation (Gr1) or betamethasone 
dipropionate 0.65 mg/g scalp formulation (Gr2). 
8 weeks The absolute change from baseline in total sign score was significantly greater in Gr1 (P=0.042). 
The percentage change from baseline in TSS was also in favor of Gr1 (NS). IGA: 8.8% more 
patients achieved controlled disease in Gr1. Skin-related drug reactions; mainly pruritus, were 
seen in 6.5% vs. 7.3% (NS).
Luger, 200868 RCT 869 (429-440) 1b Once daily application when required. Gr1: 
calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g scalp formulation vs. Gr2: calcipotriol 
50µg/g in the same vehicle.
52 weeks ADRs/specific AEs such as lesional/perilesional skin irritation reported in 17.2%/11.9% vs. 
29.5%/21.6% (p < 0.001 for both comparisons).  
AEs possibly associated with long-term corticosteroid use were seen in 2.6% vs. 3.0%. 
Satisfactorily controlled disease was reached in 92.3% vs. 80.0% of visits (p > 0.001). 
Jemec, 200867 RCT 1505 (541-556- 
272-136)
1b Once daily application of calcipotriene 50µg/g 
betamethasone dipropionate 0.5mg/g (Gr1), 
betamethasone dipropionate (Gr2), calcipotriene 
(Gr3) or vehicle (Gr4).
8 weeks IGA: ‘absence of disease’ or ‘very mild disease’ at week 8: 71.2% vs. 64.0% (p = 0.011) vs. 36.8%  
(p < 0.0001) vs. 22.8% (p < 0.0001). % reduction in TSS was 70.8% vs. 67.7% (p = 0.12) vs. 49.0%  
(p < 0.0001) vs. 35.6% (p < 0.0001). PGA ‘clear’ or ‘almost clear’: 68.6% vs. 62.5% (p = 0.2) vs. 38.3% 
(p < 0.0001) vs. 20.7% (p < 0.0001). The proportion of patients with at least one AE in Gr1 was 
similar to that in Gr2 (34.5% vs. 34.9%), significantly smaller than that in Gr3 (46.2%; p = 0.0014), 
and smaller than in Gr4 (40%; p = 0.24). Lesional/perilesional AEs, mainly pruritus and skin 
irritation, was seen in 4.7% vs. 5.3% vs. 13.2% vs. 13.3%. 
Cassano, 200769 OL 25 (25) 4 Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g ointment qd for 2 weeks. Calcipotriol 
50µg/g betamethasone dipropionate 0.5mg/g qd 
and calcipotriol 0.005% bid on alternate days for  
4 weeks.
2 weeks
and
4 weeks
Mean % reduction in total score from baseline to week 2 and week 6: 57.8% and 68.7%*  
(p < 0.05 for each evaluation). Proportion of patients that judged the efficacy / acceptability of 
the treatment as ‘good’ or ‘excellent’: 76% / 40%. 
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Saraceno, 200746 ROL 150 (75-75) 2b Calcipotriol 50µg/g betamethasone 0.5mg/g cream 
qd (Gr1) vs. calcipotriol 50µg/g cream bid (Gr2).
4 weeks Mean reduction in PASI after 4 weeks: 73.7% vs. 55.3% (p = 0.001)*. AEs (i.e. erythema, burning 
etc) were reported in 7 out of 75 (9.3%) vs. 8 out of 75 patients (10.7%) in Gr1 and 2, 
respectively. QoL assessments revealed a significantly superior improvement in Gr1 (p < 0.001).
Cassano, 200647 OL  109 (109) 4 Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g two-compound ointment qd.
4 weeks Mean % reduction in PASI and pruritus score from baseline to 4 weeks: 71.3% and 71.2%  
(p < 0.001 for both parameters). 89% of patients judged the efficacy as being good or excellent. 
Treatment was very well tolerated, with a limited number of local AEs reported, that were 
transient and of mild intensity. 92%* of patients judged the acceptability as being good or 
excellent.
Downs, 200670 OL 10 (10) 4 Once daily calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g ointment under occlusion 
overnight.
4 weeks % clearance in extent of scalp psoriasis at week 1/week 4: 50%/70%. % clearance of itch at week 
1/week 4: 80%/100%. No side effects were noted, except difficulty in washing out the ointment 
from long hair. 
Erceg, 200648 OL 8 (8-8) 4 Plaque 1: calcipotriol 50µg/g plus betamethasone 
dipropionate 0.5mg/g ointment qd. Plaque2: PDL 
on week 0, 2 and 4.
4 weeks,
8 weeks
follow-up
After 4 weeks no significant change had been observed in SUM scores. At week 12 reduction in 
SUM score was 19% in the combination group vs. 62% in the PDL group (p < 0.05). Pain at the 
treated site was reported as the major side effect of PDL therapy.
Koo, 200638 RCT 86 (44-21-21) 2b Phase 1: Gr1; clobetasol foam 0.05% plus 
calcipotriene ointment 0.005% or either agent as 
monotherapy bid (Gr2 + 3 respectively). Phase 2: 
weekday calcipotriene plus weekend pulse therapy 
with either clobetasol foam (Gr1) or vehicle (Gr2).
2 weeks
and
6 months
Mean % reduction of SUM score of trunk lesions at week 2: 69.3% vs. 48.1% vs. 36.6% (p = 0.005 
/ p < 0.0001). Mean % reduction of extremity lesion scores: 70.1% vs. 40.5% vs. 31.1%. At week 2 
the IGA showed a significant improvement for Gr1 compared to Gr2 (p = 0.008) and Gr3 (p = 
0.0001). After 6 months a consistent trend toward greater maintenance of remission was seen 
in Gr1 compared to Gr2 (92% improvement vs. 62%).
Kragballe,  
200640, 41
RCT 634 (212-213-209) 1b Gr1: calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g. Gr2: altering 4 weeks periods 
of the two-compound product and calcipotriol 
ointment. Gr3: 4 weeks two-compound product 
followed by 48 weeks calcipotriol 50µg/g. 
Treatments were used once daily when required.
52 weeks IGA: ‘absent’, ‘very mild’ or ‘mild disease’ at week 52: 35.8% vs. 27.7% vs. 24.4% (p = 0.025 between 
Gr1 and 3. Difference between Gr2 and 1 or 3 was NS). PGA: 100% satisfaction: 37.7% vs. 28.6% 
vs. 28.7% (p = 0.061 / p = 0.036). It was concluded that there was a trend in favor of Gr1 
compared to Gr3 for the overall treatment effect. The proportion of patients ≥ 1 ADR: 21.7% vs. 
29.6% vs. 37.9%. OR for ADR in Gr1 relative to Gr3 was 0.46 (95% CI: 0.30-0.70. p < 0.001). 
Differences between the other groups were NS. Adjudicated corticosteroid reactions were seen 
in 4.8% vs. 2.8% vs. 2.9%.
White, 200655 RCT 1136 (383-377- 
376)
1b Initial phase: all patients applied calcipotriene/
betamethasone dipropionate qd for 4 weeks. 
Maintenance phase: qd calcipotriene cream (Gr1) or 
calcipotriene cream on weekdays and the 
two-compound product on weekends (Gr2) or 
vehicle (Gr3).
4 weeks
and
8 weeks
Mean % reduction in PASI from baseline to 4 weeks: 64.1% vs. 63.9% vs. 65.0%. From baseline to 
EoT: 44.5% vs. 58.4% vs. 33.1%. AEs/ADRs were reported in 40.4%/11.3% vs. 36.8%/7.6% vs. 
36.7%/8.6% of patients. No significant difference in the incidence of ADRs was found. ADRs with 
the highest incidence were psoriasis, rash scaly, and ADRs associated with irritation of the skin. 
Kragballe, 200460 RCT 972 (322-323-327) 1b Gr1: 8 weeks calcipotriol 50µg/g plus 
betamethasone dipropionate 0.5mg/g ointment qd 
followed by 4 weeks calcipotriol qd. Gr2: 4 weeks 
combination therapy qd, followed by 8 weeks 
weekday calcipotriol and weekend two-compound 
product. Gr3: calcipotriol bid.
12 weeks Mean % reduction in PASI from baseline to 8 weeks: 73.3% vs. 68.2% vs. 64.1%. IGA: ‘absent’  
or ‘very mild disease’ at week 8: 55.3% vs. 47.7% vs. 40.7%. (Gr1 was significantly superior to  
Gr2 and 3 for both parameters, whereas Gr2 was NS different). AEs/ADRs were reported by 
43.5%/10.9% vs. 45.7%/11.5% vs. 53.2%/22.3%. The most frequently reported lesional/
perilesional ADR in all groups was pruritus. 
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Saraceno, 200746 ROL 150 (75-75) 2b Calcipotriol 50µg/g betamethasone 0.5mg/g cream 
qd (Gr1) vs. calcipotriol 50µg/g cream bid (Gr2).
4 weeks Mean reduction in PASI after 4 weeks: 73.7% vs. 55.3% (p = 0.001)*. AEs (i.e. erythema, burning 
etc) were reported in 7 out of 75 (9.3%) vs. 8 out of 75 patients (10.7%) in Gr1 and 2, 
respectively. QoL assessments revealed a significantly superior improvement in Gr1 (p < 0.001).
Cassano, 200647 OL  109 (109) 4 Calcipotriol 50µg/g betamethasone dipropionate 
0.5mg/g two-compound ointment qd.
4 weeks Mean % reduction in PASI and pruritus score from baseline to 4 weeks: 71.3% and 71.2%  
(p < 0.001 for both parameters). 89% of patients judged the efficacy as being good or excellent. 
Treatment was very well tolerated, with a limited number of local AEs reported, that were 
transient and of mild intensity. 92%* of patients judged the acceptability as being good or 
excellent.
Downs, 200670 OL 10 (10) 4 Once daily calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g ointment under occlusion 
overnight.
4 weeks % clearance in extent of scalp psoriasis at week 1/week 4: 50%/70%. % clearance of itch at week 
1/week 4: 80%/100%. No side effects were noted, except difficulty in washing out the ointment 
from long hair. 
Erceg, 200648 OL 8 (8-8) 4 Plaque 1: calcipotriol 50µg/g plus betamethasone 
dipropionate 0.5mg/g ointment qd. Plaque2: PDL 
on week 0, 2 and 4.
4 weeks,
8 weeks
follow-up
After 4 weeks no significant change had been observed in SUM scores. At week 12 reduction in 
SUM score was 19% in the combination group vs. 62% in the PDL group (p < 0.05). Pain at the 
treated site was reported as the major side effect of PDL therapy.
Koo, 200638 RCT 86 (44-21-21) 2b Phase 1: Gr1; clobetasol foam 0.05% plus 
calcipotriene ointment 0.005% or either agent as 
monotherapy bid (Gr2 + 3 respectively). Phase 2: 
weekday calcipotriene plus weekend pulse therapy 
with either clobetasol foam (Gr1) or vehicle (Gr2).
2 weeks
and
6 months
Mean % reduction of SUM score of trunk lesions at week 2: 69.3% vs. 48.1% vs. 36.6% (p = 0.005 
/ p < 0.0001). Mean % reduction of extremity lesion scores: 70.1% vs. 40.5% vs. 31.1%. At week 2 
the IGA showed a significant improvement for Gr1 compared to Gr2 (p = 0.008) and Gr3 (p = 
0.0001). After 6 months a consistent trend toward greater maintenance of remission was seen 
in Gr1 compared to Gr2 (92% improvement vs. 62%).
Kragballe,  
200640, 41
RCT 634 (212-213-209) 1b Gr1: calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g. Gr2: altering 4 weeks periods 
of the two-compound product and calcipotriol 
ointment. Gr3: 4 weeks two-compound product 
followed by 48 weeks calcipotriol 50µg/g. 
Treatments were used once daily when required.
52 weeks IGA: ‘absent’, ‘very mild’ or ‘mild disease’ at week 52: 35.8% vs. 27.7% vs. 24.4% (p = 0.025 between 
Gr1 and 3. Difference between Gr2 and 1 or 3 was NS). PGA: 100% satisfaction: 37.7% vs. 28.6% 
vs. 28.7% (p = 0.061 / p = 0.036). It was concluded that there was a trend in favor of Gr1 
compared to Gr3 for the overall treatment effect. The proportion of patients ≥ 1 ADR: 21.7% vs. 
29.6% vs. 37.9%. OR for ADR in Gr1 relative to Gr3 was 0.46 (95% CI: 0.30-0.70. p < 0.001). 
Differences between the other groups were NS. Adjudicated corticosteroid reactions were seen 
in 4.8% vs. 2.8% vs. 2.9%.
White, 200655 RCT 1136 (383-377- 
376)
1b Initial phase: all patients applied calcipotriene/
betamethasone dipropionate qd for 4 weeks. 
Maintenance phase: qd calcipotriene cream (Gr1) or 
calcipotriene cream on weekdays and the 
two-compound product on weekends (Gr2) or 
vehicle (Gr3).
4 weeks
and
8 weeks
Mean % reduction in PASI from baseline to 4 weeks: 64.1% vs. 63.9% vs. 65.0%. From baseline to 
EoT: 44.5% vs. 58.4% vs. 33.1%. AEs/ADRs were reported in 40.4%/11.3% vs. 36.8%/7.6% vs. 
36.7%/8.6% of patients. No significant difference in the incidence of ADRs was found. ADRs with 
the highest incidence were psoriasis, rash scaly, and ADRs associated with irritation of the skin. 
Kragballe, 200460 RCT 972 (322-323-327) 1b Gr1: 8 weeks calcipotriol 50µg/g plus 
betamethasone dipropionate 0.5mg/g ointment qd 
followed by 4 weeks calcipotriol qd. Gr2: 4 weeks 
combination therapy qd, followed by 8 weeks 
weekday calcipotriol and weekend two-compound 
product. Gr3: calcipotriol bid.
12 weeks Mean % reduction in PASI from baseline to 8 weeks: 73.3% vs. 68.2% vs. 64.1%. IGA: ‘absent’  
or ‘very mild disease’ at week 8: 55.3% vs. 47.7% vs. 40.7%. (Gr1 was significantly superior to  
Gr2 and 3 for both parameters, whereas Gr2 was NS different). AEs/ADRs were reported by 
43.5%/10.9% vs. 45.7%/11.5% vs. 53.2%/22.3%. The most frequently reported lesional/
perilesional ADR in all groups was pruritus. 
66
CHAPTER 2.2
Table 3  Continued
Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Corticosteroids and Vitamin D Analogues
Ortonne, 200449 RCT 501 (249-252) 1b Once daily treatment with calcipotriol 50µg/g plus 
betamethasone dipropionate 0.5mg/g ointment 
(Gr1) or tacalcitol (Gr2).
4 weeks Mean % reduction in PASI from baseline to 4 weeks: 65.0% vs. 33.3% (p < 0.001). Investigator / 
patient assessment of treatment efficacy: ‘clearance’ or ‘marked improvement’: 57.6%/58.4% vs. 
17.0%/17.4% (p < 0.001). AEs (mainly skin and subcutaneous tissue disorders and infections)/
ADRs (lesional and perilesional cutaneous reactions) were reported in 16.3%/2.9% vs. 
26.8%/11.8% (p = 0.005 / < 0.001).
Katoh, 200342 RCT 61 (32-29) 2b Gr1: once daily 0.005% calcipotriol ointment. Gr2: 
once daily 0.004%calcipotriol plus 0.01% clobetasol 
propionate ointment.
12 weeks SUM scores were lower in the combination group after 12 weeks. After 2 weeks the proportion 
of patients with at least 50% reduction in eruption score was 30% vs. 62.1% (p = 0.0268). Local 
irritation was seen in 28.1% vs. 0.03%. AEs occurred less frequently in the combination group  
(p < 0.0001).
Lahfa, 200344 RCT 125 (61-64) 1b All patients applied clobetasol propionate 0.05% 
cream once in the morning and calcitriol 3µg/g 
ointment (Gr1) or calcipotriol 50µg/g ointment 
(Gr2) once in the evening.
2 weeks Global improvement scores*: ‘clear’ or ‘almost clear’ at week 2/week 4: 14.8%/49.2% vs. 
30.2%/54.7% (NS). Mean reduction in PASI at week 2/week 4: 56.0%/71.8% vs. 62.9%/78.7% (NS). 
Dermatological events (ADRs) were seen in 6.6% vs. 4.7% of the patients (NS).
Papp, 200354 RCT 1033 (304-308-
313-108)
1b Twice daily application of calcipotriene 50µg/g plus 
betamethasone dipropionate 0.5 mg/g (Gr1), 
calcipotriene (Gr2), betamethasone (Gr3) or vehicle 
(Gr4).
4 weeks Mean % reduction in PASI from baseline to 4 weeks: 73.2% vs. 48.8% vs. 63.1% vs. 28.8%. Gr1 was 
significantly superior to the other groups (p < 0.001 for all comparisons). Combination therapy 
produced a more rapid onset of action than the individual treatments. IGA: ‘clearance’ or 
‘marked improvement’: 76.1% vs. 33.4% vs. 55.8% vs. 7.5% (p < 0.001 for each comparison in 
favour of Gr1). AEs/ARs (i.e. lesional and perilesional adverse reactions) were reported in 
29.6%/9.9% vs. 38.3%/17.2% vs. 28.8%/8.6% vs. 31.5%/15.7%. Significantly more AEs/ARs were 
reported in Gr2 compared to Gr1 and 3.
Kaufmann, 200250 RCT 1603 (490-476- 
480-157)
1b Gr1: calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g. Gr2: betamethasone 
dipropionate 0.5mg/g. Gr3: calcipotriol 50µg/g. Gr4: 
vehicle. All applied once daily.
4 weeks Mean % reduction in PASI from baseline to EoT: 71.3% vs. 57.2% vs. 46.1% vs. 22.7%. Gr1 was 
significantly superior to all other groups (p < 0.001 for all comparisons). IGA: ‘absence of disease’ 
or ‘very mild disease’: 56.3% vs. 37.0% vs. 22.3% vs. 10.2%. AEs/ARs (i.e. local cutaneous events) 
were reported in 24.3%/6.0% vs. 24.7%/4.9% vs. 33.1%/11.4% vs. 34.4%/13.6%. Differences 
between Gr1 and 2 were NS. Gr1 was significantly superior to Gr3 and 4. The most common 
lesional/perilesional adverse reaction in all groups was pruritus. 
Douglas, 200251 RCT 1106 (372-365- 
369)
1b Gr1: calcipotriol 50µg/g betamethasone 0.5mg/g 
ointment. Gr2: betamethasone 0.5mg/g ointment. 
Gr3: calcipotriol 50µg/g ointment. All applied  
twice daily.
4 weeks Mean % reduction in PASI from baseline to EoT: 74.4% vs. 61.3% vs. 55.3%. Gr1 was significantly 
superior to all other groups (p < 0.001). AEs/ARs (i.e. lesional/perilesional adverse reactions) 
were reported in 26.8%/8.1% vs. 32.1%/4.7% vs. 35.5%/12.0% of patients.
Guenther, 200252 RCT 828 (152-237- 
231-208)
1b Calcipotriol 50µg/g plus betamethasone 
dipropionate 0.5 mg/g ointment used twice daily 
(Gr2) or once daily plus vehicle once daily (Gr1). Gr3: 
twice daily calcipotriol. Gr4: twice daily vehicle.
4 weeks Mean % reduction in PASI at 4 weeks: 68.6% vs. 73.8% (NS) vs. 58.8% vs. 26.6% (p < 0.001 for 
both comparisons between Gr1 vs. Gr3 and Gr4). Mean % PASI reduction in Gr2 was greater 
than in Gr3 and 4 (P<0.001). IGA/PGA: ‘clearance’ or ‘marked improvement’: 63.3%/65.3% vs. 
73.5%/70.1% vs. 50.7%/51.5% vs. 9.2%/12.6%. Lesional/perilesional ARs, mainly pruritus, were 
seen in 9.9% vs. 10.6% vs. 19.8% vs. 12.5%.
Salmhofer, 200061 RCT 63 (63-63) 2b Twice daily calcipotriol 0.005% ointment on one 
side of the body (Gr1). On the other side (Gr2): 
calcipotriol 0.005% ointment in the morning and 
diflucortolone valerate 0.1% in the evening.
4 weeks,
4 weeks
follow-up
Mean PASI reduction after 1 week/2 weeks showed a significant benefit in Gr2 (P<0.05): 
42.1%/57.9% vs. 47.4%/63.2%*. Differences in mean PASI reduction after 4 weeks (66.7% vs. 
68.4%*) and during follow-up period were NS. Side effects (e.g. itching and burning) tended to 
be milder and to occur later with combination therapy, but differences were NS.
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Ortonne, 200449 RCT 501 (249-252) 1b Once daily treatment with calcipotriol 50µg/g plus 
betamethasone dipropionate 0.5mg/g ointment 
(Gr1) or tacalcitol (Gr2).
4 weeks Mean % reduction in PASI from baseline to 4 weeks: 65.0% vs. 33.3% (p < 0.001). Investigator / 
patient assessment of treatment efficacy: ‘clearance’ or ‘marked improvement’: 57.6%/58.4% vs. 
17.0%/17.4% (p < 0.001). AEs (mainly skin and subcutaneous tissue disorders and infections)/
ADRs (lesional and perilesional cutaneous reactions) were reported in 16.3%/2.9% vs. 
26.8%/11.8% (p = 0.005 / < 0.001).
Katoh, 200342 RCT 61 (32-29) 2b Gr1: once daily 0.005% calcipotriol ointment. Gr2: 
once daily 0.004%calcipotriol plus 0.01% clobetasol 
propionate ointment.
12 weeks SUM scores were lower in the combination group after 12 weeks. After 2 weeks the proportion 
of patients with at least 50% reduction in eruption score was 30% vs. 62.1% (p = 0.0268). Local 
irritation was seen in 28.1% vs. 0.03%. AEs occurred less frequently in the combination group  
(p < 0.0001).
Lahfa, 200344 RCT 125 (61-64) 1b All patients applied clobetasol propionate 0.05% 
cream once in the morning and calcitriol 3µg/g 
ointment (Gr1) or calcipotriol 50µg/g ointment 
(Gr2) once in the evening.
2 weeks Global improvement scores*: ‘clear’ or ‘almost clear’ at week 2/week 4: 14.8%/49.2% vs. 
30.2%/54.7% (NS). Mean reduction in PASI at week 2/week 4: 56.0%/71.8% vs. 62.9%/78.7% (NS). 
Dermatological events (ADRs) were seen in 6.6% vs. 4.7% of the patients (NS).
Papp, 200354 RCT 1033 (304-308-
313-108)
1b Twice daily application of calcipotriene 50µg/g plus 
betamethasone dipropionate 0.5 mg/g (Gr1), 
calcipotriene (Gr2), betamethasone (Gr3) or vehicle 
(Gr4).
4 weeks Mean % reduction in PASI from baseline to 4 weeks: 73.2% vs. 48.8% vs. 63.1% vs. 28.8%. Gr1 was 
significantly superior to the other groups (p < 0.001 for all comparisons). Combination therapy 
produced a more rapid onset of action than the individual treatments. IGA: ‘clearance’ or 
‘marked improvement’: 76.1% vs. 33.4% vs. 55.8% vs. 7.5% (p < 0.001 for each comparison in 
favour of Gr1). AEs/ARs (i.e. lesional and perilesional adverse reactions) were reported in 
29.6%/9.9% vs. 38.3%/17.2% vs. 28.8%/8.6% vs. 31.5%/15.7%. Significantly more AEs/ARs were 
reported in Gr2 compared to Gr1 and 3.
Kaufmann, 200250 RCT 1603 (490-476- 
480-157)
1b Gr1: calcipotriol 50µg/g betamethasone 
dipropionate 0.5mg/g. Gr2: betamethasone 
dipropionate 0.5mg/g. Gr3: calcipotriol 50µg/g. Gr4: 
vehicle. All applied once daily.
4 weeks Mean % reduction in PASI from baseline to EoT: 71.3% vs. 57.2% vs. 46.1% vs. 22.7%. Gr1 was 
significantly superior to all other groups (p < 0.001 for all comparisons). IGA: ‘absence of disease’ 
or ‘very mild disease’: 56.3% vs. 37.0% vs. 22.3% vs. 10.2%. AEs/ARs (i.e. local cutaneous events) 
were reported in 24.3%/6.0% vs. 24.7%/4.9% vs. 33.1%/11.4% vs. 34.4%/13.6%. Differences 
between Gr1 and 2 were NS. Gr1 was significantly superior to Gr3 and 4. The most common 
lesional/perilesional adverse reaction in all groups was pruritus. 
Douglas, 200251 RCT 1106 (372-365- 
369)
1b Gr1: calcipotriol 50µg/g betamethasone 0.5mg/g 
ointment. Gr2: betamethasone 0.5mg/g ointment. 
Gr3: calcipotriol 50µg/g ointment. All applied  
twice daily.
4 weeks Mean % reduction in PASI from baseline to EoT: 74.4% vs. 61.3% vs. 55.3%. Gr1 was significantly 
superior to all other groups (p < 0.001). AEs/ARs (i.e. lesional/perilesional adverse reactions) 
were reported in 26.8%/8.1% vs. 32.1%/4.7% vs. 35.5%/12.0% of patients.
Guenther, 200252 RCT 828 (152-237- 
231-208)
1b Calcipotriol 50µg/g plus betamethasone 
dipropionate 0.5 mg/g ointment used twice daily 
(Gr2) or once daily plus vehicle once daily (Gr1). Gr3: 
twice daily calcipotriol. Gr4: twice daily vehicle.
4 weeks Mean % reduction in PASI at 4 weeks: 68.6% vs. 73.8% (NS) vs. 58.8% vs. 26.6% (p < 0.001 for 
both comparisons between Gr1 vs. Gr3 and Gr4). Mean % PASI reduction in Gr2 was greater 
than in Gr3 and 4 (P<0.001). IGA/PGA: ‘clearance’ or ‘marked improvement’: 63.3%/65.3% vs. 
73.5%/70.1% vs. 50.7%/51.5% vs. 9.2%/12.6%. Lesional/perilesional ARs, mainly pruritus, were 
seen in 9.9% vs. 10.6% vs. 19.8% vs. 12.5%.
Salmhofer, 200061 RCT 63 (63-63) 2b Twice daily calcipotriol 0.005% ointment on one 
side of the body (Gr1). On the other side (Gr2): 
calcipotriol 0.005% ointment in the morning and 
diflucortolone valerate 0.1% in the evening.
4 weeks,
4 weeks
follow-up
Mean PASI reduction after 1 week/2 weeks showed a significant benefit in Gr2 (P<0.05): 
42.1%/57.9% vs. 47.4%/63.2%*. Differences in mean PASI reduction after 4 weeks (66.7% vs. 
68.4%*) and during follow-up period were NS. Side effects (e.g. itching and burning) tended to 
be milder and to occur later with combination therapy, but differences were NS.
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Kragballe, 199856 RCT 699 (174-174- 
175-176)
1b All patients applied calcipotriol cream 50µg/g in the 
morning and either vehicle (Gr1), calcipotriol 
50µg/g (Gr2), clobetasone 17-butyrate 0.5mg/g 
(Gr3) or betamethasone-17-valerate 1mg/g (Gr4) 
creams in the evening.
8 weeks Mean % reduction in PASI was 40.6% vs. 48.3 % vs. 53.7% vs. 57.5%. Gr1 was less effective than 
the other groups (p = 0.006). Gr2 was as effective as Gr3. and Gr3 as Gr4. And Gr4 was more 
effective than Gr2. IGA: ‘clearance’ or ‘marked improvement’: 28.5% vs. 40.2% vs. 42.5% vs. 54.0% 
(NS). PGA ‘clearance’ or ‘marked improvement’: 26.6% vs. 40.1% vs. 40.1% vs. 51.2%. Gr1 was 
inferior and Gr4 superior to the two other treatments (p = 0.04). The most frequent AE was skin 
irritation which was reported significantly less frequently in the combination groups (31.2% vs. 
34.3% vs. 23.8% vs. 17.1% (p = 0.001)).
Lebwohl, 199839 RCT 40 (20-20) 2b All patients applied calcipotriene 0.005% ointment 
in the morning and halobetasol 0.05% in the evening. 
After 2 weeks all patients applied halobetasol twice 
daily on weekends and calcipotriene (Gr1) or 
placebo ointment (Gr2) twice daily on weekdays.
2 weeks,
6 months
follow-up
In Gr1, 76% of patients were able to maintain remission for 6 months compared with 40.0%  
in Gr2 (p = 0.045). Scaling (p = 0.02), plaque thickness (p = 0.01), overall severity (p = 0.02) and 
global assessment (p = 0.01) were significantly different between groups in favor of Gr1. AEs 
consisted of an irritant contact dermatitis, were mild and developed in 4 patients vs. 1 patient.
Ruzicka, 199845 RCT 169 (87-82) 1b All patients applied calcipotriol cream 0.005% 
ointment twice daily. After 2 weeks Gr1: calcipotriol 
twice daily and Gr2: calcipotriol in the morning and 
betamethasone valerate 0.1% ointment in the 
evening.
4 weeks,
8 weeks
follow-up
Mean % reduction in PASI after 4 weeks; 45.7% vs. 68.8% (p = 0.0001)*. Mean PASI reduction 
after 8 weeks follow-up: 2.7% vs. 25.0%* (NS). IGA ‘complete healing’ or ‘distinct improvement’: 
60.5% vs. 77%. Local AEs were reported in 15% vs. 7%. The most frequently reported local AEs 
were erythema, burning and pruritus.
Lebwohl, 199643 CT 127 (42-42-43) 2b Gr1: once daily calcipotriene 0.005% ointment and 
halobetasol 0.05% ointment. Gr2: twice daily 
calcipotriene 0.005% ointment. Gr3: twice daily 
halobetasol 0.05% ointment.
2 weeks ODS was significant lower in Gr1 compared to Gr2 and 3 (p < 0.001, p = 0.017, respectively). IGA: 
‘clear’ or ‘almost clear’: 71% vs. 30% vs. 57% (p < 0.001 and NS, respectively). Mean scores for 
plaque elevation for Gr1 were significantly superior to those for Gr2 and 3. Gr1 was significantly 
superior to Gr2 for mean erythema and scaling, but not to Gr3. Local cutaneous AEs (i.e. pruritus, 
burning skin etc.) were reported less frequently in Gr1.
Retinoids plus Corticosteroids
Green, 200276 RCT 259 (92-29-29- 
29-27-28-25)
2b All patients applied tazarotene 0.1% in the evening. 
Gr2 to Gr7 applied fluocinonide 0.05%, 
mometasone furoate 0.1%, diflorasone diacetate 
ointments, betamethasone dipropionate 0.05% 
cream, fluticasone propionate 0.005% ointment, 
and diflorasone diacetate 0.05% cream respectively 
in the morning.
12 weeks Mean % reduction in overall evaluation score: 20%, 41%, 38%, and 50%, for Gr1, 3, 4, and 5, 
respectively. At week 12 ≥ 50% global improvement was achieved by 35% vs. 48% vs. 66% vs. 
55% vs. 78% vs. 57% vs. 44% in Gr1 to 7, respectively. ADRs were reported in 40% vs. 34% vs. 
17% vs. 21% vs. 33% vs. 29% vs. 32%. Most common reported ADRs involved skin reactions such 
as irritation, erythema, pruritus, and burning, and were predominantly of mild or moderate 
severity. 
Lebwohl, 200177 OL 
RCT
50 (17-17-16; 
unpublished data)
4
2b
Initial phase: tapering doses of tazarotene 0.1% gel 
plus clobetasol propionate 0.05% ointment. 
Maintenance phase: Gr1: tazarotene plus clobetasol. 
Gr2: tazarotene plus vehicle. Gr3: vehicle plus 
petroleum. (Component named first was applied 
on Monday, Wednesday, and Friday mornings, the 
second on Tuesday and Thursday evenings).
6 weeks
and
20 weeks
At week 6 100% of patients achieved ≤ 50% global improvement and 44% achieved ≤ 75% 
global improvement. At week 26 the global improvement was 77% vs. 48% vs. 30% (p ≤ 0.05 for 
both comparisons). 73% vs. 47% vs. 19% of patients retained ≥ 50% improvement relative to 
baseline. At week 6 ADRs were reported by 14% of subjects. At week 26 ADRs were seen in 24% 
vs. 29% vs. 0%. Local irritation, erythema and pruritus were most common. 
Koo, 200185 CT 73 (35-38) 2b Gr1: tazarotene 0.1% gel qd plus mometasone 
furoate 0.1% cream qd. Gr2: mometasone furoate 
0.1% cream bid.
12 weeks ≥ 50% global improvement in psoriasis was achieved by 74% vs. 58% of patients. At week 4 
ADRs were reported in 29% in Gr1. Only one patient in Gr2 reported an ADR (3%). The most 
common reported AEs were burning, pruritus, irritation, eruption and exacerbations.
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Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Corticosteroids and Vitamin D Analogues
Kragballe, 199856 RCT 699 (174-174- 
175-176)
1b All patients applied calcipotriol cream 50µg/g in the 
morning and either vehicle (Gr1), calcipotriol 
50µg/g (Gr2), clobetasone 17-butyrate 0.5mg/g 
(Gr3) or betamethasone-17-valerate 1mg/g (Gr4) 
creams in the evening.
8 weeks Mean % reduction in PASI was 40.6% vs. 48.3 % vs. 53.7% vs. 57.5%. Gr1 was less effective than 
the other groups (p = 0.006). Gr2 was as effective as Gr3. and Gr3 as Gr4. And Gr4 was more 
effective than Gr2. IGA: ‘clearance’ or ‘marked improvement’: 28.5% vs. 40.2% vs. 42.5% vs. 54.0% 
(NS). PGA ‘clearance’ or ‘marked improvement’: 26.6% vs. 40.1% vs. 40.1% vs. 51.2%. Gr1 was 
inferior and Gr4 superior to the two other treatments (p = 0.04). The most frequent AE was skin 
irritation which was reported significantly less frequently in the combination groups (31.2% vs. 
34.3% vs. 23.8% vs. 17.1% (p = 0.001)).
Lebwohl, 199839 RCT 40 (20-20) 2b All patients applied calcipotriene 0.005% ointment 
in the morning and halobetasol 0.05% in the evening. 
After 2 weeks all patients applied halobetasol twice 
daily on weekends and calcipotriene (Gr1) or 
placebo ointment (Gr2) twice daily on weekdays.
2 weeks,
6 months
follow-up
In Gr1, 76% of patients were able to maintain remission for 6 months compared with 40.0%  
in Gr2 (p = 0.045). Scaling (p = 0.02), plaque thickness (p = 0.01), overall severity (p = 0.02) and 
global assessment (p = 0.01) were significantly different between groups in favor of Gr1. AEs 
consisted of an irritant contact dermatitis, were mild and developed in 4 patients vs. 1 patient.
Ruzicka, 199845 RCT 169 (87-82) 1b All patients applied calcipotriol cream 0.005% 
ointment twice daily. After 2 weeks Gr1: calcipotriol 
twice daily and Gr2: calcipotriol in the morning and 
betamethasone valerate 0.1% ointment in the 
evening.
4 weeks,
8 weeks
follow-up
Mean % reduction in PASI after 4 weeks; 45.7% vs. 68.8% (p = 0.0001)*. Mean PASI reduction 
after 8 weeks follow-up: 2.7% vs. 25.0%* (NS). IGA ‘complete healing’ or ‘distinct improvement’: 
60.5% vs. 77%. Local AEs were reported in 15% vs. 7%. The most frequently reported local AEs 
were erythema, burning and pruritus.
Lebwohl, 199643 CT 127 (42-42-43) 2b Gr1: once daily calcipotriene 0.005% ointment and 
halobetasol 0.05% ointment. Gr2: twice daily 
calcipotriene 0.005% ointment. Gr3: twice daily 
halobetasol 0.05% ointment.
2 weeks ODS was significant lower in Gr1 compared to Gr2 and 3 (p < 0.001, p = 0.017, respectively). IGA: 
‘clear’ or ‘almost clear’: 71% vs. 30% vs. 57% (p < 0.001 and NS, respectively). Mean scores for 
plaque elevation for Gr1 were significantly superior to those for Gr2 and 3. Gr1 was significantly 
superior to Gr2 for mean erythema and scaling, but not to Gr3. Local cutaneous AEs (i.e. pruritus, 
burning skin etc.) were reported less frequently in Gr1.
Retinoids plus Corticosteroids
Green, 200276 RCT 259 (92-29-29- 
29-27-28-25)
2b All patients applied tazarotene 0.1% in the evening. 
Gr2 to Gr7 applied fluocinonide 0.05%, 
mometasone furoate 0.1%, diflorasone diacetate 
ointments, betamethasone dipropionate 0.05% 
cream, fluticasone propionate 0.005% ointment, 
and diflorasone diacetate 0.05% cream respectively 
in the morning.
12 weeks Mean % reduction in overall evaluation score: 20%, 41%, 38%, and 50%, for Gr1, 3, 4, and 5, 
respectively. At week 12 ≥ 50% global improvement was achieved by 35% vs. 48% vs. 66% vs. 
55% vs. 78% vs. 57% vs. 44% in Gr1 to 7, respectively. ADRs were reported in 40% vs. 34% vs. 
17% vs. 21% vs. 33% vs. 29% vs. 32%. Most common reported ADRs involved skin reactions such 
as irritation, erythema, pruritus, and burning, and were predominantly of mild or moderate 
severity. 
Lebwohl, 200177 OL 
RCT
50 (17-17-16; 
unpublished data)
4
2b
Initial phase: tapering doses of tazarotene 0.1% gel 
plus clobetasol propionate 0.05% ointment. 
Maintenance phase: Gr1: tazarotene plus clobetasol. 
Gr2: tazarotene plus vehicle. Gr3: vehicle plus 
petroleum. (Component named first was applied 
on Monday, Wednesday, and Friday mornings, the 
second on Tuesday and Thursday evenings).
6 weeks
and
20 weeks
At week 6 100% of patients achieved ≤ 50% global improvement and 44% achieved ≤ 75% 
global improvement. At week 26 the global improvement was 77% vs. 48% vs. 30% (p ≤ 0.05 for 
both comparisons). 73% vs. 47% vs. 19% of patients retained ≥ 50% improvement relative to 
baseline. At week 6 ADRs were reported by 14% of subjects. At week 26 ADRs were seen in 24% 
vs. 29% vs. 0%. Local irritation, erythema and pruritus were most common. 
Koo, 200185 CT 73 (35-38) 2b Gr1: tazarotene 0.1% gel qd plus mometasone 
furoate 0.1% cream qd. Gr2: mometasone furoate 
0.1% cream bid.
12 weeks ≥ 50% global improvement in psoriasis was achieved by 74% vs. 58% of patients. At week 4 
ADRs were reported in 29% in Gr1. Only one patient in Gr2 reported an ADR (3%). The most 
common reported AEs were burning, pruritus, irritation, eruption and exacerbations.
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Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Retinoids plus Corticosteroids
Guenther, 200080 RCT 120 (60-60) 1b Gr1: tazarotene 0.1% gel in the evening and 
mometasone furoate 0.1% cream in the morning. 
Gr2: twice daily calcipotriene 0.005% ointment.
8 weeks,
12 weeks 
follow-up
At week 2 45% vs. 25% of patients achieved ≥ 75% global improvement (p ≤ 0.05). Differences 
between % patients achieving ≥ 90% improvement were NS. For trunk lesions, the mean % 
reductions in plaque elevation at EoT, and for scaling, erythema and BSA after 4 weeks were 
significantly greater in Gr1. For the upper and lower limb lesions differences were NS, except for 
the % patients achieving a significantly greater reduction of BSA after 4 weeks in Gr1. AEs (i.e. 
burning, pruritus etc.) occurred in a significant greater proportion of patients in Gr1 (p ≤ 0.05).
Poulin, 199981 ROL 20 (6-5-4-5) 2b Gr1: tazarotene 0.05% gel. Gr2: tazarotene 0.1% gel. 
Gr3: tazarotene 0.1% gel and mometasone furoate 
0.1% cream as needed. Gr4: tazarotene 0.1% gel and 
mometasone cream. Tazarotene administered in the 
evening and mometasone in the morning.
12 weeks Percentage of patients attaining ≥ 50% improvement in psoriasis: 17% vs. 60% vs. 100% vs. 
100%*. All patients in Gr4 achieved an improvement in psoriasis > 75%. Proportion of patients 
reporting local AEs, like erythema, itching, stinging or burning: 50% vs. 100% vs. 75% vs. 40%*.
Lebwohl, 199882 RCT 300 (73-71-70-70) 1b All patients applied tazarotene 0.1% gel in the 
evening and either fluocinolone acetonide 0.01% 
(Gr1), mometasone furoate 0.1% (Gr2), fluocinonide 
0.05% (Gr3) or placebo (Gr4) creams in the morning.
12 weeks,
4 weeks
follow-up
At week 2/week 12 ≥ 50% global improvement was seen in 42%/80% vs. 49%/ 79% vs. 73%/ 
91% vs. 58%/95%. ≥ 50% improvement was seen in 79% vs. 91% vs. 95% vs. 80%. Gr2 and 3 
produced significantly higher treatment success rates than Gr4. Gr3 was significantly more 
successful than Gr1. Gr2 and 3 resulted in a decreased incidence of AEs, such as pruritus, 
erythema or burning, over time in comparison with Gr1 and 4. Gr2 and 3 when compared with 
Gr4 achieved significantly greater reductions in scaling, erythema, and overall lesional severity, 
and a decreased incidence of AEs.
McMichael, 199683 RCT 20 (20-20-20) 2b Betamethasone dipropionate 0.05% cream was 
applied on 2 sites in the morning. Site 1 was 
subsequently treated with tretinoin 0.1% cream in 
the evening and site 2 with vehicle. Site 3 was left 
untreated on all participating patients. 
8 weeks Marked improvement/improvement was seen in 53%/24% in Gr1 vs. 53%/18% in Gr2 and in 
0%in Gr3 at EoT. There was no difference in the speed of improvement between the treatment 
sites. Cutaneous reactions, principally characterized by erythema and scaling, were seen in 32% 
vs. 5% vs. 0%.
Other Combinations
Buder, 201086 RCT 14 (7 sites per 
patient)
2b Sites were treated with 1. Tacrolimus 0.1% ointment; 
2.Vehicle; 3. Methylprednisolone aceponate 
ointment; 4.Vehicle; 5.Methylprednisolone and 
tacrolimus; 6. Their vehicles; 7.Control. All applied 
once daily under occlusion. 
11 days SUM improvement at day 11: 69.8% vs. 93.6% vs. 95.7% vs. 13.7% at sites 1, 3, 5, and 7, 
respectively*. Reduction was significantly larger at site 5 compared to site 1 (p < 0.05). 
Differences between sites 3 and 5 were NS. Cutaneous atrophy and rebound were not seen 
after occlusive treatment.
Bowman, 200274 ROL 15 (28 target 
lesion pairs)
2b Calcipotriene 0.005% ointment plus tazarotene 
0.1% gel vs. twice daily clobetasol ointment.
2 weeks,
4 weeks
Identical reduction in scaling, plaque elevation and overall lesional severity score. Erythema 
improved significantly more in the clobetasol treated lesions (p < 0.01) Plaque elevation 
returned somewhat more rapidly in the calcipotriene/ tazarotene side (p < 0.01). No AEs were 
reported in the clobetasol treated side. Mild treatment related AEs were reported in the 
combination treated site. 
ADR, adverse drug reactions; AE, adverse events; BSA, Body Surface Area; bid, twice a day; CT, controlled trial;  
EoT, end of treatment; Gr, group; IGA, investigator global assessment; LoE, level of evidence; NS, not significant; 
ODS, overall disease severity; OL, open-label study; PASI, Psoriasis Area Severity Index; PDL, pulsed dye laser;  
PGA, patient global assessment; PSI, Psoriasis Severity Index; qd, once a day; RCT, randomized controlled trial; 
ROL, randomized open-label study; TSS, total sign score. 
* Numbers were calculated.
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Author,  
year (ref)
Study 
design
No. patients  
(per group)
LoE Treatment Duration Outcome
Retinoids plus Corticosteroids
Guenther, 200080 RCT 120 (60-60) 1b Gr1: tazarotene 0.1% gel in the evening and 
mometasone furoate 0.1% cream in the morning. 
Gr2: twice daily calcipotriene 0.005% ointment.
8 weeks,
12 weeks 
follow-up
At week 2 45% vs. 25% of patients achieved ≥ 75% global improvement (p ≤ 0.05). Differences 
between % patients achieving ≥ 90% improvement were NS. For trunk lesions, the mean % 
reductions in plaque elevation at EoT, and for scaling, erythema and BSA after 4 weeks were 
significantly greater in Gr1. For the upper and lower limb lesions differences were NS, except for 
the % patients achieving a significantly greater reduction of BSA after 4 weeks in Gr1. AEs (i.e. 
burning, pruritus etc.) occurred in a significant greater proportion of patients in Gr1 (p ≤ 0.05).
Poulin, 199981 ROL 20 (6-5-4-5) 2b Gr1: tazarotene 0.05% gel. Gr2: tazarotene 0.1% gel. 
Gr3: tazarotene 0.1% gel and mometasone furoate 
0.1% cream as needed. Gr4: tazarotene 0.1% gel and 
mometasone cream. Tazarotene administered in the 
evening and mometasone in the morning.
12 weeks Percentage of patients attaining ≥ 50% improvement in psoriasis: 17% vs. 60% vs. 100% vs. 
100%*. All patients in Gr4 achieved an improvement in psoriasis > 75%. Proportion of patients 
reporting local AEs, like erythema, itching, stinging or burning: 50% vs. 100% vs. 75% vs. 40%*.
Lebwohl, 199882 RCT 300 (73-71-70-70) 1b All patients applied tazarotene 0.1% gel in the 
evening and either fluocinolone acetonide 0.01% 
(Gr1), mometasone furoate 0.1% (Gr2), fluocinonide 
0.05% (Gr3) or placebo (Gr4) creams in the morning.
12 weeks,
4 weeks
follow-up
At week 2/week 12 ≥ 50% global improvement was seen in 42%/80% vs. 49%/ 79% vs. 73%/ 
91% vs. 58%/95%. ≥ 50% improvement was seen in 79% vs. 91% vs. 95% vs. 80%. Gr2 and 3 
produced significantly higher treatment success rates than Gr4. Gr3 was significantly more 
successful than Gr1. Gr2 and 3 resulted in a decreased incidence of AEs, such as pruritus, 
erythema or burning, over time in comparison with Gr1 and 4. Gr2 and 3 when compared with 
Gr4 achieved significantly greater reductions in scaling, erythema, and overall lesional severity, 
and a decreased incidence of AEs.
McMichael, 199683 RCT 20 (20-20-20) 2b Betamethasone dipropionate 0.05% cream was 
applied on 2 sites in the morning. Site 1 was 
subsequently treated with tretinoin 0.1% cream in 
the evening and site 2 with vehicle. Site 3 was left 
untreated on all participating patients. 
8 weeks Marked improvement/improvement was seen in 53%/24% in Gr1 vs. 53%/18% in Gr2 and in 
0%in Gr3 at EoT. There was no difference in the speed of improvement between the treatment 
sites. Cutaneous reactions, principally characterized by erythema and scaling, were seen in 32% 
vs. 5% vs. 0%.
Other Combinations
Buder, 201086 RCT 14 (7 sites per 
patient)
2b Sites were treated with 1. Tacrolimus 0.1% ointment; 
2.Vehicle; 3. Methylprednisolone aceponate 
ointment; 4.Vehicle; 5.Methylprednisolone and 
tacrolimus; 6. Their vehicles; 7.Control. All applied 
once daily under occlusion. 
11 days SUM improvement at day 11: 69.8% vs. 93.6% vs. 95.7% vs. 13.7% at sites 1, 3, 5, and 7, 
respectively*. Reduction was significantly larger at site 5 compared to site 1 (p < 0.05). 
Differences between sites 3 and 5 were NS. Cutaneous atrophy and rebound were not seen 
after occlusive treatment.
Bowman, 200274 ROL 15 (28 target 
lesion pairs)
2b Calcipotriene 0.005% ointment plus tazarotene 
0.1% gel vs. twice daily clobetasol ointment.
2 weeks,
4 weeks
Identical reduction in scaling, plaque elevation and overall lesional severity score. Erythema 
improved significantly more in the clobetasol treated lesions (p < 0.01) Plaque elevation 
returned somewhat more rapidly in the calcipotriene/ tazarotene side (p < 0.01). No AEs were 
reported in the clobetasol treated side. Mild treatment related AEs were reported in the 
combination treated site. 
ADR, adverse drug reactions; AE, adverse events; BSA, Body Surface Area; bid, twice a day; CT, controlled trial;  
EoT, end of treatment; Gr, group; IGA, investigator global assessment; LoE, level of evidence; NS, not significant; 
ODS, overall disease severity; OL, open-label study; PASI, Psoriasis Area Severity Index; PDL, pulsed dye laser;  
PGA, patient global assessment; PSI, Psoriasis Severity Index; qd, once a day; RCT, randomized controlled trial; 
ROL, randomized open-label study; TSS, total sign score. 
* Numbers were calculated.
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effective than calcipotriol monotherapy. In this study, no significant difference was 
demonstrated between the combinations of vitamin D with a potent or mid potent 
steroid. Another study on low to mid potent corticosteroids concluded that combining 
hydrocortisone with calcipotriol was not significantly more effective than vitamin D 
monotherapy when used on the body. However, when used on the face, this 
combination was found significantly more effective.57
6 Considering the 12 weeks of treatment with vitamin D analogues with potent steroids, 
the majority of the literature concerns the two-compound product. Information on 
superpotent corticosteroids is limited. Results show that the trend towards a benefit 
in favour for combination treatment compared with either monotherapy is 
approximately similar to the results found on short-term treatment. All these articles 
demonstrate a statistically significant superiority of combination treatment compared 
with either monotherapies.37, 58-60
Safety results indicate that the incidence of local adverse events due to combination 
therapy tends to be lower than due to vitamin D monotherapy, whereas this difference is 
not evident for corticosteroid monotherapy compared with combination therapy (Table 6). 
The studies on the combination of vitamin D with low to mid potent steroids, suggest 
that using a less potent steroid is less protective against local side effects, compared with 
the combination with a potent steroid. As expected, when used for a longer period of 
time, the various treatment options lead to an increased incidence of side effects. Nearly 
all reported local side effects were considered transient and relatively mild. However, 
withdrawals due to side effects have been reported. Pruritus, erythema and a burning 
sensation were reported most frequently. 
 A 52-week safety study on the use of the two-compound product as needed showed 
that the long-term use of the two-compound formulation was safe and well tolerated 
whether used exclusively or alternating every 4 weeks with calcipotriol monotherapy.40 
Adverse drug reactions, mostly related to skin irritation, were reported by 21.7%, 29.6% 
and 37.9% of patients treated with the two-compound product, the two-compound 
product altering every 4 weeks with calcipotriol and with calcipotriol monotherapy 
respectively. Serious adverse events were considered related to the study treatment in 
three cases only; two patients were admitted to the hospital due to an exacerbation of 
their psoriasis, and another patient developed pustular psoriasis. All events resolved.
Scalp Psoriasis 
All eight studies on scalp psoriasis considered the two-compound formulation63-70. Five 
RCTs63-67 described the use of the two-compound scalp formulation applied once-daily 
for up to 8 weeks. All papers showed a superior effect for the combination compared with 
either active compound alone as monotherapy or to the vehicle. 
 Luger et al.68 published a 52-week safety study on the use of this scalp formulation 
compared with the use of calcipotriol monotherapy. A high level of safety was demonstrated 
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for the long-term use of this combination and the percentage of patients reporting at 
least one adverse drug reaction was significantly lower in the two-compound group 
compared with the calcipotriol group. In two open-label studies, the safety and tolerability 
of this combined therapy was reconfirmed.69, 70 
Conclusion Grade A Treatment with a combination of corticosteroids and vitamin D 
analogous is more efficacious and faster than monotherapy with either active component 
both on plaque psoriasis and scalp psoriasis. This superiority comprises the early treatment 
phase as well as the long-term treatment. Combination therapy seems to be safe and well 
tolerated during short-term treatment as well as during long-term treatment if used as 
needed.
Topical Retinoids in Combination with Corticosteroids or Vitamin D Analogues 
On the combination of topical retinoids and vitamin D analogues, only one pilot study 
was revealed.74 Compared to twice-daily treatment with clobetasol ointment, no benefit 
for this combination therapy was found. 
 Eleven studies on the combination of topical retinoids with topical steroids were 
identified;75-85 two studies were excluded because of an unclear treatment strategy,78, 79 
and two were excluded because demographic data or a clear outcome measure were not 
described.75, 84 
 Table 7 summarizes the overall efficacy of various combinations of retinoids with 
 corticosteroids. Topical retinoids used as monotherapy led to a mean improvement of only 
20%.76 Combining topical retinoids with potent corticosteroids showed an improvement 
in clinical parameters of at least 38%, whereas this benefit increases by using a superpotent 
corticosteroid.77
  Percentages of subjects reaching ≥50% global improvement are also stated, showing 
a wide range in outcomes. At 4 weeks, the combination with low to mid potent and 
potent corticosteroids seems to have an added value. However, after 12 weeks results 
overlap. 
  All comparative studies on this combination,76, 77, 81, 82 conclusively showed that the 
degree and speed of improvement in psoriasis parameters was higher as compared with 
topical retinoid monotherapy. Two RCTs evaluated tazarotene gel combined with and 
without different classes of topical corticosteroids. Lebwohl et al.82 (LoE 1b) concluded 
that the combination with both mometasone and fluocinonide creams resulted in a 
significantly larger reduction in psoriasis severity, while reducing the incidence of local 
adverse events in time compared with retinoid monotherapy and to the combination 
with mid to low potent corticosteroids. Green et al.76 (LoE 2b) showed that the greatest 
clinical benefit was achieved by the combination with betamethasone cream, followed 
by mometasone ointment. However, the latter treatment regimen was concluded to be 
the most preferable because less local side effects were reported. 
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  A two-phase study to investigate the maintenance of improvement in psoriasis after 
a 6-week combination treatment with tapering doses of a superpotent corticosteroid was 
conducted by Lebwohl et al.77 After this initial phase, patients were randomized to receive 
combination therapy, retinoid monotherapy or vehicle. Continuing the combined therapy 
led to a further increase in the level of improvement, whereas the switch to either 
monotherapy or vehicle led to a decline in the improvement obtained in the initial phase. 
The one study comparing the combination regimen of betamethasone and tretinoin to 
betamethasone monotherapy83 (LoE 2b) found no clinical advantage adding tretinoin to 
betamethasone, whereas more adverse events were reported in the combination group. 
However, Koo et al.85 (LoE 2b) showed that patients treated with the combination of 
tazarotene gel and mometasone cream achieved a greater, and more rapid, global 
improvement in psoriasis than patients treated with mometasone monotherapy. But, 
combined therapy led to more side effects than monotherapy. This combination was 
compared with vitamin D monotherapy in another paper80 (LoE 1b) and seemed to be 
more efficacious than calcipotriol monotherapy. 
 Safety results show that the adjunctive use of corticosteroids to retinoid monotherapy 
reduces the incidence of side effects (Table 8). The percentage of patients experiencing 
one or more local reactions was notably lower in the groups treated with combination 
therapy compared to retinoid monotherapy. 
Conclusion Grade B When compared with monotherapy with topical retinoids alone, the 
combination of corticosteroids and topical retinoids seems to be more efficacious, at least 
when potent or superpotent corticosteroids are taken into account. Complementary, 
combining these components results in a decrease in the incidence of side effects as 
compared with retinoid monotherapy. However, when compared with corticosteroid 
monotherapy, the additive value of this combined regimen has not been demonstrated 
convincingly as the efficacy is comparable to corticosteroid monotherapy and the 
combination has more side effects.
Calcineurin Inhibitors in Combination with Topical Corticosteroids or 
Vitamin D Analogues 
Only one article on each combination was revealed by our search.86, 87 The case report on 
tacrolimus combined with calcipotriol was excluded because it was not on plaque 
psoriasis.87 
 Buder et al.86 conducted a double-blind pilot study to investigate the presumed 
synergistic effect of corticosteroids and calcineurin inhibitors. The authors found a greater 
reduction in clinical parameters for both the combination regimen and corticosteroid 
monotherapy than for tacrolimus monotherapy. However, no additional benefit was 
found using the combination therapy compared with corticosteroid monotherapy. No 
side effects were described.
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Conclusion Grade C Combining corticosteroids and topical calcineurin inhibitors seem to 
improve the efficacy of monotherapy with calcineurin inhibitors. However, no additive 
benefit seems to be achieved by combining both components compared with 
corticosteroid monotherapy, and information on safety and tolerability of this combination 
is lacking. Therefore, combination therapy cannot be recommended. 
Discussion
The present systematic literature review on combinations of first-line topical treatments for 
chronic plaque psoriasis reconfirms our previous finding that study designs and outcome 
criteria are at great variance and inconstant.4 Logically, this prohibits proper comparisons 
between different combinations and different studies. Moreover, it is noteworthy that the 
evidence for efficacy and safety is limited for some combinations. 
 The combinations of potent and superpotent corticosteroids with vitamin D analogues 
provide an improvement of psoriasis within 2 weeks and a maximal improvement after 
4 weeks in the majority of patients which improvement was maintained up to at least 
12 weeks. The fixed combination was evaluated in large comparative and controlled 
studies, which showed the superiority of this two-compound product to monotherapies. 
When used as needed the majority of patients experienced satisfaction and safe control 
for at least 52 weeks. Fast and long-term effective safe control was provided by this 
combination. The differences between potent and superpotent corticosteroids were 
negligible using this combination. The two-compound combination product permits 
once-daily treatment and therefore is a good solution from the point of view of compliance. 
 Combinations of topical corticosteroids with either retinoids or calcineurin inhibitors do 
not provide an advantage above corticosteroid monotherapy. Therefore, these combinations 
do not offer an added value to corticosteroid monotherapy and should be avoided as 
combining different topicals introduces a more complex treatment schedule as compared 
with monotherapy without bringing an advantage. However, it is possible that tazarotene 
may reduce corticosteroid induced atrophy,88 although such has not been proven 
indisputably in studies.
 As noted before, for future research, it is of great importance to develop a consensus 
between researchers operating on the same field to facilitate the comparison of study data. 
Evidence-based data on long-term efficacy and safety at the highest quality level are limited. 
It is important that these data become available since most patients are convicted to a life- 
long treatment and the real significance of a treatment is the alteration of the long-term course 
of this chronic disease. Is a treatment a disease modifier, simply a control for the moment or 
a factor which has a negative impact on the long-term course of the disease? Long-term 
prospective studies on a large cohort of patients may provide the best data. An alternative 
may be the long-term registration of disease characteristics in high quality patient registries. 
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 In our dermatology department, a combination of vitamin D with a potent cortico-
steroid is the mainstay for the vast majority psoriasis patients. Considering compliance, 
the two-compound formulations provide a good solution for patients with plaque 
psoriasis including scalp psoriasis. The optimal treatment duration is indefinite. However, 
at this point, the treatment should not be used continuously for months without any 
intermissions, since data on prolonged continuous usage are lacking. Regular monitoring by 
health care professionals seems to be essential to guide patients in their life-long treatment.
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Abstract
Background Research has revealed new insights into the pathogenesis of psoriasis, 
leading to new therapeutic options. So far the order of changes in the pathogenesis of 
psoriasis is unclear. The responses to cutaneous leukotriene B4 (LTB4) application have 
been studied in the past as an in vivo model for inflammation. The aim of the present 
study is to find out the order of changes of key steps in inflammation, which all have been 
shown to be involved in mature psoriatic lesions.
 Objectives To study the dynamics of the consecutive stages of inflammation in challenged 
skin as a reflection of a psoriasis-like inflammatory response.
Methods We examined the dynamics of epidermal growth control and the key representatives 
of the innate and acquired immune system during the first 72 hours after challenging the 
skin by LTB4 application. 
Results Interleukin 17-positive (IL-17+) cells dominate the acute phase of inflammation, 
whereas T-Bet+ cells seem to increase gradually during the entire observation period. 
This indicates a more important role for IL-17 in the unstable phase of inflammation and a 
more prominent role for T-Bet+ cells within the chronic phase.
Conclusions The present model is highly reproducible and is useful in studying the 
dynamics of a psoriasis-like inflammation with respect to key components of immunity. 
It could provide a useful tool to study the immediate biological effects of new therapies 
like anti-IL-17 drugs on IL-17 production and effects on cutaneous inflammation and 
epidermal proliferation in vivo.
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Introduction
Affecting about 2% of the population, psoriasis is one of the most common chronic 
inflammatory skin disorders, causing an extensive burden of disease for both patients and 
health care systems. The pathogenesis of psoriasis is still unclear but research has revealed 
important drivers in the pathogenesis of this disease, which also appeared to be targets 
for antipsoriatic treatments. It is known from the classical picture of the histopathology of 
psoriasis that the polymorphonuclear leukocytes (PMNs), cells of the innate immune 
system, are well presented within active psoriatic lesions. The accumulations of PMNs as 
micropustules of Kogoj (spongiform pustules in the stratum spinosum) and as micro- 
abscesses of Munro (accumulation of remnants of PMNs in the stratum corneum) are 
pathognomonic for psoriasis. These accumulations of PMNs are a key component of the 
innate immune system in psoriasis. Further exploration of the role of the immune system 
has revealed an important assignment for T cells. At first, psoriasis was thought to be a T 
helper 1 (Th1) cell-mediated process, due to a disturbed balance between Th1 and Th2 
cells.1 However, a few years ago a novel T cell subset was discovered: the T helper 17 (Th17) 
cells.2, 3 Since their discovery, researchers have found that Th17 cells play an important role 
in several inflammatory diseases including psoriasis, rheumatoid arthritis, inflammatory 
bowel disease and atherosclerosis.4, 5 Moreover, new drugs targeting the interleukin 17 
(IL-17) pathway seem to be very effective in psoriasis.6, 7
 To further unravel the pathogenesis of psoriasis, research on the consecutive cascade 
of events, finally leading to psoriatic lesions, is essential. Unfortunately, studying psoriasis 
before it becomes clinical manifest is rather difficult since examining the very first changes 
would require the prediction of the formation of new lesions. At this point, our knowledge 
is mainly based on existing psoriatic lesions and the clinically uninvolved skin from 
psoriasis patients, without the various phases in between. 
 To enable the investigation of the early alterations and consecutive cascade leading 
to the cutaneous inflammation and the disease-specific phenotype, the inflammatory 
processes have to be imitated in a controlled manner. One way to study single aspects of 
the important drivers of psoriasis is to use in vitro experiments. These experiments allow 
studying single cell types and isolated events over time while all other environmental 
influences can be controlled. Unfortunately, these experiments are carried out under 
rather artificial in vitro conditions. 
 During the past decades, the inflammatory response to epicutaneous application of 
leukotriene B4 (LTB4) has been studied extensively and can be regarded as an established 
model to mimic psoriasis-like inflammation of the skin.8-12 It is known that in psoriatic 
lesions high levels of LTB4 are present13, 14 which are produced by activated innate immune 
cells.15, 16 Concurrently, it is a potent chemo-attractant for inflammatory cells,15, 17 and 
cutaneous application triggers an acute inflammation, with PMNs penetrating into the 
psoriatic epidermis, mimicking the micro-pustules of Kogoj and the microabscesses of 
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Munro. These microscopic collections of PMNs are found in the stratum spinosum and 
stratum corneum of lesional skin and indicate active disease. By application of LTB4 directly 
onto the skin, it is possible to introduce an isolated influx of PMNs and to induce a 
psoriasis-like inflammatory reaction. Because this inflammatory reaction of the skin is 
inflicted in a controlled manner, all processes can be followed over time. With respect to 
the newly discovered drivers in the field of psoriasis, this model may enable us to be 
informed on the consecutive events in an inflammatory process, sharing the 
pathognomonic PMN accumulations as seen in psoriasis. 
 The aim of this research was to further elucidate the dynamics of the early and 
consecutive stages of a psoriasis-like skin inflammation. Therefore, the early epidermal and 
dermal changes due to challenging the skin were studied at subsequent moments after 
LTB4-application. In particular, the epidermal compartment (i.e. epidermal proliferation 
(Ki-67) and differentiation (keratins 10 and 16, K10 and K16)), and both the innate (i.e. 
neutrophils (elastase), epithelial proteinase inhibitor (elafin) and antimicrobial peptides 
(human β-defensin-2, hBD-2)), and the adaptive immune systems (Th1 cells (T-Bet)), and 
the key cytokine IL-17 were studied. 
Material and Methods
Subjects
Ten healthy volunteers (7 females and 3 males, 19 – 56 years) without signs or history of 
skin disorders participated in this study. Written informed consent was given by all 
volunteers before inclusion. The experiments were approved by the local medical ethics 
committee and conducted according to the Declaration of Helsinki principles. 
LTB4 Application 
Aliquots of 100 ng LTB4 dissolved in 10 µl ethanol were applied on 5 sides of the skin of the 
lower back through a plastic cylinder (8 mm diameter). The ethanol was evaporated under 
a stream of nitrogen gas, leaving the LTB4 on the skin. To prevent the LTB4 from being 
displaced, the test sites were covered with impermeable dressings and held in place by 
tape. After 8 hours the dressings were removed by the investigators. 
Biopsy Procedures
Punch biopsies with a diameter of 3 mm were taken after local  anaesthesia. Biopsies were 
taken 8, 24, 32, 48 and 72 hours after LTB4 application. Time intervals were based on 
previous studies. One additional biopsy was taken from non-challenged skin serving as an 
internal control. All specimens were formalin fixed, embedded in paraffin and sectioned 
at 4 µm. 
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Immunohistochemistry 
Staining procedures were performed using the Envision Kit according to the regulations 
of our laboratory. Paraffin-embedded sections were deparaffinezed and rehydrated. 
Endogenous peroxidase activity was blocked by 2% H2O2 in phosphate-buffered saline, 
and sections were incubated with 1% bovine serum albumin (Dako, Glostrup, Denmark). 
Antigen retrieval was achieved by 0.1% trypsin solution (pH 7.8, 10 minutes at 37 ⁰C) for K10 
staining, citrate buffer (pH 6.0, 10 minutes at 100 ⁰C) for K16 and Ki-67 staining, and Tris/
EDTA buffer (pH 9.0, 10 minutes at 100 ⁰C) for IL-17 staining. The other primary antibodies 
used did not require antibody retrieval steps. Sections were incubated overnight at room 
temperature with primary antibodies dissolved in 1% bovine serum albumin (Table 1). 
Visualization of the primary antibody was achieved with 3,3’-diaminobenzidine tetrahydro-
chloride solution (Sigma-Aldrich, St. Louis, Mo., U.S.A.) and counterstaining with Mayer’s 
haematoxylin (Sigma-Aldrich). Substitution with 1% bovine serum albumin served as a 
negative control.
Microscopic Quantification of Immunohistochemical Markers
Skin sections were assessed semi-quantitatively using an Axiokop 2 MOT microscope 
(Zeiss) at a magnification of x 100, digital camera (Axiocam MRc5; Zeiss) and AxioVision 
software (Zeiss). The whole section was analyzed. All microscopic evaluations were 
performed by two observers (A.H. and R.K.) and repeated on two different occasions per 
specimen. With respect to the epidermis an area was measured across the whole section, 
without stratum corneum, using ImageJ 1.38× software (National Institutes of Health). 
Table 1  Primary antibodies
Biochemical 
specifity
Marker for Designation and source  
of antibodies
Dilution
Keratin 10 Normal epidermal  
differentiation
RKSE60; Euro-Diagnostica BV, Arnhem,  
The Netherlands
1:5 000
Keratin 16 Abnormal epidermal  
differentiation
LL025; Sanbio BV, Uden, The Netherlands 1:50
Ki-67 Epidermal proliferation MIB-1, Dako 1:100
Elastase Neutrophils NP57, Dako 1:10 000 
Human  
β-defensin 2
Antibiotic peptide Abcam, Cambridge, U.K. 1:50
Elafin Epithelial proteinase  
inhibitor
HM2063 / TRAB2F 1:500 000
T-Bet Th 1 cells H-210 sc-21003, R&D Systems 1:1 500
IL-17 IL-17 cytokine Polyclonal goat IgG, R&D Systems 1:500
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The region of interest of the dermal compartment was defined as the surface from the 
basement down to 350 µm across the whole section and was assessed using the same 
software. For analysis of T-Bet, IL-17 and elastase, the dermal surface area was measured as 
mm2, and positive cells were counted. The cell counts were expressed as number of 
positive cells per mm2 dermis. Cells positive for Ki-67 were counted and expressed as 
positive cells per mm length of basement membrane. For quantification of the epidermal 
K10, K16, elafin and hBD-2 stainings, the percentage of the epidermis with a positive signal 
was measured using the ImageJ macro ‘color deconvolution’, adapted from Ruifrok and 
Johnston.18 
Statistical Analysis 
The results were expressed as means ± standard error of the mean. Time-related changes 
in immunohistochemical variables were assessed using a Wilcoxon matched-pairs signed 
rank test. Throughout the analyses, p values < 0.05 were considered statistically significant.
Results
In all healthy subjects a slight to moderate erythematous discoloration of the skin appeared 
after LTB4 application. At baseline and at 8, 24, 32, 48 and 72 hours after application biopsies 
were taken. During the study, LTB4 led to acanthosis, parakeratosis and an inflammatory 
infiltrate as is displayed in Figure 1. Figure 2 provides an overview of the histological data 
Figure 1  Representative photographs of haematoxylin-eosin staining of the skin
Representative photographs of haematoxylin-eosin staining of the skin at baseline and 8, 24, 32, 48 and 72 hours 
after LTB4 application, showing acanthosis, parakeratosis and an inflammatory reaction, resembling the histological 
hallmarks of psoriasis. After 24 hours, accumulations of elastase+ cells were present in the subcorneal zone of 
the stratum corneum. Bars represent 200 µm.
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over time, and two representative photographs of all makers used are depicted in Figure 3. 
 Already after 8 hours, LTB4 application induced the influx of the first immune cells 
within the dermis. Almost all of these infiltrating cells stained positive for elastase, mainly 
consisting of PMNs. Maximal accumulation in the dermis was seen after 24 and 32 hours 
(p = 0.0020 for both time points). Within the epidermal compartment, the accumulations 
of microscopic collections of PMNs were found in the stratum corneum after 24 hours. 
Thereafter, the number of elastase+ cells started to decline. 
 Within the normal unchallenged skin at t = 0 hours there were already some sporadic 
cells positive for IL-17 present within the dermal compartment. The course of IL-17 nicely 
coincided with the elastase+ cells with a significant increase starting after 24 hours and 
declining after 32 hours. 
Figure 2  Overview of histological data
Number of elastase+ ( a ), IL-17+ ( b ) and T-Bet+ ( c ) cells per mm2 of dermis, the percentage of elafin+ ( d ), 
hBD-2+ ( e ) and K16+ ( f ) epidermal surface, and the number Ki-67+ cells ( g ) per mm length of basement 
membrane at baseline and 8, 24, 32, 48 and 72 hours after LTB4 application. Means ± SEM. * p < 0.05: statistically 
significant compared to baseline.
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 At the same time, a statistically significant but modest increase in cells positive for 
the transcription factor for Th1-specific cytokines (T-Bet+ cells) was seen at 24 hours 
(p = 0.0195). In contrast to the course of elastase+ cells and IL-17+ cells, the number of cells 
positive for T-Bet lasted until 72 hours without declining. 
 The peak accumulation of elastase+ and IL-17+ cells at 32 hours within the dermis and 
epidermis was accompanied by the onset of epidermal differentiation, compatible with 
subsequent activation of the innate immune system. The latter is depicted by the increase 
in the percentage epidermis expressing the elastase-specific protease inhibitor elafin 
(elafin+ epidermal surface) and the skin antimicrobial peptide hBD-2 (hBD-2+ epidermal 
surface). The same pattern is seen for both the percentage of elafin+ epidermis as for the 
percentage hBD-2+ epidermis. Both markers showed a significant increase at 32 hours and 
increased until 72 hours to reach a maximum, well after the maximum of elastase+ and 
IL-17+ cells. 
 Furthermore, the expression of K10 within the epidermal compartment showed the 
same gross overall expression pattern at all time points (results not shown). LTB4 application 
Figure 3  Representative photographs
Representative photographs of elastase+ ( a, b ), IL-17+ ( c, d ), and T-Bet+ ( e, f ) cells at baseline and 32 hours after 
application of LTB4, and of elafin+ ( g, h ), hBD-2+ ( i, j ), and K16+ ( k, l ) epidermal surface, and the number Ki-67+ cells 
( m, n ) at baseline and 72 hours after LTB4 application. The bar represents 100 µm.
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led to an increase in the expression of K16 at 48 hours and further expansion at 72 hours 
(p = 0.0195 and 0.0020, respectively). This was followed at 72 hours by a marked increase 
in the number of cycling epidermal cells, reflecting keratinocyte proliferation, depicted by 
an increasing number of both basal and suprabasal Ki-67+ nuclei (p = 0.0039). 
Discussion
In this study the dynamics of the consecutive stages of inflammation were investigated in 
normal skin challenged by topical LTB4 application as a reflection of a psoriasis-like 
inflammatory response. The changes in both the innate and adaptive immune system 
were followed during the first 72 hours after skin challenging and related to epidermal 
proliferation and differentiation. 
 The haematoxylin-eosin staining displayed acanthosis, parakeratosis and an inflammatory 
infiltrate within the tissue samples, resembling the histological hallmarks of psoriasis (Fig. 1). 
This was reconfirmed by the other observed staining patterns which were quite similar to 
those found in psoriasis, with an increase in epidermal proliferation, the influx of epidermal 
and dermal PMNs, resulting in the characteristic intra-epidermal accumulations and the 
presence of T lymphocytes within the dermis. These results confirm that challenging the 
skin by LTB4 application can be used as a model to investigate psoriasis-like inflammation 
in a dynamic fashion.
 Furthermore, the changes in proliferation and differentiation markers found after 
challenging the skin resemble the findings of previous studies,8, 9, 19 indicating that this 
model is highly reproducible and that the execution of the LTB4 application was done 
accurately. 
 In psoriatic lesions, inflammatory changes within the epidermal and dermal compartments 
are accompanied by vascular changes. Histology shows elongated and dilated, tortuous 
blood vessels within the dermal papillae. In the present study, the course of the 
 vascularization was not taken into account. However, since there is a remarkable and rapid 
increase in various immune cells due to the application of LTB4, it is attractive to 
hypothesize that there is an increase in the vascularization as well to make this substantial 
influx of immune cells possible. LTB4 is an arachidonic acid derivative involved in 
inflammation and is able to induce the adhesion and activation of leukocytes directly. 
However, it is a chemical compound that has to penetrate the stratum corneum first to 
turn the inflammatory cascade on. First elastase+ cells are attracted, which in turn trigger 
the influx of Th1 lymphocytes. In addition, LTB4 is able to induce the formation of reactive 
oxygen species in neutrophils and the release of lysosomal enzymes, which in turn affects 
the epidermal compartment. We observed an increase in the percentage elafin+ and 
hBD-2+ epidermal surface, and an increase in K16 expression just after the peak 
accumulation of the elastase+ cells.
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 For years, psoriasis was considered a Th1 cell-dominated disease. However, nowadays 
Th17 cells are thought to play an important role, mainly caused by the production of IL-17, 
along with Th1 cells. To visualize the specific T cell subsets, T-Bet was used as a unique 
Th1-specific transcription factor.20 Within the unchallenged skin there were already some 
T-Bet+ cells present. In addition, skin biopsies also showed an elementary level of IL-17+ 
cells at baseline, which may have been produced by mast cells. Previous studies found 
IL-17+ mast cells within complicated atherosclerotic plaques and in the synovium in 
rheumatoid arthritis.21, 22 These cells were also found within chronic plaque psoriasis by 
our group.23 After challenging the skin, a quick influx of elastase+ cells was seen with an 
identical increase in IL-17+ cells. After the early peak of elastase+ and IL-17+ cells, these 
subsets tended to decrease already after 24 hours. Regarding the T-Bet+ cells only a 
minimal increase was observed which lasted until 72 hours. According to these results, the 
influx of elastase+ and IL-17+ cells seems to play a more important role in the acute phase 
of inflammation rather than T-Bet+ cells. This suggests that in this model the elastase+ 
PMNs may play an important role producing IL-17 rather than Th17 cells, which was 
described before by Lin et al.24 The authors showed that neutrophils contain IL-17 using 
dual-colour immunofluorescence and concluded that the release of IL-17 from innate 
immune cells may be central in the pathogenesis of psoriasis, representing a fundamental 
mechanism by which the IL-23/IL-17 axis mediates host defense and autoimmunity.24
 Moreover, it was already proposed by Christophers25 that there are two different 
immune pathways which orchestrate the lesional activity leading to the different pheno- 
types of psoriasis. It was suggested that the IL-23/IL-17 directed pathway leads to an active 
eruptive psoriasis with the formation of new lesions, whereas the pathway directed by Th1 
cells marked by the IL-12/interferon-y pathway is predominant within chronic plaque 
psoriasis. Moreover, Christophers25 argued that rerouting the cutaneous inflammation 
form the IL-12 pathway towards the IL-23 pathway and vice versa had a bearing on both 
the diversity of phenotypes as well as their instability, which is one of the characteristics of 
psoriasis. In addition, Choe et al.26 showed that IL-17A was more elevated in patients with 
an eruptive inflammatory psoriasis compared with patients with chronic stable psoriasis. 
 However, we used a model to study the psoriasis-like inflammatory response, not 
psoriatic skin itself. It would be interesting to examine different phenotypes of psoriatic 
lesions, both acute and more chronic lesions for the same set of markers. Such could learn 
us more about the importance of all the above-mentioned cells and ultimately about the 
pathogenesis of psoriasis. Furthermore, new methods to predict psoriatic development 
should be explored to examine the different stages of disease more closely.
 In conclusion, this study showed that the response to the epicutaneous application of LTB4 
is highly reproducible and is useful in studying the dynamics of a psoriasis-like inflammation. 
Elastase+ and IL-17+ cells dominate the acute phase of inflammation, indicating a more 
important role in the instable phase of inflammation, whereas T-Bet+ cells seem to have a 
more gradual role and could probably be more prominent within the stable situation. 
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 In addition, the present study described the course of different immunohistochemical 
markers over time, including the course of IL-17+ cells, which may be expected after 
LTB4 has been applied to the healthy skin. With this information, the LTB4 model could 
provide a useful tool to study the biological effects of new therapies such as anti-IL-17 
drugs and provide information on the production of IL-17 and IL-17-driven changes in vivo 
during a short intervention of only 72 hours. 
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Abstract
Background In healthy skin, tape stripping induces a transient wave of histological changes 
resembling immune-mediated skin diseases, such as psoriasis. The response to surface 
trauma may harbor mechanisms which are also relevant to the development of Koebner- 
positive skin disorders. However, studies on newly discovered drivers of inflammation in 
regenerative skin are lacking.
 Methods The course of epidermal proliferation and keratinization as well as key representatives 
of innate and acquired immunity were studied during the first 72 hours after tape stripping.
Results Epidermal rupture rapidly activates various epidermal processes, which remain 
upregulated for 72 hours. Elastase+ and IL-17+ cells dominate the acute phase and their 
numbers decrease rapidly thereafter. The number of T-Bet+ cells increases more gradually, 
reaching maximum levels several hours later when the other cell types decrease.
Conclusions This model permits investigations on the sequence of crucial inflammatory 
processes set off by cutaneous injury, which are presumed to play a role within the 
pathogenesis of immune-mediated skin diseases exhibiting the Koebner phenomenon.
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Introduction 
The skin separates the body’s internal environment from the external environment and 
provides a barrier to the outside world. The skin barrier function results from the physical 
properties of the outer layer of the epidermis, the stratum corneum, which exists out of 
terminally differentiated keratinocytes.1, 2 Recently, research showed that the epidermal 
compartment, in more particular the skin barrier function, is involved in the pathogenesis 
of immune-mediated skin disorders such as atopic dermatitis3 and psoriasis.4 In addition, 
some skin diseases such as lichen planus, vitiligo and psoriasis arise at sites of a disrupted 
skin barrier, which is known as the Koebner phenomenon.5
 Already in 1876, the appearance of psoriatic lesions in the uninvolved skin of psoriasis 
patients after disruption of the skin barrier as a consequence of surface trauma was 
described by Heinrich Koebner.6, 7 Studies have shown that about 25% of psoriasis patients 
have a history of developing new psoriatic lesions within traumatized skin.8, 9 However, 
the Koebner phenomenon is not restricted to psoriasis and diseases such as lichen planus 
and vitiligo proved to respond to surface injury with skin lesions as well.5 So, koebnerization 
is not a disease-specific phenomenon but rather a pathogenetic principle in several 
 immune-mediated diseases. In healthy individuals, skin injury induces transient changes 
in the epidermis with hyperproliferation, abnormal keratinization and inflammation, but 
without development of a persisting inflammatory skin lesion. It is speculated that the 
response to surface trauma in normal skin might harbor mechanisms which are also 
relevant to the development of skin conditions exhibiting the Koebner response. 
 Removing the stratum corneum by tape stripping has been used for decades as an 
in vivo model for disruption of the skin barrier for studies on regenerative epidermal 
proliferation and keratinization.10-12 The regenerative skin transiently presents histological 
features resembling to the histological hallmarks of skin inflammation, such as epidermal 
thickening, parakeratosis and a mixed inflammatory infiltrate. Repeated application of 
tape until glistening of the skin proved to induce a highly reproducible regenerative 
response with respect to hyperproliferation and regenerative differentiation. Not only the 
magnitude of the response, but also the time frame between injury and appearance of 
epidermal changes was highly reproducible. The skin regenerating from standardized 
surface trauma represents a trigger for development of skin diseases arising at sites of 
cutaneous injury. The appearances of inflammatory cells and relevant cytokines have not 
been studied in depth in this context. 
 In the present study, the regenerative skin is used as a simplified model to study the 
dynamics of newly discovered drivers of the pathogenesis of immune-mediated diseases 
after standardized barrier disruption. We focused on T-Bet+ Th1 cells, representing the 
adaptive immune system, elastase+ polymorphonuclear leukocytes as representatives of 
the innate immune system, human β-defensin 2 (hBD-2) and elastase proteinase inhibitor 
(elafin) as host defense proteins, and the key cytokine interleukin 17 (IL-17). In addition, 
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epidermal differentiation (Ki-67) and proliferation (keratin 10 and 16, K10 and K16) as 
well-established markers for epidermal regeneration were studied immunohistochemically.
Subjects and Methods
Subjects
Ten healthy volunteers, three males and seven females, aged between 18 and 46 years, 
participated in this investigation. None of the subjects had any signs or history of skin 
disorders. The experiments were approved by the local medical ethics committee and 
conducted according to the Declaration of Helsinki principles. After having given informed 
consent, the subjects were seen five times for tape stripping and biopsy procedures. 
Tape Stripping and Biopsy Procedures
Tape stripping was performed on two areas of the lower back measuring 3 x 2 cm. 
Sellotape was applied to the skin and removed repeatedly (50 - 80 times) until the surface 
became slightly shining. Three mm punch biopsies were taken after local anaesthesia 
from the center of the tape stripped sides after 16, 24, 48, and 72 hours. Time intervals 
were based on previous studies. One additional biopsy was taken at baseline from 
non-challenged skin, serving as an internal control. Tissue samples were formalin-fixed, 
embedded in paraffin and sectioned at 4 µm. 
Histological Assessments 
Staining procedures were performed using the Envision Kit according to the regulations 
of our laboratory. Paraffin-embedded sections were deparaffinezed and rehydrated. 
Endogenous peroxidase activity was blocked by 2% H2O2 in phosphate-buffered saline, 
and sections were incubated with 1% bovine serum albumin (BSA) (Dako, Glostrup, 
Denmark). Antigen retrieval was achieved by 0.1% trypsin solution (pH 7.8, 10 minutes at 
37 ⁰C) for K10 staining (RKSE60, Euro-Diagnostica BV, 1:5,000), citrate buffer (pH 6.0, 10 
minutes at 100 ⁰C) for K16 (LL025, Sanbio BV, 1:50) and Ki-67 staining (MIB-1, Dako, 1:100) 
and Tris/EDTA buffer (pH 9.0, 10 minutes at 100 ⁰C) for IL-17 staining (polyclonal goat IgG, 
R&D Systems, 1:500). The other primary antibodies used for elastase (NP57, Dako, 1:10,000), 
HBD-2 (Abcam, Cambridge, 1:50), elafin (HM2063 / TRAB2F, 1:500,000), and T-Bet staining 
(H-210 sc-21003, R&D Systems, 1:1,500) did not require antigen retrieval steps. Sections 
were incubated overnight at room temperature with primary antibodies dissolved in 1% 
BSA. Visualization of the primary antibody was achieved with 3,3’-diaminobenzidine tetra-
hydrochloride solution (Sigma-Aldrich, St. Louis, Mo., U.S.A.) and counterstaining with 
Mayer’s haematoxylin (Sigma-Aldrich). Substitution with 1% BSA served as a negative 
control.
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Microscopic Quantification of Immunohistochemical Markers
Skin sections were assessed semi-quantitatively using an Axiokop 2 MOT microscope 
(Zeiss) at 100x magnification, digital camera (Axiocam MRc5, Zeiss) and AxioVision 
software (Zeiss). All microscopic evaluations were performed by two observers (A.H. and 
R.K.) and repeated on two different occasions per specimen, analyzing the whole section. 
With respect to the epidermis, an area was measured across the whole section, without 
stratum corneum, using ImageJ 1.38× software (National Institutes of Health). For 
quantification of the epidermal expression of K10, K16, elafin and hBD-2, the percentage of 
the epidermis with a positive signal was measured using the ImageJ macro ‘color 
deconvolution’, adapted from Ruifrok and Johnston.13 The region of interest of the dermal 
compartment was defined as the surface from the basement down to 350 µm across the 
whole section and was assessed using the same software. For analysis of T-Bet, IL-17 and 
elastase, the dermal surface area was measured as mm2 and positive cells were counted. 
The cell counts were expressed as number of positive cells per mm2 dermis. Cells positive 
for Ki-67 were counted and expressed as positive cells per mm length of basement 
membrane. 
Statistical Methods
The results were expressed as means ± standard error of the mean. Time-related changes 
in immunohistochemical variables were assessed using a Wilcoxon matched-pairs signed 
rank test. Throughout the analyses, p values < 0.05 were considered statistically significant.
Results
Within all volunteers, erythematous erosions with finally some crust formation were 
observed on the tape stripped sites. Also, in some of the test areas pinpoint bleedings 
were seen immediately after tape stripping, reminiscent of the Auspitz phenomenon (Fig. 1). 
Figure 2 shows an example of a haematoxylin and eosin staining of the skin before and 16 
hours after tape stripping. An overview of the immunohistological results is shown in 
Figure 3.
 Removing the stratum corneum led to a rapid activation of the epidermal compartment. 
At baseline, there was barely any sign of abnormal differentiation, depicted by the absence 
of K16 expression throughout the epidermis. Only in some of the tissue samples a minimal 
staining was found. Already 16 hours after disrupting the skin barrier, the expression of K16 
significantly increased (p = 0.0273) as compared to baseline. The extended K16 expression 
increased further during the course of the study, with a peak accumulation at 48 hours. 
 Approximately the same pattern was seen for the expression of the elastase-specific 
protease inhibitor elafin (percentage of elafin+ epidermal surface) in the epidermal 
compartment. After 16 hours the expression of elafin started to increase, with a maximal 
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expression after 24 hours (p = 0.0020), which declined after 48 hours. Along with the onset 
of elafin expression, tape stripping led to an increased expression of the skin antimicrobial 
peptide hBD-2 (percentage of hBD-2+ epidermal surface) after 16 hours (p = 0.0020). 
However, in contrast to the expression of K16 and elafin, no further increase in expression 
of hBD-2 was observed thereafter. 
 The number of cycling epidermal cells reflecting epidermal proliferation, depicted by 
the number of Ki-67+ nuclei, decreased significantly as compared to baseline 16 and 24 
hours after tape stripping (p = 0.0039, and 0.0098 respectively). This was followed by a 
marked increase after 48 hours (p = 0.0078). The expression of K10 showed the same gross 
overall intensity at all time intervals (results not shown).
 Along with the activation of these epidermal markers, tape stripping resulted in an 
influx of immune cells within the dermal compartment within 16 hours. At this time 
Figure 1   Erythematous erosion with  
pinpoint bleedings
Photograph taken immediately after tape stripping.
Figure 2   Haematoxylin-eosin staining before and 16 hours after removal of  
the stratum corneum
( a ) Haematoxylin-eosin staining at baseline, ( b ) Haematoxylin-eosin staining 16 hours after tape stripping at an 
objective magnification of x10 and x40. Arrows show polymorphonuclear leukocytes.
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almost all of these immune cells stained positive for elastase, indicative for neutrophils 
and monocytes (Fig. 2b). In contrast to the ongoing activation of the epidermal 
compartment, the number of elastase+ cells started to decline immediately after the peak 
accumulation at 16 hours (p = 0.0020); 72 hours after the skin had been traumatized, the 
number of elastase+ cells had almost restored back to normal. 
 Along with the influx of the elastase+ cells at 16 hours, a significant increase of IL-17+ 
cells was observed (p = 0.0020). During the course of the study, their pattern coincided 
with the elastase+ cells, with a peak accumulation 16 hours after removal of the stratum 
corneum and a declining number of IL-17+ cells thereafter.
 Already at baseline, a small number of T-Bet+ cells was present within the dermis. 
Along with the increase of the above-mentioned immune cells, the T-Bet+ cells showed a 
Figure 3  Overview of immunohistological results
The percentage K16+ ( a ), elafin+ ( b ) and hBD-2+ ( c ) epidermal surface, the number of Ki-67+ cells ( d ) per mm 
length of basement membrane, and the number of elastase+ ( e ), IL-17+ ( f ) and T-Bet+ ( g ) cells per mm2 dermis at 
baseline and 16, 24, 48 and 72 hours after removal of the stratum corneum by tape stripping are shown. Columns are 
means ± standard error of the mean. * Statistically significant compared to baseline (p < 0.05).
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significant but modest increase (p = 0.0020) 16 hours after tape stripping as compared to 
baseline. However, where the other cell types started to decline after 16 hours, the amount 
of T-Bet+ cells remained more or less consistently increased until 72 hours after tape 
stripping.
Discussion
In the present study, the immunohistochemical effects of disrupting the epidermal barrier 
were studied as a model for the regenerative skin to investigate the response to the 
trigger leading towards the formation of new cutaneous lesions in Koebner-positive 
diseases. It was demonstrated that epidermal rupture by tape stripping results in the 
activation of the epidermal compartment, accompanied by a reproducible inflammatory 
reaction of the skin. Both the biological markers representing the epidermal differentia-
tion and keratinization processes and the markers representing components of the 
immune system were rapidly activated after removal of the stratum corneum. 
 Tape stripping led to the formation of erythematous erosions at all test sites. The 
well-established reproducibility of the clinical responses could be reconfirmed.
 The epidermal compartment was activated within 16 hours after removal of the 
stratum corneum. Keratinocytes expressed almost no K16 at baseline, whereas an 
increased expression was already seen after 16 hours. As the expression of K10, which is 
known as a marker for normal differentiation, showed the same gross overall expression at 
all time intervals (results not shown), the expansion of K16 is more likely a consequence of 
the mechanical stress and not the result of abnormal differentiation. Moreover, at the 
same time the innate immune system was activated, depicted as the increase in the 
percentage of hBD-2+ and elafin+ epidermal surface. 
 Peak accumulation of the number of cycling epidermal cells was found 48 and 72 
hours after tape stripping, which reconfirms earlier observations.10, 14 Surprisingly, before 
this significant increase in epidermal proliferation became evident, the number of Ki-67+ 
nuclei decreased significantly as compared to baseline 16 and 24 hours after barrier 
disruption. This transient early decrease has not been reported before. One may speculate 
that this mechanical stressor transiently paralyzed the basal keratinocytes, resulting in a 
significant decrease in the amount of cycling cells after 16 and 24 hours. 
 An influx of elastase+ cells was seen 16 hours after traumatizing the skin. This observation 
confirms earlier observations.10 Our results show that, after a rapid upregulation and peak 
accumulation after 16 hours, the number of elastase+ cells already start to decline. This 
indicates that these innate immune cells play an important role within the acute phase 
after skin injury.
 IL-17+ cells appeared within the dermal compartment, coinciding with the course of 
the elastase+ cells over time. In addition to Th17 cells, various immune cells such as 
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elastase+ polymorphonuclear leukocytes and mast cells are able to produce IL-17 as 
well.15-18 Since these previous studies show that elastase+ cells can produce IL-17, and our 
results show that the course of the IL-17+ cells coincides with the course of the elastase+ 
cells, it is attractive to speculate that, within this model, IL-17 is produced by the elastase+ 
cells rather than by Th17 cells. The present study suggests that both elastase+ and IL-17+ 
cells play a major role predominantly in the acute inflammatory response. 
 On the other hand, T-Bet+ cells, corresponding to Th1 cells,19 showed an entirely 
different course over time. Along with the above-mentioned immune cells, a significant 
increase in T-Bet+ cells was seen after 16 hours. However, all other cell types started to 
decline already after 16 hours while the amount of T-Bet+ cells remained increased during 
the study period. These results indicate that IL-17+ and elastase+ cells dominate the acute 
phase following removal of the stratum corneum, whereas Th1 cells gradually increase 
several hours later when the numbers of other immunocytes are already decreasing.
 The Koebner phenomenon was first described by Heinrich Koebner in psoriasis 
patients.6 However, koebnerization is also observed in other cutaneous diseases, such as 
vitiligo and lichen planus.5 The pathogenesis of both vitiligo and lichen planus are only 
partly understood. In vitiligo the interaction between oxidative stress and both players of 
the adaptive and innate immune system appear to play a key role in initiating the disease.20 
Lichen planus is thought to be a T cell-mediated skin disease with an important role in the 
production of a variety of cytokines.21 In all three cutaneous diseases the imbalance of the 
immune system seems to play an important role in pathogenesis. The results of this study 
confirm that disruption of the skin barrier triggers the epidermal compartment and 
subsequently leads towards a broad array of immunological changes in the normal skin. 
This may suggest that the regulation of the activated immune system in Koebner-positive 
diseases may be impaired, leading towards an ongoing cutaneous inflammation as in the 
normal skin the immune response extinguishes within several days. 
 In summary, the present findings demonstrate that this highly reproducible in vivo 
model, in which the upper layers of the skin are removed mechanically, causes a rapid 
activation of the epidermal compartment, while immune cells rapidly fill the dermal 
compartment. Therefore key processes set off by cutaneous injury, which are presumed to 
play a role within the pathogenesis of Koebner-positive immune-mediated skin disorders, 
may be studied in a dynamic fashion.
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Abstract
Background Angiogenesis represents a key phenomenon in psoriasis. Insights in the 
 micro circulation within psoriatic lesions in a whole field are lacking. Recently, the Twente 
Optical Perfusion Camera (TOPCam) was developed, which provides the possibility of 
evaluating the superficial cutaneous microcirculation in a whole field.
Objectives This pilot study aims to examine whether the TOPCam can be used to visualize 
the microcirculation within and around psoriatic lesions, and whether it is capable of 
revealing vascular changes during topical treatment.
 Methods Five patients with chronic plaque psoriasis were included. The superficial micro-
circulation and clinical local scores (SUM score) were analyzed in two comparable lesions 
within one patient. At baseline and after 2, 4, 6, and 8 weeks the disease’s natural course 
was evaluated in one plaque versus topical treatment in the other.
Results The TOPCam was able to visualize an increased microcirculation within psoriatic 
lesions and perfusion variability due to the heartbeat. Whole field images demonstrated 
heterogeneity in perfusion intensity (hot and coldspots) within clinically homogeneous- 
looking plaques. Topical therapy induced a decrease in overall perfusion and a significant 
decrease in SUM score.
Conclusions The TOPCam is the first non-invasive technique to visualize the microcirculation 
of psoriatic lesions in a whole field, to correct images for the heartbeat, and to reveal 
heterogeneity in perfusion intensity.
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Introduction
Psoriasis is a common inflammatory disease affecting 2–3% of the Caucasian population.1 
It causes itch, and the stigma associated with visible skin lesions creates a serious 
psychological burden resulting in a severe impairment of quality of life.2-4 
 The pathophysiology of psoriasis is a complex unsolved riddle, involving components of 
the innate and adaptive immune system, genetics, and environment. It has been suggested 
that there are complex, intensive interactions between immune cells and keratino cytes 
establishing an interactive cytokine network, responsible for the development of psoriasis.5-11 
 However, the process of angiogenesis presents a key phenomenon in the development 
of this disease.12 Histologically, psoriatic lesions show elongated and dilated, slightly tortuous 
blood vessels within the dermal papillae. These vascular modifications of cutaneous 
micro circulation represent one of the earliest detectable histological changes and are 
typical in all stages of lesional development.13 In addition, the increased dilatation, 
tortuosity, and permeability of these dermal papillary capillaries precede visual epidermal 
hyperplasia14, 15 and disappear with disease clearance.12 The vascular changes during early 
stages of psoriasis pathogenesis closely correlate with enhanced cutaneous blood flow, 
even in the neighboring perilesional, clinically unaffected skin.16, 17 However, data on the 
microcirculation in a whole field are lacking. Major limitations of the techniques used 
previously are the small radius of only a few millimeters and slow scanning speed. This 
prohibits visualizing an overview of the whole superficial microcirculation within psoriatic 
lesions. 
 Nonetheless, there is a variety of different technical methods available for non-invasive 
investigation of vessels and vessel formation in health and disease.18, 19 Laser Doppler 
Perfusion Imaging (LDPI) is a non-invasive method widely used to evaluate the vascular 
abnormalities in dermatology. A major disadvantage of scanning-beam LDPI devices is 
their slow scanning speed, leading to patient discomfort and imaging artifacts. Recently, 
the BMPI group developed the Twente Optical Perfusion Camera (TOPCam),20 which is 
two orders of magnitude faster than scanning-beam LDPI systems which provides the 
possibility of rapidly evaluating the perfusion (roughly speaking the product of concentration 
and velocity of moving erythrocytes) in the microcirculation of the skin in a whole field up 
to 15 x 15 cm2. 
 This pilot study aims to examine whether the TOPCam can be used to visualize the 
microcirculation within psoriatic lesions in a whole field, and to evaluate whether it is 
capable of revealing vascular changes within a plaque after topical treatment and during 
the natural course of the disease.
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Materials and Methods
Subjects
Five patients with chronic plaque psoriasis (2 females and 3 males; age range 56–71) 
participated in this study. Written informed consent was given by all patients before 
inclusion. The experiments were approved by the local medical ethics committee and 
conducted according to the Declaration of Helsinki principles.
Study Procedures 
Two representative psoriatic lesions, the ‘target lesions’, were defined at the screening 
visit. Patients with systemic antipsoriatic treatment were excluded from enrollment into 
the study. Two weeks prior to the baseline visit, topical treatment of the target lesions was 
stopped. From baseline visit, betamethasone dipropionate/calcipotriol monohydrate 
ointment was applied on one target lesion once a day, whereas the second target lesion 
was left untreated. At baseline visit, after 2, 4, 6 and 8 weeks of follow-up, perfusion images 
were made using the TOPCam, clinical color photographs were made, and clinical severity was 
assessed by performing a SUM score (scoring the erythema, infiltration an desquamation, 
but without considering the area). Before perfusion images were constructed, the target 
lesions were outlined with a black marker for orientation. Patients were instructed every 
visit to avoid scratching, local pressure and heavy physical exercise at least 30 minutes 
before measurements were performed. All clinical examinations and perfusion measurements 
were performed by the same investigator (A.H.). 
 The TOPCam, including its signal processing, is described in detail in reference 20. 
This whole field LDPI device uses an expanded rectangular laser beam with wavelength 
671 nm that illuminates a tissue area up to 15 x 15 cm2 at once. We used the TOPCam on a 
distance of 40 cm from the skin, corresponding with a measured tissue area of 
approximately 7 x 7 cm2. The incorporated CMOS camera provides a black-and-white 
photograph from the same location as the perfusion image and can be used for 
orientation purposes afterwards. The diaphragm was adjusted manually to have a 
maximum intensity of around 70–95% of saturation level (displayed on the screen by the 
Labview program). All measurements were conducted within the same air-conditioned 
room, with the room illumination turned off and curtains closed to minimize the influence 
of ambient light. Per pixel the perfusion was estimated as M1/DC, which is the first-order 
moment M1 of the power spectrum of photocurrent fluctuations, normalized with the 
average photocurrent value DC. More details are given in reference 20. To minimize 
variations in microcirculation by environmental influences like temperature and internal 
influences from the heart cycle, a background correction was conducted. A series of 
consecutive images at 24.4 frames per second was made during 7 seconds to visualize the 
perfusion cycle due to the heartbeat. To visualize the influence of the heartbeat on the 
microcirculatory perfusion in the skin, we first studied this within a healthy volunteer after 
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removal of the stratum corneum by tape stripping.21-23 Eight representative images 
measured at diastole were used to calculate the average perfusion image by averaging 
each individual pixel. Within this average diastole image, an internal control was selected 
from an area of unaffected skin by drawing three rectangles, which were kept the same 
during follow-up. As previous research showed that the arterioles supplying psoriatic 
lesions are still able to react on changes in temperature,24 the mean perfusion of these 
three rectangles was calculated in all measurements and this average was defined as 
‘normal’. Subsequently, all following images were rescaled to obtain this normal perfusion 
value within these rectangles. This means that when the normal perfusion was set 0.6 and 
the mean perfusion of the rectangles in the following measurement was 0.8, the resulting 
perfusion image was rescaled with a factor 0.75. 
 Results are presented as mean ± standard error of the mean. Time-related changes 
in clinical score (SUM) were assessed using the nonparametric Mann-Whitney test. 
Throughout the analyses, p values < 0.05 were considered statistically significant. 
Results
The superficial perfusion of the skin varies with the heart cycle. By making a series of 
consecutive perfusion images, a video could be composed and the perfusion cycle due 
to the heartbeat could be visualized. An example of the differences due to the heartbeat in 
the cutaneous microcirculation in a volunteer after tape stripping is shown in Figure 1. 
The video of the complete perfusion cycle can be seen on the movie file shown under the link 
to this article in ‘Supplementary material’ available at http://informahelthcare.com/toc/jdt.
 At baseline, the psoriatic lesions of all five patients showed a higher perfusion 
intensity compared to the distant uninvolved skin. In addition, a heterogeneity in the 
superficial microcirculatory perfusion within a clinical homogeneous-appearing plaque 
was found. Hot and coldspots were determined and defined as an area with the highest 
or lowest perfusion intensity, respectively (Fig. 2). 
 In addition, whole field images showed a higher perfusion intensity in the perilesional 
skin surrounding psoriatic lesions. Perfusion images depicted active edges, with a higher 
perfusion than the distant uninvolved skin, and inactive edges with approximately the 
same perfusion intensity as compared with the distant unaffected skin.
The microcirculation could be followed over time and differences between untreated and 
treated lesions could be nicely demonstrated by the TOPCam (Fig. 3). During topical 
treatment with betamethasone dipropionate/calcipotriol monohydrate ointment, the 
overall perfusion within the treated lesion decreased and restored back to the perfusion 
level of the unaffected skin (Fig. 3).
 Perfusion images clearly showed the increased superficial microcirculation within 
the untreated psoriatic plaques as compared to the distant unaffected skin (Fig. 2). With 
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Figure 1   Video images of tape stripped skin in a healthy volunteer showing the 
 influence of the heart cycle
The green line shows the mean perfusion in the image at a certain time point. The maximal and minimal 
 perfusion intensities are depicted with red and black, respectively (scale bar).
Figure 2   Perfusion differences within a psoriatic lesion with a clinical homogeneous 
appearance
Clinical photograph without and with overlying TOPCam image showing heterogeneity in perfusion intensity 
within one psoriatic lesion (patient 5). The hot and cold spots (i.e. the most and least perfused area) are depicted 
with the black and white circles, respectively.
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normalization of the overall superficial perfusion within the plaques, topical treatment 
also induced a decrease in erythema, infiltration and desquamation resulting in a remarkable 
decrease in SUM scores (Fig. 4). Already after 4 weeks of treatment a decrease in SUM 
scores was observed compared to baseline scores (p = 0.0112), and decreased further until 
week 8 (p = 0.0107).
 Regarding the untreated target lesions, the perfusion intensities stayed approximately 
the same during follow-up. After 8 weeks, all untreated lesions showed a higher perfusion 
intensity compared to the distant uninvolved skin, in contrast to the treated target lesions. 
Figure 3   Clinical photographs with and without integrated perfusion images at  
baseline and after 8 weeks of topical treatment
Clinical photographs with and without integrated perfusion images at baseline and after 8 weeks of topical 
treatment (patient 1). 
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This was also shown by the SUM scores, which did not differ significantly from baseline at 
any point during follow-up (Fig. 4). 
Discussion
This is the first study using a technique which is able to visualize the microcirculation 
within a psoriatic lesion in a whole field with minimal imaging artifacts. The scanning 
speed prevents patients from keeping absolutely still for more than 7 consecutive seconds, 
allowing measurements with minimal artifacts due to inevitable (micro) movements. 
 By means of the TOPCam the influence of the heart cycle on the superficial perfusion 
of the skin can be demonstrated. This is an important improvement regarding all other 
available systems to measure the superficial cutaneous blood flow, as we are no able to 
compare the perfusion at comparable moments within the heart cycle. The images show 
that due to the heartbeat, remarkable change in the superficial cutaneous perfusion can 
be observed. To our knowledge this is the first technique which is able to visualize the 
heartbeat and to correct for this. 
 The results showed that the TOPCam is able to visualize the microcirculatory perfusion 
within and around psoriatic lesions in a whole field. In addition, whole field images 
showed that within a clinical homogenous-appearing lesion, striking differences in 
perfusion intensities (hot and coldspots) can be detected by the TOPCam. Areas with a 
higher perfusion intensity were distinguished from areas with a lower perfusion intensity, 
indicating that there are remarkable differences in the perfusion while no obvious 
deviations in clinical appearance are present. Subsequently, perfusion intensity decreased 
Figure 4   SUM scores during the course of the study
Topical therapy induced a significant decrease in SUM scores (MEAN + SD) at week 8 (p = 0.0088). 
Compared to baseline, changes in SUM scores within the untreated target lesions were nonsignificant at any 
moment of follow-up.
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with clinical improvement. Therefore, it is very plausible that an area with the highest 
perfusion indicates an area with the highest disease activity, which we defined as hotspots. 
This raises the question whether immunohistological examination of areas with different 
disease activities could teach us more about the pathogenesis of psoriasis and the 
dynamics of the ongoing process of inflammation. Therefore, tissue samples from hot and 
coldspots (high- and low-activity areas, respectively) will be examined in the future. 
 As shown before, in the clinical unaffected skin surrounding psoriatic lesions, an 
increased perfusion was detected.16, 17 However, this was only seen at some edges and 
also only in some plaques. Assuming that angiogenesis is one of the first signs of psoriasis 
and correlates with disease activity, the perilesional skin with an increased perfusion could 
indicate the locations were psoriatic expansion may be expected. If this hypothesis holds 
true, the TOPCam could be important in the prediction of the development of new 
psoriatic lesions. 
 In conclusion, the TOPCam is the first non-invasive technique to visualize whole field 
imaging of the superficial microcirculation of psoriatic lesions with minimal imaging 
artifacts. For the first time it is possible to correct perfusion images for the influence of the 
heartbeat and a straight comparison between the consecutive measurements of one 
lesion can be made. In addition, the TOPCam can detect changes in the microcirculation 
due to local treatment and is able to reveal heterogeneity in perfusion intensity. This 
non-invasive technique could be of great value in future psoriasis research.
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Abstract
Background Previous research revealed heterogeneity in the perfusion intensity (PI) within 
clinically homogenous appearing plaques, without differences in erythema. In addition, 
an increased perfusion was found within the perilesional skin. This raises the question 
whether the heterogeneity in perfusion found both inside and outside a lesion, influences 
the expression levels of genes and proteins involved in the pathogenesis of psoriasis.
Objectives To correlate the PI to mRNA and protein expression of genes associated with 
the pathogenesis of psoriasis and to visualize the dynamics of the PI over time using Laser 
Doppler Perfusion Imaging (LDPI).
Methods Fourteen patients with plaque psoriasis were included. The superficial micro-
circulation and clinical local scores (SUM scores) were analyzed in one representative lesion 
every two weeks. After eight weeks four biopsies were taken; one from a highly perfused 
area (hotspot) and one from a low perfused area (coldspot) of the lesional skin, one biopsy 
from the highly perfused perilesional skin, and one from the distant uninvolved skin.
Results Statistically significant differences in mRNA and protein expression, including IL-17 
and TBX21/T-Bet, were found between hotspots and coldspots, and between the highly 
perfused perilesional and the uninvolved skin. Hotspots tend to remain on the same 
location during eight weeks of follow-up.
Conclusions Within homogenously appearing psoriatic plaques, there are remarkable 
differences in mRNA and protein levels, which are correlated with the PI and can be 
detected by using LDPI. In addition, differences in mRNA and protein expression between 
the highly perfused perilesional skin and the uninvolved skin were found, indicating that 
several biological changes occur well before clinical changes become manifest.
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Introduction 
Psoriasis is a common inflammatory disorder of the skin that has both genetic and 
environmental causes to its aetiology. The pathophysiology is complex and thought to 
involve an interaction between the innate and adaptive immune system, the epidermis 
and the vascular system.1-11 Psoriatic lesions are histologically characterized by vascular 
alterations which are typical in all stages of lesional development12 and represent one of 
the earliest detectable histological changes.12, 13 In addition, visual epidermal hyperplasia 
is preceded by an increase in dilatation, tortuosity and permeability of the papillary 
capillaries in the dermal compartment,14, 15 which disappears again with remission of the 
cutaneous lesions.13 These vascular changes closely correlate with an increase in the 
cutaneous blood flow, even in the perilesional, clinically unaffected skin.16, 17 
 Until recently, investigations on the microcirculation within psoriatic lesions were 
limited as the perfusion was measured with laser Doppler perfusion monitors using fiber 
optic probes,13, 14 or laser Doppler perfusion imagers with slow scanning beams,18 
prohibiting the rapid visualization of a proper overview of the superficial microcirculation 
of psoriatic lesions in a whole field.16, 17 In a pilot study19 we showed that the non-invasive 
Twente Optical Perfusion Camera (TOPCam)20 can be used to visualize the superficial 
 microcirculation of psoriatic lesions with minimal imaging artifacts in a whole field. This 
full field Laser Doppler Perfusion Imager (LDPI) provides the possibility of rapidly visualizing 
the perfusion (defined as the product of the concentration and the velocity of moving 
erythrocytes) in the microcirculation of the skin in a whole field. One of the additional 
major advantages of this scanning method is the possibility to correct perfusion images 
for the influence of the heartbeat. Whole field perfusion images showed that within a 
clinically homogenously appearing lesion, striking differences in perfusion intensities 
could be detected indicating that there is a remarkable perfusion variation, whilst these 
changes were not paralleled by overt deviations in clinical appearance.19 By means of the 
TOPCam we identified areas with a high perfusion intensity and low perfused areas, which 
we defined as hotspots and coldspots, respectively.19 Subsequently, as has been described 
before,13, 14 perfusion images revealed an enhanced perfusion intensity in the clinical 
unaffected perilesional skin as compared to the distant uninvolved skin.19 As angiogenesis 
is one of the first detectable signs of the formation of new psoriatic lesions and normalizes 
with disease clearance, these results raised the question whether further examination of 
areas with different perfusion intensities could teach us more about the pathogenesis of 
psoriasis and the dynamics of the ongoing process of inflammation.
 This study aims to correlate the perfusion intensity (i.e. hotspots versus coldspots, and 
HPls versus distant uninvolved skin) to the expression levels of genes associated with the 
pathogenesis of psoriasis. We analyzed epidermal proliferation (Ki-67) and differentiation 
(keratin 16, (K16)), human β-defensin 2 (hBD-2) and elastase proteinase inhibitor (elafin) as 
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host defense proteins, elastase+ polymorphonuclear leukocytes as cellular representatives 
of the innate immune system, and the key cytokine interleukin 17 (IL-17). In addition, CD3 
as a general marker for T cells and T-Bet as a marker for T helper 1 cells were studied 
as representatives of the adaptive immune system. CD31 was used as a marker for the 
presence of dermal capillaries. In addition, we sought to visualize the dynamics of the 
perfusion intensity within a psoriatic lesion over time using the TOPCam.
Materials and Methods
Subjects
Fourteen patients with chronic plaque psoriasis were included in this study. Written 
informed consent was given by all subjects before enrollment. The experiments were 
conducted according to the Declaration of Helsinki principles and were approved by the 
local medical ethics committee.
Study Procedures 
Two weeks prior to the baseline visit, one representative psoriatic lesion was defined for 
follow-up and will be referred to as the ‘target lesion’. Patients on systemic antipsoriatic 
drugs were excluded from participation in the study and all topical treatment of the target 
lesion was stopped two weeks before start of the study. At baseline visit, after 2, 4, 6 and 
8 weeks of follow-up, perfusion images were constructed using the TOPCam after 
outlining the target lesion with a black marker for orientation. Clinical severity was 
assessed every visit by performing a SUM score (scoring the erythema, infiltration and 
desquamation, but without considering the area), which were all performed by the same 
investigator (A.H.). Patients were instructed every visit to avoid scratching, local pressure 
and heavy physical exercise at least 30 minutes before measurements were performed. 
 To conduct perfusion images, the TOPCam was used on a distance of 40 cm from the 
skin, corresponding with a measured tissue area of approximately 7 x 7 cm2. To achieve a 
maximal intensity of around 70-95% of saturation level (displayed on the screen by the 
Labview program controlling the measurements), the camera diaphragm was adjusted 
manually. To minimize the influence of ambient light, all measurements were conducted 
within the same air conditioned room, with the room illumination turned off and curtains 
closed. The perfusion per pixel was estimated as M1/DC, which is the first order moment 
M1 of the power spectrum of photocurrent fluctuations, normalized with the average 
photocurrent value DC. More details on the TOPCam and its signal processing are given in 
full detail in reference 20. To account for variations in microcirculation by environmental 
influences like temperature and internal influences from the heart cycle, a correction was 
conducted using the background perfusion. A series of consecutive images at 24.4 frames 
per second was made during 7 seconds to visualize the perfusion cycle due to the 
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heartbeat. The images measured at diastole were used to calculate the average perfusion 
image by averaging each individual pixel. Within this average diastole image, an internal 
control was selected from an area of unaffected skin by drawing three rectangles. As 
previous research showed that the arterioles supplying psoriatic lesions are still able to 
react on changes in temperature,21 the mean perfusion of these three rectangles was 
calculated and this average was defined as the ‘background perfusion intensity’. Every 
pixel of the perfusion image was then divided by this average, making the background 
value around one. This means that a perfusion intensity of 10 corresponds to a perfusion 
intensity which is 10 times higher as the background perfusion intensity. 
 At the end of follow-up, four punch biopsies (diameter 4 mm) were taken after local 
anaesthesia (xylocaine 2% ⁄adrenaline 1:200 000). Two biopsies were taken from the 
lesional skin, one from a hotspot (an area with a high perfusion intensity) and one from a 
coldspot (an area with a low perfusion intensity), one biopsy was taken from the highly 
perfused perilesional skin (HPls), and one biopsy was taken from the distant uninvolved 
skin. Specimens were cut into half, one half was formalin-fixed, embedded in paraffin and 
sectioned at 4 µm for immunohistochemical evaluation, and one half was snap frozen and 
stored for quantitative polymerase chain reactions (qPCR).
Immunohistochemistry 
After deparaffinizing and rehydrating the paraffin-embedded sections antigen retrieval 
was achieved by citrate buffer (pH 6.0, 10 minutes at 100⁰C) for CD31, K16 and Ki-67 
staining, EDTA/Tween buffer (pH 8.0, 10 minutes at 100⁰C) for CD3 staining and Tris/EDTA 
buffer (pH 9.0, 10 minutes at 100⁰C) for IL-17 staining. All other stainings did not require 
antibody retrieval steps. The endogenous peroxidase activity was blocked by using 3% 
H2O2 in methanol and after being pre-incubated with 1% bovine serum albumin (BSA) 
(Dako, Glostrup, Denmark), sections were incubated overnight at room temperature 
with primary antibodies dissolved in 1% BSA (for all primary antibodies used see Table 1). 
3,3’-diaminobenzidine tetrahydrochloride (DAB) solution (Sigma-Aldrich, St. Louis, U.S.A.) 
was used to visualize the primary antibody and sections were counterstained with Mayer’s 
hematoxylin (Sigma-Aldrich). 
Microscopic Quantification of Cells and Surface Area
The Axiokop 2 MOT microscope (Zeiss) at 100x magnification, digital camera (Axiocam 
MRc5; Zeiss) and AxioVision software (Zeiss) were used to assess the skin sections 
semi-quantitatively. All microscopic evaluations were repeated on two different occasions 
per specimen and were all performed by one observer (A.H.). Regarding the epidermis an 
area across the whole section was measured, excluding the stratum corneum, using 
ImageJ 1.38× software (National Institutes of Health). Regarding the dermal compartment, 
the region of interest was defined as the surface from the basement down to 350 µm 
across the whole section and was assessed using ImageJ. For assessment of CD3, elastase, 
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IL-17 and T-Bet staining, all positive cells within the region of interest were counted and 
were expressed as number of positive cells per mm2 dermis. Cell nuclei staining positive 
for Ki-67 were counted and expressed as positive cells per mm length of the basement 
membrane. For quantification of the dermal CD31 staining and epidermal K16, elafin and 
hBD-2 stainings, the percentage of the dermis and epidermis, respectively with a positive 
signal was measured using the ImageJ macro ‘color deconvolution’, adapted from Ruifrok 
and Johnston.22
RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction 
One half of each biopsy was frozen in liquid nitrogen, grinded using a Micro Dismembrator U 
(B.Braun Biotech International, Melsungen, Germany), and subsequently dissolved in Trizol 
(Invitrogen). Total RNA for real-time qPCR was purified as previously described.23 From 
each sample 0.5 µg isolated RNA was used to generate strand cDNA using the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA, U.S.A.) according to the manufacturer’s 
recommendation. Real-time qPCR was performed with the CFX96 Real-Time Detection 
System for quantification with SYBR Green and melting curve analysis (Bio-Rad) as 
previously described.24 Expression of the genes of interest was normalized to the 
expression of the housekeeping gene human ribosomal phosphoprotein P0 (RPLP0) to 
determine relative expression for each gene which was measured with the delta-delta 
cycle threshold (ΔΔCt) method.25 Primers for qPCR (Biolegio, Nijmegen, The Netherlands) 
were only accepted if their efficiency was 100 ± 10%. Corrections were made for primer 
efficiency. All primer sequences and efficiency of amplification are given in Table 2. To give 
an impression of the degree of gene expression, the average Ct values for ever gene are 
included in Table 2.
Table 1  Overview of the primary antibodies used
Target Function and/or cell source Designation and source Dilution used
CD3 T cells 17143; F7.2.38, AbCAM 1:500
CD31 Dermal capillaries M0823; JC70A, Dako 1:80
Elafin Host defense protein HM2063 / TRAB2F 1:500 000
Elastase Neutrophils M0752; NP57, Dako 1:10 000  
hBD-2 Host defense protein Abcam, Cambridge, U.K. 1:50
IL-17 Interleukin 17 AF-317-NA; rhil-17, R&D Systems 1:500
K16 Abnormal epidermal  
differentiation
LL025; Sanbio BV, Uden,  
The Netherlands
1:50
Ki-67 Epidermal proliferation M7240; MIB-1, Dako 1:100
T-Bet T helper 1 cells sc-21003; H-210, R&D Systems 1:1 500
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Statistical Analysis 
All results were expressed as means ± standard error of the mean (SEM). Statistical analysis 
was performed by using SPSS v16.0 (SPSS, Benelux BV, Nieuwegein, The Netherlands). 
Differences in immunohistochemical variables and clinical scores were assessed using a 
Wilcoxon matched-pairs signed rank test. For the qPCR experiments, statistical analysis by 
Wilcoxon matched-pairs signed rank test was performed on ΔCt values (the difference 
between the target gene and the reference gene RPLP0) which were corrected for primer 
efficiency. P values < 0.05 were considered statistically significant.
Results
The subjects’ baseline characteristics are displayed in Table 3. Clinical scores of the target 
lesions showed no evident changes during follow-up, demonstrating the chronic 
character of the measured psoriasis plaques (Fig. 1). 
Perfusion Intensity
In a previous pilot study19 we proved that the TOPCam is able to visualize heterogeneity 
of the microcirculation within psoriatic lesions with a more or less homogenous appearance. 
After correcting the images for the influence of the heart cycle and the background 
perfusion as described in the methods section, the target lesions of all 14 patients showed 
some degree of heterogeneity in the perfusion intensity. Figure 2 depicts a series perfusion 
images of a psoriatic lesion located on the upper thigh, corrected for the influence of the 
heart beat and the background perfusion. Moreover, Figure 3 shows the same series of 
perfusion images after adjusting the scale of the perfusion units visualising only the areas 
with the highest perfusion intensity. These results showed that hotspots only exhibited 
minimal changes in location during follow-up in all patients. This indicates that variation 
in perfusion intensity within a psoriatic lesion tends to change slowly. 
Table 3  Baseline characteristics of the study population
Patients 14
     Males 10
     Females 4
Mean age (years) 59
     Range 37 – 71 
Mean SUM score at baseline 5.9
     Range 4  – 7 
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Figure 1   Course of the SUM score measured during follow-up
Bars represent mean ± SEM.
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Figure 2   Example of a series perfusion images corrected for the influence of the heart 
beat and the background perfusion
Hotspots and coldspots can be seen during the entire follow-up. The scale bar is identical for all images. 
The graph depicts the course of the corresponding clinical SUM score of this patient during follow-up. 
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 To obtain results on gene and protein expression levels, biopsies were taken from 
hotspots and coldspots within a psoriatic lesion, from HPls and the distant uninvolved 
skin. Figure 4 provides an illustration of the biopsy sites within two different psoriatic 
plaques showing a more or less homogenous appearance. 
Protein Expression
All immunohistological parameters showed a clear, stepwise increase in expression with 
the lowest levels within the distant uninvolved skin and the highest expression within 
hotspots. A summary of all immunohistological data is given in Figure 5. The number of 
cycling epidermal cells, indicative for the number of proliferating keratinocytes, was 
significantly higher within hotspots as compared to coldspots (p = 0.0134). Compared to 
Figure 3   Example of the course of the position of hotspots after adjusting the intensity 
scale within a psoriatic lesion
Highly perfused areas tend to stay on more or less the same location during 8 weeks of follow-up and seem to 
change positions only slowly. White and red arrows indicate the follow-up of 2 different highly perfused areas. 
It is to be noted that perfusion images are presented in different scales and are adjusted to visualize only the 
highest perfused areas. 
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the distant uninvolved skin, the number of Ki-67+ nuclei was significantly higher in the 
HPls (p = 0.0001). The proportion of abnormally differentiating keratinocytes, depicted by 
the percentage of epidermal surface staining positive for K16, was significantly higher 
within hotspots compared to coldspots (p = 0.0081), while only a small non-significant 
difference in expression was observed between the distant uninvolved skin and HPls. 
 Concerning epidermal markers for the innate immune system, the same pattern was 
seen for elastase-specific protease inhibitor elafin (percentage elafin+ epidermal surface) 
and the skin antimicrobial peptide human β-defensin 2 (percentage hBD-2+ epidermal 
Figure 4   Biopsy sites
The circles indicate the biopsy sites shown on the clinical picture and the corresponding perfusion image. 
Black circles indicate hotspots, white circles indicate coldspots, and red circles indicate highly perfused 
 perilesional skin (HPls), respectively. Note that different scales are used. 
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surface), showing a significant higher epidermal expression within hotspots as compared 
to coldspots (p = 0.0039 and 0.0015, respectively) and a significant higher expression in 
HPls as compared to the distant uninvolved skin (p = 0.0017 for both markers). 
 Regarding the cellular components of the innate immune system, the elastase positive 
polymorphonuclear lymphocytes within the dermis, no significant differences were 
found between the hotspots and coldspots (p = 0.0574) or between HPls and the distant 
uninvolved skin (p = 0.6257). 
 The cells staining positive for IL-17 showed significant differences between both 
hotspots and coldspots (p = 0.0093), and HPls and distant uninvolved skin (p = 0.0215).
 The amount of T cells present in the dermal compartment as depicted by the number 
of CD3+ cells was significantly higher within the HPls as compared to the distant uninvolved 
Figure 5  Data on immunohistochemical staining
The number of Ki-67+ cells ( a ) per mm length of basement membrane, the percentage K16+ ( b ), elafin+ ( c ) 
and hBD-2+ ( d ) epidermal surface, the number of elastase+ ( e ), IL-17+ ( f ) and T-Bet+ ( g ) cells per mm2 dermis, 
and the percentage CD31+ ( i )  dermal surface within the distant uninvolved skin, the highly perfused perilesional 
skin (HPls), within coldspots and in hotspots are shown. It is to be noted that protein levels are presented in 
different scales. Bars indicate mean ± SEM. * Statistically significant (p < 0.05).
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skin (p = 0.0034). The number of T cells found within the lesional skin was elevated, with 
the highest numbers found within the hotspots. However, differences between hotspots 
and coldspots were non-significant (p = 0.0771). Regarding the T-Bet+ Th1 T cell subset, 
the same pattern was seen as for the CD3+ cells. The highest numbers of T-Bet+ cells were 
found within the hotspots (p = 0.0034 as compared to the coldspots), and regarding the 
Figure 6  Data on relative mRNA expression
Bars indicate the relative epidermal mRNA expression levels; the intra-individual mRNA expression of the 
household gene (RPLP0) was used as a reference value in calculating the relative quantities of mRNA expression 
levels.  It is to be noted that the relative quantity is presented in different scales. Bars represent mean ± SEM. 
* Statistically significant (p < 0.05).
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non-lesional skin, the highest number Th1 cells was found in the HPls (p = 0.0134 as 
compared to the distant uninvolved skin).
 The percentage dermal surface staining positive for CD31, indicative for dermal 
capillaries, was significantly higher within hotspots compared to coldspots (p = 0.0479). In 
addition, within the HPls the percentage CD31+ dermal surface was significantly higher as 
compared to the distant uninvolved skin (p = 0.0002).
mRNA Expression
An overview of the mRNA expression levels of selected genes is summarized in Figure 6. 
The mRNA levels of keratin 16 (KRT16), elafin (PI3) and hBD-2 (DEFB4) were significant higher 
within hotspots as compared to coldspots and within HPls as compared to the distant 
uninvolved skin. In addition, a significant higher mRNA expression within hotspots versus 
coldspots was found for T-Bet, IL-17a and IL-8 (CXCL8). All other genes showed more or less 
the same trend with a higher expression within the lesional skin as compared to the 
non-lesional skin, except for TNF-α. No unambiguous differences between the biopsy 
sides were seen for this gene.
Discussion
This is the first study investigating the differences in perfusion intensity of clinically 
homogenously appearing psoriatic lesions in a whole field and the correlation of perfusion 
heterogeneity and important drivers in the pathogenesis of psoriasis. Results on the eight 
week follow-up of the localizations of hotspots showed that hotspots only exhibited 
minimal changes in location in all patients analyzed; indicating that variation in perfusion 
intensity within a psoriatic lesion tends to change slowly. These findings point out that 
hotspots are not a coincidental finding, but are a structural part of the homogenously 
looking psoriatic lesion. As differences in perfusion intensity correlate well with protein 
levels and the gene expression of important drivers in the pathogenesis of psoriasis, we 
might conclude that the psoriatic lesion has a focal organization of active psoriatic sites, 
involving endothelial, immunological and keratinocyte related aspects. 
 The cutaneous microcirculation has been investigated before and differences in the 
blood flow within psoriatic lesions have been described. The major limitation of the 
techniques used so far was the slow scanning speed of the devices, resulting in discomfort 
for the patient and therefore in movement artifacts. In addition, the small scanning radius 
prohibited the researchers to investigate larger areas at once.16-18 Histological assessment 
of the clinically unaffected skin immediately adjacent to the most active edge was done, 
but was limited to the analysis of a small selection of markers.16-18 The current approach 
with the TOPCam permits scanning of psoriatic lesions in a whole field.
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 Without consideration of the perfusion intensity, the perilesional skin has been 
histological assessed before. The study by Keijsers et al.26 did show significant differences 
in T cell counts in the perilesional skin as compared to the distant uninvolved, which was 
also found by Davison et al.18 The latter research group also identified the active edge of a 
psoriatic lesion as a representation of the evolving psoriatic skin by using scanning beam 
laser Doppler perfusion imaging.18
 In our study, we sought to identify differences in the perfusion intensity both in the clinically 
unaffected skin and in the psoriatic skin with a homogenous appearance. Remarkable 
differences on both protein and gene expression levels were found. Almost all markers 
used for epidermal proliferation and differentiation, markers for the innate and adaptive 
immune system, as well as the marker used for the amount of dermal capillaries showed 
a clear stepwise increase in expression with the lowest levels in the distant uninvolved skin 
and the highest expression in hotspots. An important exception is the mRNA expression 
level of TNF-α, showing no significant differences. These findings fit the results of previous 
studies that the TNF-α expression is regulated post-transcriptionally.27-30 This indicates 
that there is a heterogeneous cell biological composition within a clinically homogenous 
appearing lesion as well as within the clinically unaffected skin, which is related to the 
perfusion intensity. In addition, the significant differences on both protein expression and 
gene expression levels within a homogenous appearing psoriatic lesion indicate that the 
biopsy site influences the histological findings. 
 In a previous pilot study19 we found that topical treatment led to a reduction of the 
clinical scores as well as to the normalization of the perfusion intensity of psoriatic lesions. 
Because the results of this study show that the perfusion intensity correlates with 
important cell biological processes, it is interesting to further investigate the dynamics of 
the changing perfusion intensity during topical treatment. 
 In conclusion, this study shows that there are remarkable differences in both the RNA 
and protein expression levels, including IL-17 and TBX21/T-Bet, within homogenously 
appearing psoriasis plaques as well as within the non-lesional skin and that these findings 
correlate to the perfusion intensity as measured by the TOPCam. As perfusion is clearly 
correlated to biological modifications, even well before clinical changes become manifest, 
perfusion images might serve as a non-invasive tool to identify disease activity in cases 
where the naked eye is not able to do so.  
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Abstract
Background Vascular modifications represent a key feature in psoriatic plaques. Previous 
research with Laser Doppler Perfusion Imaging (LDPI) revealed a remarkable heterogeneity 
in the cutaneous perfusion within homogenous-appearing psoriatic lesions. Insights in 
the relation between perfusion during treatment and related biological changes are 
lacking.
Objectives To study the effect of calcipotriol-betamethasone dipropionate ointment on 
the microcirculation and the expression levels of immunohistochemical markers in 
psoriatic lesions compared to the distant uninvolved skin.
Methods Psoriatic lesions of fourteen patients were treated once a day during 8 weeks. 
Clinical  SUM scores and the perfusion intensity by means of LDPI were assessed every two 
weeks. After 8 weeks, a biopsy from the target lesion and one from the distant uninvolved 
skin were taken and stained for psoriasis-related markers, like IL-17 and CD31.
Results After 8 weeks, seven patients reached a SUM score of 0 or 1, and were classified as 
good-responders. The other patients were classified moderate-responders. The perfusion 
intensity decreased in all lesions during therapy. In the good-responders, all investigated 
psoriasis-related proteins within the treated lesions reached the expression level found 
within the distant uninvolved skin. The expression of CD31 however, was significantly 
higher in the treated lesions as compared to the distant uninvolved skin (p=0.0156). In the 
moderate-responders, almost all expression levels remained significantly elevated 
compared to the uninvolved skin.
Conclusions In the skin of good-responders the expression of dermal CD31+ endothelium 
remains significantly elevated within the treated lesions compared with the distant 
uninvolved skin, whereas a marked reduction in the perfusion intensity and SUM score 
was found. This indicates that clinical improvement might outrun endothelial changes.
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Introduction 
Psoriasis is a multifactorial disease in which vascular modifications play a key role in the 
pathogenesis.1-3 In a previous study4 we used the Twente Optical Perfusion Camera5 
(TOPCam), a Laser Doppler Perfusion Imager, to study the superficial microcirculation within 
psoriatic lesions. Results showed a remarkable heterogeneity in the perfusion intensity 
within homogenous-appearing psoriatic lesions. In addition, perfusion images showed 
increased perfusion intensity within the clinically unaffected perilesional skin,4 which has 
been described before.6-8
 The cutaneous blood flow in psoriatic lesions decreases during Goekerman therapy9 
and the results of a pilot study showed that the improvement in clinical scores due to 
topical treatment coincides with a decrease in the perfusion intensity.4 
 In the current study we sought to evaluate the effect of calcipotriol-betamethasone 
dipropionate (CBD) ointment on changes in perfusion intensity over time by using the TOPCam 
and on important psoriasis-related proteins. We focused on epidermal differentiation 
(Ki-67) and proliferation (keratin 16) as well established markers for epidermal regeneration, 
CD31+ dermis, representing dermal endothelium, T-Bet+ Th1 cells, representing the adaptive 
immune system, elastase+ polymorphonuclear leukocytes as representatives of the innate 
immune system, human β-defensin 2 (hBD-2) and elastase proteinase inhibitor (elafin) 
as host defense proteins, and the key cytokine interleukin 17 (IL-17). 
Methods
Fourteen patients with mild to moderate chronic plaque psoriasis, all candidates for 
topical treatment, were included in the study after having given written informed consent. 
The study was approved by the local medical ethics committee and was performed 
according to the Helsinki principles. 
 Patients were not allowed to use systemic antipsoriatic treatment, and were instructed 
to leave one representative psoriatic plaque, the target lesion, untreated during two 
weeks before baseline. After this wash out period, this lesion was treated once a day with 
CBD ointment during eight weeks. Every two weeks, the SUM score (summing severity 
scores for erythema, infiltration and desquamation, but without considering the area, 
ranging from 0 to a maximum of 12) was taken from the target lesion and perfusion 
images were obtained by using the TOPCam, displaying the perfusion intensity as the 
product of the concentration and the velocity of moving erythrocytes. Perfusion images 
were made in the same air-conditioned room and were corrected for the influence of the 
heart cycle and the background perfusion as has been described in detail before.4 After 
eight weeks one 4 mm punch biopsy was taken from the treated lesion and one additional 
biopsy was taken from the distant uninvolved skin serving as an internal control. The 
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collected specimens were formalin-fixed, embedded into paraffin and sectioned at 4 µm 
for immunohistological assessments. 
 Immunohistochemical procedures and microscopic evaluations have been described 
before in detail.10 For dermal CD31 staining (M0823/JC70A, Dako, Glostrup, Denmark, 1:80), 
antigen retrieval was achieved by citrate buffer (pH 6.0) for 10 minutes at 100⁰C.  The 
percentage of the dermis with a positive signal for CD31 was assessed microscopically and 
measured using the ImageJ macro ‘color deconvolution’.10
 All results are expressed as means ± standard error of the mean (SEM). Statistical 
analysis was performed by using SPSS v16.0 (Benelux BV, Nieuwegein, The Netherlands). 
Differences in immunohistochemical variables were assessed using a Wilcoxon matched- 
pairs signed rank test. P-values < 0.05 were considered statistically significant.
Results 
Four woman and ten men, aged 37-71 years, were included. At baseline, the mean SUM 
score of the target lesions was 6.0 (SEM 0.314). After two weeks of treatment a reduction in 
SUM score in all patients was observed and the mean SUM score dropped to 3.0 (SEM 
0.296), and declined further to a mean SUM score of 1.64 (SEM 0.341) after eight weeks of 
treatment. Seven subjects reached a SUM score of 0 or 1 (mean 0.57, SEM 0.202) after eight 
weeks of follow-up and were classified as good-responders. All other subjects were 
classified as moderate-responders and reached a mean SUM score of 2.71 (SEM 0.286). 
 The perfusion intensity decreased in all patients during therapy. Figure 1 shows 
examples of the course of the perfusion intensity over time within two patients (a good 
and a moderate responder), as well as the localization of the biopsy sites. 
 In the good-responder group, all of the investigated psoriasis-related proteins within 
the treated lesions reached the level of expression found within the distant uninvolved 
skin (Table 1). The only exception was the expression of CD31+ endothelium within the 
dermal compartment (Fig. 2). In these good-responders, the expression of CD31 was 
significantly higher in the treated lesions as compared to the distant uninvolved skin 
(Table 1).
 In contrast, almost all expression levels of all psoriasis-related proteins in the moderate- 
responders group were still elevated in the treated lesions compared to the distant 
uninvolved skin (Fig. 2).
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Figure 2  Immunohistochemical data
Data are reported as mean ± SEM. Blue rectangles represent the good-responders (n=7). Black dots represent the 
moderate-responders (n=7). The number of Ki-67+ cells per mm length of basement membrane ( a ); the 
percentage K16+ ( b ), elafin+ ( c ), and hBD-2+ ( d ) epidermal surface; the number of elastase+ ( e ), IL-17+ ( f ), 
and T-Bet+ ( g ) cells per mm2 dermis, and the percentage of CD31+ dermal surface ( h ) within the distant 
uninvolved skin and the treated lesional skin.
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Discussion
In the present study, the effect of CBD ointment on changes in lesional perfusion intensity 
and important psoriasis-related proteins was investigated. Disease severity, measured by 
the SUM score (range 0 to 12), declined during topical treatment. In addition, within all 
treated psoriatic lesions the perfusion intensity by means of the TOPCam, decreased. 
 Remarkably, while the SUM score of the good-responders was 0 or 1, and the 
perfusion intensity decreased markedly, the immunohistochemical expression of all 
investigated psoriasis related proteins decreased significantly and reached the level of 
intensity of the uninvolved skin except for the expression of CD31. The dermal expression 
of CD31 in the treated skin of these good-responders was still significantly elevated as 
compared to the clinically unaffected skin. 
Table 1  Immunohistochemical data 
Good-responders Moderate-responders
Distant
uninvolved 
skin
Treated
lesional 
skin
P-value
Distant 
uninvolved 
skin
Treated
lesional 
skin
P-value
Ki- 67 17.77 (2.524) 31.28 (8.971) 0.2969 20.73 (3.736) 76.51 (10.517) 0.0156
K16 0.01 (0.010) 0.09 (0.055) 0.5000 0.00 (0.000) 18.36 (8.685) 0.0625
Elafin 0.01 (0.010) 1.09 (0.738) 0.2500 0.00 (0.000) 18.65 (4.713) 0.0156
hBD-2 0.03 (0.010) 0.77 (0.479) 0.3430 0.02 (0.020) 23.67 (6.238) 0.0313
Elastase 12.03 (9.925) 12.61 (4.368) 0.4375 11.24 (3.473) 61.54 (30.645) 0.2969
IL-17 71.62 (8.215) 106.44 (24.604) 0.2188 65.93 (7.161) 112.32 (27.387) 0.0156
T-Bet 20.29 (3.055) 36.38 (4.532) 0.0625 45.61 (11.279) 113.53 (39.746) 0.2969
CD31 1.82 (0.269) 5.79 (0.677) 0.0156 2.39 (0.340) 7.99 (1.191) 0.0156
Immunohistochemical data are reported as mean (SEM) in the good-responder group (n=7) and moderate- 
responder group (n=7). 
The number of Ki-67+ cells are reported as the mean number of positive cells per mm length of basement 
membrane; K16, elafin, and hBD-2 are reported as the mean percentage of epidermal surface with a positive 
signal; the number of elastase+, IL-17+, and T-Bet+ cells are reported as the mean number of positive cells per 
mm2 dermis; CD31 is reported as the mean percentage of dermal surface with a positive signal within the 
distant uninvolved skin and the treated lesional skin. 
Differences in immunohistochemical variables between the distant uninvolved skin and the treated lesional 
skin are assessed using a Wilcoxon matched-pairs signed rank test. 
P-values < 0.05 are considered statistically significant.
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 The TOPCam displays the perfusion intensity as the product of the concentration and 
the velocity of moving erythrocytes5 and seems to be rather a reflection of the blood flow 
instead of the amount of dermal endothelium. Our results support this assumption as we 
found a spectacular decrease in blood flow, while the amount of dermal endothelium, as 
measured by the CD31 expression, remained elevated. 
 The elevated levels of CD31 expression in a effectively treated psoriasis plaque 
suggests that vascular modifications might be the last of all pathological changes present 
within psoriatic lesions, to normalize entirely. One could speculate that there is some sort 
of immunological scar present within the endothelium which only heals slowly or might 
not normalize entirely at all. This could explain why psoriasis tends to relapse at multiple 
small foci in a former psoriatic plaque. It is attractive to speculate that these foci may 
coincide with the elevated expression of CD31.
 In addition, it would be interesting to investigate whether the amount of CD31+ 
endothelium restores back to normal if treatment duration is prolonged. Possibly, a former 
psoriatic lesion (with a SUM score of 0 or 1) should be treated for a longer period of time 
in order to reach endothelial normalization to accomplish a longer remission. If this 
hypothesis holds true, the level of CD31 expression in a plaque could be a marker for 
treatment efficacy, and could give an indication of the most efficient treatment duration 
with the longest disease-free interval after ending therapy.
 In conclusion, results of the present study show that topical treatment with CBD 
ointment leads to normalization of the cell biological composition of treated lesions in 
good-responders as compared to the unaffected skin, except for the amount of CD31+ 
endothelium within the dermal compartment. Results indicate that clinical improvement 
might outrun the endothelial changes which may explain why new psoriasis lesions tend 
to appear at remission sites. Further studies are needed to elucidate the role of the 
endothelium within the pathogenesis of psoriasis. 
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Abstract
Background The use of recently introduced biologics targeting specific immune 
mechanisms has identified crucial steps in the pathogenesis of psoriasis. Studying the 
dynamics of changes of these target mechanisms in sequential skin biopsies during 
treatment with biologics may reveal potential biomarkers. Correlation between clinical 
parameters and the expression of specific genes during treatments may identify markers 
indicative of treatment response.
Objectives This observational open-label study aimed to provide an overview of important 
cell biological changes in lesional skin during treatment with adalimumab, and their 
relation to clinical improvement.
Methods Ten patients with moderate-to-severe plaque psoriasis were included and 
treated with adalimumab for 16 weeks. At baseline, and after 10 days and 16 weeks of 
treatment clinical scores were assessed and biopsies were taken to examine gene 
expression at the mRNA and protein level.
Results The expression of marker genes for innate immunity, and epidermal differentiation 
and proliferation was rapidly restored to normal levels, whereas genes of the adaptive 
immune system showed a delayed decrease. The static and dynamic course of CD1a+ 
Langerhans cells as well as Ki-67+ nuclei showed a significant strong correlation to the 
Psoriasis Area and Severity Index score. No correlation between interleukin-17 expression 
and clinical scores was found. 
Conclusions The innate immune system is affected during adalimumab treatment well 
before the changes in the adaptive immune system become apparent. We may speculate 
that the addition of a treatment with an early effect on adaptive immunity to adalimumab 
may result in superior effectiveness compared with monotherapies.
165
ADALIMUMAB CELL BIOLOGY STUDY
5
Introduction
Psoriasis is a chronic disease affecting about 2% of the Caucasian population. Over the 
years, various hypotheses on the pathogenesis of psoriasis have been proposed. At first, 
psoriasis was considered a keratinocyte-centered disorder with epidermal hyperplasia as 
the most prominent clinical and histological feature.1 From the 1980s onwards, a role for 
the immune system in its pathogenesis was suggested, based on the presence of large 
numbers of immune cells within psoriatic lesions.2-4 This hypothesis was supported by the 
beneficial therapeutic effect of systemic drugs targeting the immune system.5, 6 Further 
exploration of the role of the immune system revealed an important involvement of 
T cells. Until recently, psoriasis has been considered mainly to be a T helper (Th) 1 cell- 
mediated process,7 but today it is thought to be a complex multifactorial disease, with 
involvement of the adaptive immune system, with an important role for Th1 and Th17 
cells,8, 9 the innate immune system, with a significant role for polymorphonuclear 
leukocytes (PMNs), and for the skin barrier function of the epidermis.10
 Targeting tumor necrosis factor alpha (TNF-α) is an important approach in the 
treatment of patients with severe psoriasis. TNF-α is a naturally occurring cytokine that is 
involved in normal inflammatory and immune responses. Elevated levels of TNF-α play an 
important role within inflammatory diseases, such as psoriasis. Numerous clinical trials 
have demonstrated that the treatment of psoriasis with anti-TNF-α agents has an 
impressive clinical efficacy,11-13 which indicates the actual relevance of TNF-α in its 
pathogenesis. One of the current anti-TNF-α agents for psoriasis treatment is adalimumab. 
It is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only 
human peptide sequences. Adalimumab is produced by recombinant DNA technology 
and binds with high affinity and specificity to soluble TNF-α.14 It neutralizes the biological 
function of this cytokine by blocking its interaction with the cell surface TNF-α receptors. 
Adalimumab modulates biological responses that are induced or regulated by TNF-α, 
including changes in the expression of adhesion molecules, which are responsible for 
leukocyte migration.14 Recently, a few studies have been conducted to investigate the 
mechanism of action by which adalimumab leads to a clinical improvement of psoriasis, 
focusing on different components thought to play an important role in the pathogenesis 
of psoriasis. Various authors have investigated the effect of anti-TNF-α on different parts of 
the immune system. Marble et al.15 reported a rapid restoration of keratinocyte differentiation 
and a significant reduction in the number of dendritic cells, followed by the reduction of 
macrophages and T cells. In another study, the rapid restoration of the epidermal Langerhans 
cell density within the psoriatic lesions was described.16 In addition, the investigation by 
Soegaard-Madsen et al.17 demonstrated an association between neutralization of TNF-α 
due to adalimumab treatment and the inhibition of p38 mitogen-activated protein kinase 
(MAPK). Subsequently, a reduction in the p38 MAPK phosphorylation and a decrease in 
the expression of p38 MAPK-regulated genes, such as IL8 and IL17C, were shown.18
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 In the present study a broad range of key aspects of the pathogenesis of psoriasis was 
examined, including markers of the epidermal compartment (genes involved in epidermal 
proliferation and differentiation), and markers for both the innate immune system (including 
neutrophils, epithelial proteinase inhibitors and antimicrobial peptides), and the adaptive 
immune system (including Th1 cells and interferon (IFN)-γ), and some key cytokines 
(including interleukin (IL-)17, IL-8 and TNF-α), which have been shown to be relevant 
therapeutic targets. These markers were studied both at the mRNA and the protein level. 
The aim of this comprehensive study was to elucidate the dynamics of a broad range of 
cell biological changes, which have been suggested to be crucial for psoriasis, in lesional 
skin during the treatment with adalimumab. In particular, we investigated the dynamics 
of adalimumab-induced changes within one single study population. In addition, the 
correlation between clinical and cell biological changes was studied.
Material and Methods
Patients
Ten patients (five women and five men; age 42–73 years) with moderate-to-severe chronic 
plaque psoriasis were enrolled in the present observational open-label study. All experiments 
were approved by the local medical ethics committee prior to the study and were 
conducted according to the principle of the Declaration of Helsinki and in accordance 
with the Medical Research Involving Human Subjects Act (WMO). Written informed 
consent was given by all patients before inclusion. We included patients who were aged 
≥ 18 years, and had moderate-to-severe plaque psoriasis as defined by a Psoriasis Area 
and Severity Index (PASI) score ≥ 10 or a PASI score ≥ 8 in combination with a Skindex 
(instrument to measure the effects of skin diseases on patients’ health-related quality 
of life19) total score > 35 at the baseline visit. The patients had failed, were intolerant or 
had contraindications to methotrexate, phototherapy and cyclosporin. Patients with a 
known history of an allergic reaction or significant hypersensitivity to the constituents of 
adalimumab were excluded. Other exclusion criteria were: non-plaque psoriasis, recent 
infections, HIV or hepatitis B or C positivity, active tuberculosis, a history of malignancies 
(other than successfully treated non-metastatic cutaneous squamous cell or basal cell 
carcinoma, or cervical carcinoma in situ), and female patients who were pregnant or 
breastfeeding, or considered becoming pregnant during the study or within 5 months of 
the last dose of adalimumab. Prior to enrollment no systemic antipsoriatic treatment or 
phototherapy was used for 4 weeks. Participants were allowed to use topical antipsoriatic 
therapy until the baseline visit. One patient had to be at week 12 because his psoriasis 
worsened despite treatment. Therefore, the samples collected from this patient were not 
taken into account during analysis; data were only used in calculating the correlation 
between clinical and cell biological changes.
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Study Procedures
An initial dose of 80 mg adalimumab was given subcutaneously, followed by 40 mg 
adalimumab subcutaneously every other week starting 1 week after the initial dose. 
Treatment duration was 16 weeks. One representative psoriasis lesion, the ‘target lesion’, 
was defined at the baseline visit. At each visit, PASI and body surface area (BSA) scores 
were assessed and clinical photographs were taken. Before treatment, after 10 days and 4, 
8, 12 and 16 weeks of treatment, SUM scores (scoring the erythema, infiltration and 
desquamation, but without considering the area) were assessed from the target lesion. At 
baseline and after 10 days and 16 weeks of treatment, two punch biopsies (diameter 4 
mm) were taken from the target lesion after local anaesthesia (xylocaine 2% ⁄ adrenaline 
1:200 000). One biopsy was stored in Trizol (Invitrogen, Carlsbad, CA, U.S.A.) for quantitative 
polymerase chain reactions (qPCR) and the other biopsy was formalin-fixed, embedded in 
paraffin and sectioned at 4 µm.
Immunohistochemistry
After cutting, paraffin-embedded sections were deparaffinezed and rehydrated. Staining 
procedures were performed as described before.20 In short, after blocking endogenous 
peroxidase activity by 2% H2O2 in phosphate-buffered saline, sections were incubated 
with 1% bovine serum albumin (BSA). Antigen retrieval steps were used for keratin 10 (K10) 
staining (0.1% trypsin solution; pH 7.8, 10 minutes at 37 ⁰C), for keratin 16 (K16) and Ki-67 
staining (citrate buffer; pH 6.0, 10 minutes at 100 ⁰C) and IL-17 staining (Tris / ethylenedi-
amine tetra-acetic acid buffer; pH 9.0, 10 minutes at 100 ⁰C). Incubation with the primary 
antibodies (Table 1) dissolved in 1% BSA occurred overnight at room temperature. 
Visualization of the primary antibody was achieved with peroxidase-based EnVisionTM kits 
Table 1  Primary antibodies
Target Function and/or cell source Designation and source Dilution used
CD1a Langerhans cells M3571; 010, Dako 1:100
CD3 T cells 17143; F7.2.38, AbCAM 1:500
Elafin Host defense protein HM2063 / TRAB2F 1:500 000
Elastase Neutrophils M0752; NP57, Dako 1:10 000  
hBD-2 Host defense protein Abcam, Cambridge, U.K. 1:50
IL-17 Interleukin 17 AF-317-NA; rhil-17, R&D Systems 1:500
K16 Abnormal epidermal differentiation LL025; Sanbio BV, Uden,  
The Netherlands
1:50
Ki-67 Epidermal proliferation M7240; MIB-1, Dako 1:100
T-Bet T helper 1 cells sc-21003; H-210, R&D Systems 1:1 500
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(Dako, Glostrup, Denmark), 3,3’-diaminobenzidine tetrahydrochloride solution (Sigma-
Aldrich, St. Louis, Mo., U.S.A.) and counterstaining with Mayer’s haematoxylin (Sigma-
Aldrich). Substitution with 1% BSA served as a negative control.
Histological Quantification of Cells and Surface Area
All microscopic evaluations were performed by the same observer (A.H.) and repeated on 
two different occasions per specimen. Whole skin sections were assessed as described 
before20 using ImageJ 1.38× software (National Institutes of Health). In short, with respect 
to the epidermis an area without the stratum corneum, across the whole section was 
measured. The region of interest of the dermal compartment was defined as the surface 
from the basement membrane down 350 µm across the whole section. For analysis of 
CD1a the epidermal surface area, and for analysis CD3, T-Bet (a Th1-specific T box 
transcription factor), IL-17 and elastase, the dermal surface area was measured and positive 
cells were counted and expressed as number of positive cells per mm2 epidermis and 
dermis, respectively. Cells positive for Ki-67 were counted and expressed as positive cells 
per mm length of basement membrane. For quantification of the epidermal K10, K16, 
elafin and human β-defensin 2 (HBD-2) stainings, the percentage of the epidermis with a 
positive signal was measured.
mRNA Isolation and Real-Time Quantitative Polymerase Chain Reaction
Total RNA was isolated from the epidermis as previously described.21 A DNase I treatment 
was performed according to the manufacturer’s protocol (Invitrogen). First strand cDNA 
was synthesized using an input of 1 µg of DNase 1-treated RNA with the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA, U.S.A.) according to the manufacturer’s recommendation. 
Real-time qPCR was performed with the CFX96 Real-Time Detection System for quantification 
with SYBR Green and melting curve analysis (Bio-Rad) as previously described.22 Primer 
validation, qPCR reactions and determination of relative mRNA expression were performed 
as previously described.21 Expression of the genes of interest was normalized to that of 
human ribosomal phosphoprotein P0 (RPLP0). The relative quantity of gene expression 
was measured using the delta-delta cycle threshold (ΔΔCt) method.23 Primers for qPCR 
(Biolegio, Nijmegen, The Netherlands) were only accepted if their efficiency was 100 ± 
10%. Corrections were made for primer efficiency. Primer sequences and efficiency are 
shown in Table 2.
Statistical Analysis 
The results of immunohistochemical analysis are expressed as means ± standard error of 
the mean (SEM), and time-related changes were assessed using a one-way ANOVA 
repeated measures test, followed by a Bonferroni post hoc test. For the qPCR experiments, 
statistical analysis by ANOVA was performed on ΔCt values corrected for primer efficiency, 
followed by a Bonferroni post hoc test using SPSS v16.0 (SPSS, Benelux BV, Nieuwegein, The 
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Netherlands). ΔCt is the difference between the target gene and reference gene (RPLP0) Ct. 
The Spearman rank correlation analysis was used to explore the relationship between 
continuous variables. Throughout the analyses, p < 0.05 was considered statistically 
significant.
Results
Clinical Results
The baseline demographics and characteristics of the study population are specified in 
Table 3. The percentages of patients who previously received topical and systemic treatments 
are displayed in Figure 1. After 10 days of adalimumab therapy, a clinical improvement 
in PASI score was seen in half of the patients. The mean PASI score decreased from 16.93 
(SEM 2.64) at baseline to 14.94 (SEM 2.63) after 10 days, and to 1.07 (SEM 0.42) after 16 
weeks of therapy. The mean SUM score from the target lesions declined from 6.90 (SEM 
0.35) at baseline to 6.00 (SEM 0.69) after 10 days and to 0.40 (SEM 0.27) after 16 weeks. 
An overview of the improvement in clinical parameters during adalimumab treatment is 
depicted in Figure 2. 
Immunohistochemical Analysis
An overview of the results of the immunohistochemical analysis is shown in Figure 3. At 
baseline, all tissue samples revealed the classical psoriatic features: acanthosis, parakeratosis, 
elongated rete ridges and a mixed cellular infiltrate. 
Table 3  Demographic characteristics of the study population (n=10)
Patients, n 10
     Males 5
     Females 5
Age (years) 55 (42 – 73 )
Disease duration (years) 25.2 (6 – 47)
Age at onset (years) 29.1 (6 – 58) 
PASI at baseline 16.93 (9.7 – 38.4) 
BSA at baseline 24.96 (5.6 – 76.0) 
SUM score at baseline 6.9 (5 – 9)
PASI, Psoriasis Area and Severity Index; BSA, body surface area; SUM, score of erythema, infiltration and 
desquamation. Values are mean (range) unless otherwise indicated.
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Figure 1   The number of patients who previously received topical and systemic 
 treatments
ADA, adalimumab; CyA, cyclosporin; DTR, dithranol; EFA, efalizumab; ETA, etanercept; FAE, fumaric acid esters; IFX, 
infliximab; MTX, methotrexate; PDL, pulsed-dye laser; PUVA, psoralen plus ultraviolet; RTX, retinoids; TCS, topical 
corticosteroids; TCV, combination therapy with TCS and topical vitamin D analogues (TVD); UVB, ultraviolet B.
Figure 2   Clinical parameters during treatment with adalimumab as measured in the 
responding patients (n=10)
Dots indicate mean ± SEM. PASI, Psoriasis Area and Severity Index; SUM, score of erythema, infiltration and 
desquamation. 
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Figure 3  Overview of immunohistological results
The number of ( a ) CD3+, ( b ) T-Bet+, ( c ) elastase+ and ( d ) IL-17+ cells per mm2 dermis; percentage of ( e ) hBD-2, 
( f ) elafin+ and ( g ) K16+ epidermal surface; ( h ) the number of Ki-67+ nuclei per mm length of basement 
membrane; and ( i ) the number of CD1a+ per mm2 epidermis at baseline, and at 10 days and 16 weeks after 
adalimumab treatment. Note that protein levels are presented in different scales (n=10); bars indicate mean ± SEM. 
* Statistically significant compared with baseline (p < 0.05).
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 Within the dermal compartment, high numbers of CD3+ cells were present at 
baseline. After 10 days of treatment a slight decrease in CD3+ cells was found; however, 
differences were not statistically significant. The number of CD3+ cells decreased further 
until the end of the study. The course of the cells positive for the transcription factor for 
Th1-specific cytokines (T-Bet+ T cells) coincided with the CD3+ cells, with only a slight 
decrease after 10 days and a significant decrease after 16 weeks of treatment (p < 0.0001). 
 Within the chronic psoriatic lesions, only small numbers of dermal elastase+ PMNs 
were found. However, after 10 days of treatment with adalimumab, there was a significant 
decrease in elastase+ cells (p = 0.0371), and after 16 weeks, there were only some sporadic 
cells positive for elastase present within the tissue samples. 
 The cells staining positive for IL-17 showed a moderate, gradual decrease, with only a 
minimal, nonsignificant, decrease at the end of the study. 
 With respect to the epidermal compartment, along with the rapidly disappearing 
elastase+ cells, other markers of the innate immune system showed a significant decrease 
after only 10 days. This is depicted by the decrease of elastase-specific protease inhibitor 
elafin (percentage elafin+ epidermal surface) and the skin antimicrobial peptide hBD-2 
(percentage hBD-2+ epidermal surface). For both markers the same pattern is seen, with 
after 16 weeks hardly any epidermal surface area staining positive for elafin or hBD-2.
 The proportion of abnormally differentiating keratinocytes diminished, depicted by 
the declining percentage of epidermal surface staining positive for K16 after 10 days and 
16 weeks (p < 0.0001). At the same time, there was a decrease in the number of cycling 
epidermal cells, reflecting keratinocyte proliferation, depicted by a decreasing number of 
Ki-67+ nuclei within 10 days (p = 0.0098). Regarding the density of the CD1a+ Langerhans 
cells within the epidermal compartment, a significant increase was seen after only 10 days 
of treatment, further increasing until the end of treatment (p < 0.0001). 
Correlation of Protein Levels and Clinical Scores
The correlations between the PASI score and all examined protein markers were calculated 
in Table 4. In addition, the correlation between the local SUM score and the overall PASI 
score was calculated. Results show a significant but weak-to-moderate correlation 
between the SUM score and the PASI score (Spearman R = 0.49, p = 0.0043), and a strong 
correlation between the change in SUM score (ΔSUM) and change in PASI score (ΔPASI) 
(Spearman R = 0.78, p < 0.0001). Regarding the correlations between the protein markers 
and the clinical scores, there were two markers showing a significant strong correlation 
between both the static PASI score, measured at a certain time point and the corresponding 
number of positive cells, and between the dynamic changes in PASI score (ΔPASI) and 
the expression of these proteins over time. These were found for the static and dynamic 
correlation of CD1a+ Langerhans cells (Spearman R = -0.75 and -0.76, respectively; 
p < 0.0001 for both correlations) and for the course of the nuclei staining positive for Ki-67 
(Spearman R = 0.73 and 0.75, respectively; p < 0.0001 for both correlations) (Fig. 4).
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Gene Expression Levels during Treatment
An overview of the mRNA expression levels of selected genes, at baseline and during 
treatment, is summarized in Figure 5. Most genes showed a significant decrease after 16 
weeks of treatment. No significant decrease was detected in the mRNA levels of TNF-α, in 
contrast there was even a slight, but nonsignificant increase. In addition, the mRNA levels of 
CD26 and elastase showed a nonsignificant increase after 10 days of treatment, declining 
subsequently. Only the levels of IL-8 mRNA and Ki-67 mRNA showed a significant reduction 
after just 10 days of treatment.
Table 4  Correlations between clinical score and protein levels (n=11)
Correlation between PASI score  
and the expression of:
Correlation between ΔPASI  
and the change in the expression of:
Spearman R A p value Spearman R B p value
CD1a -0.75 < 0.0001 -0.76 < 0.0001
CD3   0.05    0.0045 0.33    0.1394
Elafin   0.64 < 0.0001 0.67    0.0007
Elastase   0.53    0.0015 0.25    0.2546
hBD-2   0.75 < 0.0001 0.69    0.0003
IL-17   0.15    0.4174 0.17    0.4523
K16   0.75 < 0.0001 0.54    0.0091
Ki67   0.73 < 0.0001 0.75 < 0.0001
T-Bet   0.61    0.0002 0.64    0.0015
hBD, human β-defensin; IL, interleukin; K, keratin; PASI, Psoriasis Area and Severity Index. 
Bold indicates a strong correlation (Spearman R ≥ 0.7 and ≤ -0.7). 
A Correlation between the PASI score and the different protein levels.
B Correlation between the change in PASI score (ΔPASI) and the change in the different protein levels.
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Figure 4  Overview of strong correlations
( a ) Levels of CD1a+ Langerhans cells and ( d ) the number of Ki-67+ nuclei, measured at three different times, 
with varying disease severity were plotted against the Psoriasis Area and Severity Index (PASI) score. A significant 
correlation was found; Spearman R = -0.75 ( a ) and 0.73 ( d ); p < 0.0001 for both correlations. ( b, e )  Correlation 
between the change in clinical score (ΔPASI) and ( b ) the change in the number of CD1a+ cells (ΔCD1a+ cells) or 
( e ) the change in  the number of nuclei expressing Ki-67 (ΔKi-67+ nuclei). Results show a strong correlation; 
Spearman R = -0.76 ( b ) and 0.75 ( e ); p < 0.0001, for both correlations (n=11). Note that 10 patients showed clinical 
improvement (negative ΔPASI) and that there was only one patient who showed an exacerbation (positive 
ΔPASI). ( c, f ) An overview of the course of the PASI score in relation to ( c ) the number of CD1a+ cells and ( f ) the 
relation to the number of Ki-67+ nuclei. Dots indicate mean ± SEM.
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Figure 5  Relative epidermal mRNA expression levels of target genes
Relative epidermal mRNA expression levels of target genes; the intra-individual mRNA expression of the 
household gene (RPLP0) was used as a reference value in calculation the relative quantities of mRNA expression 
levels. Note the relative quantity is presented in different scales (n=9); bars indicate mean ± SEM. * Statistically 
significant compared with baseline (p < 0.05).
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Discussion
This is the first study providing an overview of the dynamics of a broad range of important 
cell biological changes during adalimumab treatment on both mRNA and protein levels in 
one single study population. As all results have been obtained from the same subjects, all 
results regarding the various processes can be compared with each other without the bias 
of inter-individual variation.
 As the biopsies taken from the target lesions were used for analyses as a reflection of 
overall disease severity, we calculated the correlation between the local SUM score and 
the PASI score concerning the total skin. We showed that there was a significant correlation 
between both scoring systems and it was concluded that the target lesions were 
essentially representative for the overall disease severity.  
 Within the first 10 days we found a notable decrease of the PASI score in half of the 
patients. In parallel with the fast clinical response, a rapid normalization of epidermal dif-
ferentiation and proliferation was observed, depicted by the decline in the expression of 
K16 and number of cycling nuclei, respectively (Fig. 3g, h).
  Along with the restoration of homeostasis within the epidermal compartment, a 
rapid decrease in the activity of the innate immune system was observed, whereas 
decrease of the adaptive immune system markers seemed to occur more slowly. At the 
mRNA level, a similar trend of a rapidly normalizing innate immune system was seen. 
However, only the decrease in IL-8 and Ki-67 expression was significant after 10 days, 
probably because of large inter-individual variations. At the protein level, we found a 
significant drop in the number of dermal elastase+ cells, but the number of dermal CD3+ 
and T-Bet+ cells showed no significant decrease, whereas previous studies have shown 
that other antipsoriatic treatments such as potent topical corticosteroids24 are capable of 
reducing the number of T cells after only 7 days of treatment. The elastase+ PMNs are 
important cellular representatives of the innate immune system in psoriasis. PMNs 
accumulating in the stratum corneum forming microabscesses of Munro and spongiform 
pustules in the stratum Malpighi (micropustules of Kogoj) are indicative of active psoriasis. 
Moreover, studies have shown that PMNs and mast cells are capable of producing IL-17, 
and that the release of IL-17 from these innate immune cells may be central in the 
pathogenesis of psoriasis.25 
 Besides the well-accepted importance of IL-17 in the pathogenesis of psoriasis, there 
is an established role for Th1 cells and IFN-γ as well.26 It has been suggested that the IL-23/
IL-17-directed pathway leads to an active eruptive psoriasis, whereas the IL-12/
IFN-γ-directed pathway is predominant within chronic plaque psoriasis.26 Moreover, the 
results from two previous studies,20, 27 investigating the involvement of elastase+, IL-17+ 
and T-Bet+ cells within normal skin in the acute phase after leukotriene B4 application and 
removal of the stratum corneum, respectively, showed that the acute phase of 
inflammation in challenged skin is dominated by elastase+ and IL-17+ cells, suggesting a 
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more important role in the acute phase of inflammation. In contrast, T-Bet+ cells showed 
a more gradual course and may be more prominent in the more chronic and stable 
situation. In the present study, all patients were suffering from longstanding chronic 
plaque psoriasis and were not in a phase of acute exacerbation. In these patients we 
observed relatively high numbers of T-Bet+ cells and relatively low numbers of elastase+ 
and IL-17+ cells. Moreover, only a nonsignificant reduction in IL-23A mRNA was found. 
Regarding IL-17A mRNA, a reduction was found, which was only significant after 16 weeks 
of treatment, whereas no significant reduction on the protein level was found during the 
study. These findings fit the hypothesis that differences in cytokine composition may be 
indicative for a more acute disease or a more chronic disease. 
 During the study, one patient had to be withdrawn from the study at week 12 
because the psoriasis worsened despite adalimumab treatment. Therefore, the samples 
collected from this patient were not taken into account during analysis. However, there are 
some notable differences between the amount of cells stained positive for T-Bet within 
the baseline sample of this patient and the mean cell numbers found within the baseline 
samples of the 10 patients who completed the study, while PASI scores did not differ 
significantly. At baseline the mean number of T-Bet+ Th1 cells found in the responders was 
224 cells mm-2 (SD 45), while only 106 cells mm-2 were found in the baseline sample of the 
nonresponder. Regarding the number of cells positive for IL-17 and elastase, no remarkable 
differences were found between the nonresponder and the responders. Results should 
be interpreted carefully, because they were derived from one patient only. However, it 
would be interesting to investigate the cytokine composition in the lesional skin of more 
patients with an insufficient response to adalimumab treatment.
 As the disease severity of the target lesions was shown to be representative of the 
disease activity, as measured by the PASI score, we investigated the correlation between 
the PASI score and protein levels of the inflammation markers. We chose to investigate the 
correlation with protein levels because mRNA expression has high standard deviations. 
Only the presence and course of CD1a+ Langerhans cells and Ki-67+ nuclei showed a 
strong significant correlation with the PASI score at a single time point as well as for the 
changes during follow-up. As CD1a+ cells and Ki-67+ nuclei are not only indicative of the 
disease activity of the target lesion but proved to correlate with the overall skin 
involvement, it would be interesting to study whether reduction of these parameters 
precedes clinical improvement and whether these markers could serve as biomarkers 
predicting treatment response. 
 As has been described before, the expression of TNF-α mRNA did not change 
significantly during adalimumab treatment, as TNF-α expression in lesional psoriatic skin is 
regulated post-transcriptionally.17, 18, 28 Other studies have demonstrated that the early 
effects of adalimumab therapy are mediated by the reduction in p38 MAPK phosphoryla-
tion and a subsequent decrease in the mRNA expression of IL-1β, IL-8 and IL-20, which are 
all regulated through the p38 MAPK signaling pathway.18 Our findings reconfirm the rapid 
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decrease in IL-8 expression, as only the expression of IL-8 mRNA (and Ki-67 mRNA) showed 
a significant decrease after only 10 days of treatment. 
 In conclusion, this study provides a dynamic overview of the course of important 
players in the pathogenesis of psoriasis. During adalimumab treatment, representatives 
of both the epidermal differentiation and proliferation, and those of the innate immune 
system revert rapidly back to normal, while representatives of the adaptive immune system 
lag behind. As the principle of combining two drugs can be promising, it is attractive to 
speculate that a combination of drugs with different and synergistic mechanisms of action, for 
example targeting the innate and adaptive immune systems or targeting immunity and 
epidermal differentiation may provide a highly effective combination therapy. A synergistic 
approach may lead to a superior effectiveness and may help to prevent excessive use of 
the individual components thereby preventing adverse events. 
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Main Study Objective 
The main objectives of this thesis were to investigate niches in clinical evidence regarding 
topical treatments and niches in pathomechanistic insights relevant for current and future 
targeted treatments of psoriasis. In this chapter we will revert to the aims of this thesis, 
which were formulated in Chapter 1, summarize the most important conclusions and 
discuss the findings as reached according to these aims.
  An extensive systematic literature search was conducted to give an evidence-based 
overview of all the available combinations of topical treatments in psoriasis. To structure 
the results, topical antipsoriatic treatments were divided into classical topical therapies; 
comprising dithranol, coal tar and penetration enhancers (chapter 2.1), and first-line topicals, 
including topical corticosteroids, vitamin D analogues, retinoids and calcineurin inhibitors 
(chapter 2.2). The major conclusions on the efficacy and safety of each combination were 
described separately and recommendations were given. 
 Biological models provide the opportunity to study isolated events or cells of 
interest in a simplified environment. As the complexity of the multifactorial pathogenesis 
of immune mediated skin diseases such as psoriasis becomes more complex with the 
discovery of each new player in the field, such models may offer an important opportunity. 
For decades, two established in vivo models have been used, as an approach to study a 
psoriasis-like inflammatory reaction. Two immunohistological studies were set up to 
revise the dynamical effect of the application of leukotriene B4 (LTB4) (chapter 3.1) and 
the removal of the stratum corneum by tape stripping (chapter 3.2) in the light of our 
current knowledge regarding important drivers in the pathogenesis of psoriasis. 
Throughout this thesis we mainly focused on epidermal differentiation and proliferation 
representing the epidermal compartment; T helper 1 (Th1) cells representing the adaptive 
immune system; neutrophils as representatives of the innate immune system; human 
β-defensin 2 (hBD-2) and elastase proteinase inhibitor as host defense proteins; and the key 
cytokine interleukin 17 (IL-17). The most important conclusions were summarized separately 
and discussed subsequently. 
 As stated above, psoriasis is a multifactorial disease and among the role of keratino -
cytes and all important players of the innate and adaptive immune system, an increase in 
the cutaneous blood flow is thought to be a key phenomenon in the development and 
maintenance of psoriatic lesions. The pilot study described in chapter 4.1 was set up to 
explore the usability of the Twente Optical Perfusion Camera (TOPCam), a new Laser 
Doppler Perfusion Imager (LDPI), in the research on the superficial perfusion intensity of 
psoriatic lesions. In chapter 4.2, a correlation study was described investigating the relation 
between the superficial perfusion intensity by means of the TOPCam and the expression 
of important psoriasis-related genes and proteins.
 To further explore the effects on the above mentioned representatives of involved 
players in the pathogenesis of psoriasis during treatment with the combination of topical 
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corticosteroids and vitamin D analogues, research was performed in patients suffering 
from mild to moderate psoriasis (chapter 5.1). The effects of adalimumab, an anti-TNF-α 
agent, on these representatives were studied in patients with moderate-to-severe psoriasis 
(chapter 5.2).
Niches in Clinical Evidence
Aim 1:   To obtain an overview of efficacy and safety of combinations of topical therapies in 
psoriasis 
Combinations of Classical Topical Treatments
Penetration enhancers combined with topical corticosteroids: The combination of corticosteroids 
and penetration enhancers is well tolerated and more efficacious than monotherapy with 
either component.
Penetration enhancers and calcineurin inhibitors: Tacrolimus treatment with salicylic acid 
should be preferred above salicylic acid monotherapy. However, the superiority of the 
combination compared with tacrolimus monotherapy was not found.
Penetration enhancers combined with coal tar: Regarding the combination of coal tar with 
salicylic acid, no recommendations could be made. 
Coal tar in combination with topical corticosteroids: This combination regimen was shown less 
effective than another commonly used topical treatment with vitamin D monotherapy, whereas 
the safety seemed to be equal. Therefore, this combination therapy cannot be recommended. 
Coal tar in combination with dithranol: Combination therapy of coal tar and dithranol is at 
least as effective as both monotherapies, and could be preferred above coal tar monotherapy, 
whereas dithranol lipogel monotherapy seems to be favourable regarding the occurrence 
of skin irritation and staining. 
Dithranol combined with topical corticosteroids: Combination therapy may be preferred 
when using superpotent corticosteroids, whereas adding corticosteroids with a lower 
class of strength does not improve therapeutic efficacy. 
Dithranol combined with topical vitamin D analogues: The combination enhances the 
therapeutic efficacy of dithranol monotherapy within the first weeks of treatment, without 
a negative impact on its safety profile.
Combinations of Current First-Line Topical Treatments
Topical corticosteroids in combination with vitamin D analogues: The combination regimen 
seems to be safe and more efficacious than monotherapy with either active component 
in both the early treatment phase as well as in the long-term treatment. 
Calcineurin inhibitors in combination with topical corticosteroids: Combination therapy 
seems to improve the efficacy of calcineurin inhibitors monotherapy while no additive 
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benefit seems to be achieved compared to corticosteroid monotherapy, whilst no data on 
safety and tolerability of this combination is available. 
Topical retinoids in combination with topical corticosteroids: The combination with potent or 
superpotent corticosteroids seems to be more efficacious with a decreased incidence of 
side effect as compared with retinoid monotherapy. However, when compared with 
corticosteroid monotherapy, the additive value of this combined regimen has not been 
demonstrated. 
Topical retinoids in combination with vitamin D analogues: The combination showed no 
additive value above corticosteroid monotherapy. 
An overview of the amount of evidence found on efficacy and safety is stated in table 1, 
indicating the imbalance of evidence available between combinations on classical and 
first-line topicals. There is only limited evidence to support the use of combinations of 
classical topical therapies which is remarkable as these therapies have been used for 
decades by dermatologists. In some cases, the execution of double blind randomized 
controlled trials is impossible due to treatment characteristics. For example, the efficacy of 
dithranol is reached by gradual concentration increments until mild irritation, and the 
smell of coal tar therapy is undeniable. In addition, regarding the classical topicals, the lack 
of studies included is, partially, caused by the lack of standardized utilization methods. It 
Table 1  Overview amount of available evidence
Coal tar +
Dithranol * +
Corticosteroids ++ + +
Vitamin D analogues – – + +++
Calcineurin inhibitors + – – + –
Topical retinoids – – – + + –
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– no evidence found; + little evidence found; ++ moderate amount of evidence found; +++ much evidence 
found. 
* Penetration enhancers are used as a stabilizer for dithranol preventing oxidation, therefore this combination 
was not taken into account.
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would be more effective if investigators reached a consensus about using the same 
application methods and variables so results could be more easily compared to each 
other. For references the reader is referred to Chapter 2.
In conclusion: an overview of the available data on the efficacy and safety of 
combinations of topical antipsoriatic therapies was obtained. The amount of 
evidence found per combination is displayed in table 1. 
Aim 2:  To formulate recommendations on topical combination therapy
Combinations of Classical Topical Treatments
According to the results described in Chapter 2.1 the following combinations of topical 
classical therapies could be recommended:
· Combination therapy with topical corticosteroids and penetration enhancers; as penetration 
enhancers, like salicylic acid, seem to be useful particularly in case of plaques covered 
by thick scales, this combination is recommended principally for this group of psoriasis 
patients. In addition, the combination might be considered in case corticosteroid 
monotherapy is inadequate. 
As described in the section above, there is only limited evidence to support the use of 
combinations of classical therapies. The available evidence shows that only the combination 
of dithranol with tar or superpotent corticosteroids, and the combination of dithranol 
with calcipotriol is favourable above monotherapy. 
 From daily clinical practice it is known that treatment with classical topicals, mainly 
dithranol therapy, is used as an intervention to induce clinical improvement in patients 
suffering from moderate disease which cannot be treated with systemic therapies for any 
reason. These topicals are preferably used in specialized day care centers were patients are 
guided by specialized personnel. Therefore, using combinations of classical topicals could 
be implemented into the daily care without overloading patients with (more) complicated 
treatment patterns. As the literature showed that particular combinations lead towards a 
faster clinical improvement, the disease becomes faster manageable again for patients 
themselves, and this might shorten the treatment duration needed in a day care center, 
resulting in a decrease in health care costs and an increase in patient acceptability.
Combinations of First-Line Topical Treatments
According to the results described in Chapter 2.2 the following topical first-line combination 
therapies could be recommended:
· Combination of topical corticosteroids and vitamin D analogues; this combination has generally 
been proven to be more effective than monotherapy with topical corticosteroids or 
monotherapy with vitamin D analogues, while having a favourable safety profile.
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Among clinicians it is known that treatment compliance is a major issue for patients who 
are bound to the burden of daily topical treatment. Particularly in patients using first-line 
topicals such may be a limitation as patients themselves are responsible for the daily 
application, which is time consuming and may lead to cosmetic complains as ointments 
may stain clothes and leave a shiny film on the skin. The therapeutic efficacy of topicals 
mainly depends on regular application and irregular use may have only limited therapeutic 
effect leading to unmotivated patients. To optimize treatment compliance it is desirable 
that patients are rewarded by quick clinical results for all the effort they take, without the 
occurrence of severe side effects. On the long run this could lead towards a bigger part of 
the patients that can be treated sufficiently by topicals alone and thereby decreasing the 
number of patients in need for more expensive systemic drugs, which is desirable in our 
current society in which the costs of medical health care are continuously under debate. 
 The majority of psoriasis patients suffers from mild to moderate disease and in most 
cases the disease is limited to the skin and might be controlled with effective topical 
therapy only, which can be conducted by general practitioners. According to the Dutch 
guidelines for general practitioners (NHG standaard), the first step in treatment is to start 
with monotherapy with potent topical corticosteroids.1 Only when 4 weeks of treatment 
with potent topical corticosteroids fails, the combination of corticosteroids with vitamin D 
analogues is recommended. It is conceivable that when 4 weeks of topical treatment have 
not led to satisfactory therapeutic results, patients are less motivated when they receive 
another topical therapy thereafter. Therefore, it might be considered to use the combination 
of a topical corticosteroid and vitamin D analogues earlier.
 The combination of topical corticosteroids and vitamin D analogues are available in 
one formulation. This two-compound preparation is more expensive than combining the 
separate formulations; however, it is obvious that only one application a day improves 
treatment compliance and thereby improving clinical outcome. Subsequently, a better 
and quicker decrease in disease severity may lead to a decrease in the number of patients 
with mild to moderate disease that have to be treated by a dermatologist, resulting in an 
overall decrease in the costs for health care systems. 
 The lack of studies on the long-term efficacy and safety of combinations is remarkable. 
Data on the long-term use are very relevant as psoriasis is a chronic disease and patients 
are often bound to lifelong treatment. It might be interesting to investigate whether the 
extended use of topicals is still as effective as it is on the short run or that it might lead 
towards a loss of efficacy, which has been reported for some biologic agents.2, 3
In conclusion: although the concept of combining drugs can be very promising, 
there is only convincing evidence to recommend the treatment with penetration 
enhancers and topical corticosteroids, and the combination of topical cortico-
steroids and vitamin D analogues. Data on efficacy and safety regarding long-term 
treatment with topicals are lacking.
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Niches in Pathomechanistic Insights
Aim 3:   To further elucidate the dynamics of the early and consecutive stages of skin inflammation 
in two established in vivo models (i.e. the application of LTB4 and the removal of the 
stratum corneum by tape stripping) with respect to newly discovered drivers in the 
pathogenesis of psoriasis
The Application of Leukotriene B4
In chapter 3.1 the results on the immunohistochemical evaluation before and during the 
first 72 hours after the application of LTB4 on the skin of healthy volunteers was described. 
Neutrophils infiltrated the dermis within 8 hours after application. A peak accumulation of 
IL-17 producing cells and neutrophils was seen within the first 24 to 36 hours after 
application and dominated the acute phase of inflammation, indicating an important role 
in the instable phase of inflammation. On the other hand, from 24 hours on the Th1 cells 
showed a gradual increase during the entire observation period, which might imply a 
more prominent role in the chronic stage of inflammation. The epidermal compartment 
was activated only after 48 to 72 hours. 
Tape Stripping
The results on the removal of the stratum corneum, representing the regenerative skin, 
were described in chapter 3.2. An Immunohistochemical analysis of the healthy skin was 
conducted before and during the first 72 hours after inflicting standardized trauma to the 
skin. Rupture of the skin barrier, by using Sello tape, led to an activation of the epidermal 
compartment within the first 16 hours, which endured until the end of the observation 
period. The number of proliferating keratinocytes decreased significantly after 16 and 24 
hours as compared to baseline, increasing thereafter. The acute phase was dominated by 
neutrophils and IL-17 producing cells, whereas the number of Th1 cells increased gradually 
and stayed upregulated until 72 hours. 
Once again the results on both in vivo models proved to be highly reproducible as well 
known histological outcomes4-7 were also found in our investigations (Chapter 3). A high 
reproducibility is required if investigative methods want to be used in further studies. 
As both models have repeatedly proved to be highly reproducible, they provide reliable 
supporting tools for studying the regenerative skin and neutrophil dominated inflammatory 
reactions of the skin. 
 In the models investigated, two different triggers were used to set off an inflammatory 
reaction. The application of LTB4 (Chapter 3.1) was used as elevated levels of LTB4, produced 
by activated innate immune cells, are found within psoriatic lesions.8-12 This arachidonic 
acid derivative is able to induce leukocyte adhesion and activation directly and to induce 
a pronounced inflammatory reaction within the healthy skin by the formation of reactive 
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oxygen species in neutrophils and the release of lysosomal enzymes, which in turn affects 
the epidermal compartment.
 The mechanical removal of the upper layers of the epidermis (Chapter 3.2) led to a 
similar inflammation of the skin as was seen after the application of LTB4, even if not via 
the same order of events over time. This suggests that different triggers may lead towards 
a similar cutaneous inflammatory reaction. In psoriasis several triggers have been 
described, such as a streptococcal infection or inflicted trauma to the skin, the latter well 
known as the Koebner phenomenon. Although this phenomenon was first described in 
patients suffering from psoriasis,13 it is not disease specific and koebnerization is also seen 
in other cutaneous diseases. In chapter 3.2 it was shown that by disrupting the skin barrier 
the epidermal compartment is triggered and subsequently sets off a broad array of 
epidermal and immunological changes in the normal skin. Within the disease-free skin 
this immune response extinguishes within several days after disrupting the skin barrier. 
However, within Koebner positive skin diseases the upregulation of the immune system 
sustains and an ongoing cutaneous inflammation is found.
 The immunohistochemical changes which were seen in both models resemble, at 
least to some extent, the changes which are seen in the psoriatic skin. These changes are 
not disease specific as they can be seen also in healthy skin after application of LTB4 and 
after disrupting the skin barrier. The inflammatory changes within the epidermal and 
dermal compartments of psoriatic skin are accompanied by vascular changes and 
elongated and dilated, tortuous blood vessels within the dermal papillae are found. Within 
the models used, a rapid infiltration in various immune cells was observed after triggering 
the skin. Therefore, it is attractive to hypothesize that there is an increase in the vascular-
ization as well to make this rapid influx of immune cells possible. 
 The results from both investigations suggest that neutrophils and IL-17 producing 
cells may play a more important role in the acute inflammatory reaction of the skin just 
after the trigger is inflicted onto the healthy skin. Both cell types showed a rapid peak 
accumulation and declined thereafter showing a nicely coinciding course over time in 
both models. The Th1 cells on the other hand showed a much more gradual course over 
time. It has been suggested that overexpression of the IL-23/IL-17 axis leads towards active 
disease with the formation of new lesions,14 and that dominance of the Th1 cells and over-
expression of the IL-12/interferon-Ύ axis is found in chronic disease. Further examination 
by Keijsers et al.,15 investigating the role of neutrophils within these models showed that 
within these models, neutrophils are more likely to be responsible for the production of 
IL-17 than CD4+ T helper cells.15 It was shown that apart from the coinciding course over 
time, neutrophils expressed the transcription factor for producing IL-17 and that they were 
able to release IL-17 true specialized structures.15 
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In conclusion: the LTB4 model and the tape strip model, which have been used for 
decades, can also be used to study the newly discovered players in the field of the 
pathogenesis of psoriasis, like IL-17 producing cells and Th1 cells, in a dynamic 
fashion. 
Aim 4:   To explore the usability of a new whole field Laser Doppler Perfusion Imager in studying 
the superficial cutaneous perfusion within psoriatic lesions
Knowledge regarding the early changes in perfusion intensity may harbor important 
information about the (early) development of newly formed psoriatic lesions. Therefore, 
numerous studies have been conducted to investigate the superficial perfusion of a 
psoriatic lesion. The advantage of the Twente Optical Perfusion Camera (TOPCam), a novel 
Laser Doppler Perfusion Imager, is the ability to rapidly scan psoriatic lesions in a whole 
field up to 15 x 15 cm allowing measurement with minimal imaging artifacts due to (micro) 
movements, as the techniques used before had a small radius of only a few millimeters or 
slow scanning speed.16-18
 The results described in chapter 4.1 showed that the TOPCam is able to visualize the 
perfusion intensity in psoriatic lesions and the perilesional skin before and after treatment. 
The device can be used to scan an area up to 15 x 15 cm at once. However, to measure this 
surface area at once, the device has to be placed further away from the skin at the expense 
of scanning sharpness. Therefore, in our investigations we used the device at a distance of 
40 cm above the skin, corresponding to an area of 7 x 7 cm, as has been used before to 
investigate cutaneous burn wounds by another research group.19 
 Another very important advantage of the TOPCam is the ability to visualize the 
influence of the heart cycle on the cutaneous perfusion. Obviously, contractions of the 
cardiac ventricles determine the perfusion intensity of the vascular system, including the 
microcirculation within the skin. Therefore, imaging the cutaneous perfusion intensity 
should not be limited to only one random measurement in time, as no correction for the 
influence of the heart cycle can be made and perfusion images over time cannot be 
compared to each other. For example, if two perfusion images are taken shortly after one 
another, one taken during systole and one during diastole, a remarkable difference in the 
perfusion intensity will be displayed. However, this variation does not reflect a change in 
the mean perfusion intensity and therefore is not useful if the perfusion intensity within 
one lesion is followed over time. With the TOPCam 170 images were made during 7 
consecutive seconds so the heart cycle could be visualized as described in chapter 4. This 
enabled us to compare perfusion images at comparable moments within the heart cycle. 
We chose to take the average perfusion intensity during diastole into account, as the 
systolic blood pressure is more subject to physiological variations like temperature and 
arousal. 
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 Previous research showed that the arterioles supplying psoriatic lesions are still able 
to react on changes in temperature.20 Therefore, all measurements were corrected for the 
‘normal’ perfusion intensity of the unaffected skin, by calculating the average perfusion 
intensity of three selected areas of unaffected skin. Besides this correction for environmental 
and physiological variations, all measurements were conducted by the same investigator 
within the same air-conditioned room, serving as an additional correction for external 
variations.
 It was shown that this non-invasive technique can be of great value in future psoriasis 
research regarding the perfusion intensity. However, at this moment it is unfeasible to use 
this device in daily practice, and several aspects might be improved to enhance practical 
use. For example, a hand held device would be better manageable within patient care. In 
addition, at this moment there is no standardized possibility to measure the exact same 
location on the skin without using markers and to correct for the angle of the laser head 
regarding the skin, which might influence outcome measures. And using a faster camera 
might shorten the loading time of the images, therefore making it possible to scan more 
lesions in a shorter period of time. 
In conclusion: the TOPCam is suitable to non-invasively visualize the superficial 
cutaneous perfusion within psoriatic lesions, with minimal imaging artifacts. By 
using this device it is now possible to scan a larger area at once, to correct perfusion 
images for the influence of the heart cycle and correct them for the background 
perfusion. 
Aim 5:   To investigate the relation between the cutaneous perfusion intensity and newly discovered 
drivers in the pathogenesis of psoriasis 
Upon investigating the usability of the TOPCam remarkable variations in the perfusion 
intensity were seen, whereas the psoriatic lesion had a homogenous appearance. We 
defined areas with the highest perfusion intensity as hotspots and areas with the lowest 
perfusion intensity as coldspots (Chapter 4.1). In addition, within the clinically unaffected 
perilesional skin an increased perfusion intensity was seen as compared to the distant 
uninvolved skin. As it was unknown whether the differences found in perfusion intensity 
were of any significance and whether it influenced the composition of important 
cytokines and cellular components of the innate and acquired immune system the study 
described in Chapter 4.2 was set up. 
 During eight weeks of follow-up the localizations of hotspots showed only minimal 
changes in location in all patients analyzed. This indicated that the perfusion intensity 
within psoriatic lesions tended to change slowly and that hotspots are not a coincidental 
finding, but rather a structural part of the homogenously looking psoriatic lesion. Further 
evaluation showed remarkable differences on both protein and gene expression levels, 
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including IL-17 and T-Bet/TBX21, between hotspots and coldspots and also between the 
highly perfused perilesional skin and the distant uninvolved skin. Almost all markers used 
for epidermal proliferation and differentiation, markers for the innate and adaptive 
immune system, as well as the marker used for the amount of dermal capillaries showed 
a clear stepwise increase in expression with the lowest levels in the distant uninvolved skin 
and the highest expression in hotspots. These findings might indicate that there is a 
heterogeneous cell biological composition within clinically homogenous appearing 
lesions as well as within the clinically unaffected skin.
 Moreover, these findings might indicate that psoriatic lesions have a focal organization 
of active psoriatic sites and less active sites, involving endothelial, immunological and 
keratinocyte related aspects.
 
In conclusion: differences in the expression levels of psoriasis-related genes and 
proteins, including IL-17 and TBX21/T-Bet, within homogenously appearing 
psoriatic lesions as well as within the non-lesional skin correlate with variations in 
the cutaneous perfusion intensity as measured by the TOPCam.
Aim 6:   To further explore the effects of a combination of topical corticosteroids and vitamin D 
analogues, and of anti-TNF-α on the newly discovered drivers in the pathogenesis of psoriasis 
Calcipotriol - Betamethasone Dipropionate Ointment
In chapter 5.1 the results of the immunohistochemical analyses of psoriatic lesions after 
eight weeks of treatment with calcipotriol – betamethasone dipropionate (CBD) ointment 
were described. Topical treatment with CBD ointment led to an improvement in clinical 
parameters in all patients; who were divided into good-responders when reaching a SUM 
score of 0 or 1, and moderate-responders when reaching a SUM score > 1 at the end of the 
treatment period. The cell biological composition of the treated lesions of good-respond-
ers was comparable to the unaffected skin, except for the expression of dermal CD31+ 
endothelium which remained significantly elevated. Despite the remaining expression of 
CD31, a marked reduction in the perfusion intensity, as measured by the TOPCam, and 
SUM score was found. These results indicated that clinical improvement might outrun the 
endothelial changes. 
The amount of endothelium (as measured immunohistochemically by the expression of 
CD31) in the treated skin of the good-responders was still significantly elevated as 
compared to the clinically unaffected skin, while the SUM score reached 0 or 1, and the 
perfusion intensity measured, by means of the TOPCam, decreased markedly. The 
perfusion intensity is displayed by the TOPCam as the product of the concentration and 
the velocity of moving erythrocytes21 and seems to be rather a reflection of the blood 
flow instead of the amount of dermal endothelium.
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 The elevated levels of CD31 expression found, suggest that the vascular modifications 
might be the last of all pathological changes present within psoriatic lesions to normalize 
entirely. As psoriasis tends to relapse at multiple small foci at sites of former psoriatic 
lesions, these foci might coincide with sites with a higher amount of dermal endothelium. 
The question remains whether prolonged treatment duration would lead towards 
complete endothelial normalization. 
Anti - Tumor Necrosis Factor-α
Anti-psoriatic treatment with adalimumab, neutralizing the soluble cytokine TNF-α by 
blocking its interaction with the cell surface receptor,22 resulted in a quick clinical 
improvement, which was already notable within the first ten days in half of the patients. 
The expression of representatives for innate immunity, and epidermal differentiation and 
proliferation restored rapidly back to normal levels on both mRNA and protein expression 
levels. Significant differences in expression levels of these marker genes were seen already 
after ten days of treatment. However, representatives of the adaptive immune system 
showed a delayed decrease upon treatment. 
The rapid improvement of the homeostasis in the epidermal compartment within the first 
ten days of treatment explains the coinciding improvement in clinical parameters. At the 
same time, the number of dermal neutrophils, important cellular representatives of the 
innate immune system, showed a rapid decrease. Accumulations of these cells are 
indicative for active psoriasis, as they accumulate within the stratum corneum as 
microabscesses of Munro and within the stratum Malpighi as spongiform micropustules 
of Kogoj. There is increasing evidence that these innate cells are capable of releasing 
IL-1715, 23 and thereby play a crucial role within the pathogenesis of psoriasis, in particular 
in active eruptive disease.14 The patients attending in our study suffered from long existing 
chronic plaque psoriasis. This might explain the relatively low numbers of neutrophils and 
IL-17 producing cells we found during immunohistochemical evaluation as compared to 
the numbers found in the acute phase of inflammation after the application of LTB4 and 
the removal of the stratum corneum by tape stripping (Chapter 3). In addition, during 
adalimumab treatment only a non-significant reduction in IL-23A mRNA was found. 
Regarding the expression of IL-17A mRNA, only a significant reduction was found after 16 
weeks of treatment, whereas on the protein level no significant reduction was found 
during the study. These findings fit the hypothesis that differences in cytokine composition 
may be indicative for a more acute disease or a more chronic disease. However, studies 
investigating the efficacy of newly developed biologic agents targeting the IL-17 pathway 
show that these drugs are very effective treating chronic plaque psoriasis.24, 25 
 The adaptive immune system showed a delayed decrease upon adalimumab 
treatment as compared to the innate immune system and the epidermal compartment. 
The number of T cells, important representatives of the adaptive immune system, showed 
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no significant decrease after ten days of treatment. Previous studies have shown that 
other anti-psoriatic treatments like potent topical corticosteroids26 are capable of reducing 
the number of T cells already after 7 days of treatment. Combining these treatments might 
have a superior effectiveness with fastening of the clinical improvement. The use of 
potent topical corticosteroids might have a place in supporting adalimumab treatment as 
a synergistic approach may help preventing the excessive use of individual components 
and adverse events. 
 The TNF-α expression in lesional psoriatic skin did not change significantly during 
adalimumab treatment, which is in line with earlier studies indicating that TNF-α is 
regulated posttranscriptionally.27-29 It has been demonstrated before that the early effects 
of adalimumab therapy are mediated by the reduction in p38 MAPK phosphorylation and 
a subsequent decrease of the p38 MAPK signaling pathway resulting in a decrease in the 
mRNA expression of IL-1β, IL-8 and IL-20.28 The rapid decrease in IL-8 expression was 
reconfirmed, as only the expression of IL-8 mRNA showed a significant decrease already 
after ten days of treatment (Chapter 5.2). 
In conclusion: topical treatment with CBD ointment results in an improvement in 
clinical parameters and important psoriasis-related proteins, except for the 
expression levels of CD31+ endothelium. Systemic therapy with adalimumab leads 
to a rapid decrease in representatives of the innate immune system and epidermal 
differentiation and proliferation as well as in clinical parameters. Representatives 
of the adaptive immune system showed a delayed improvement.
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Main Conclusions of this Thesis
Overview of the Available Evidence Regarding the Combinations of Topicals 
· The lack of standardized treatment protocols of classical therapies results in a hampered 
interpretation of study results and proper generalization. (Chapter 2.1)
· Evidence-based data on long-term efficacy and safety at high quality level are limited. 
(Chapter 2.2)
· The combination of topical corticosteroids with penetration enhancers or with vitamin 
D analogues is recommended above the corresponding monotherapies. (Chapter 2)
Update on Two In Vivo Models for Introduction of Cutaneous Inflammation
· The LTB4 model is highly reproducible and therefore permits further investigations on 
the dynamics of a psoriasis-like inflammation with respect to newly discovered key 
components of immunity. (Chapter 3.1)
· The tape strip model permits investigations on the sequence of crucial inflammatory 
processes set off by cutaneous injury, which are presumed to play a role within the pathogenesis 
of immune mediated skin diseases exhibiting the Koebner phenomenon. (Chapter 3.2)
· Neutrophils and IL-17 producing cells dominate the acute phase of a cutaneous inflammatory 
reaction, indicating a more important role in the instable situation. Th1 cells seem to 
play a more important role within the chronic stage of inflammation. (Chapter 3)
The Heterogeneity of Inflammation in the Psoriatic Lesion 
· The TOPCam, a novel Laser Doppler Perfusion Imager, is able to non-invasively visualize 
the superficial perfusion intensity within psoriatic lesions. (Chapter 4.1)
· There is a remarkable heterogeneity in the perfusion intensity by means of the TOPCam 
within psoriatic lesions with a homogeneous appearance. (Chapter 4)
· Differences in the cutaneous perfusion intensity in psoriatic lesions are correlated to 
differences in the expression levels of psoriasis-related genes and proteins. (Chapter 4.2) 
· Differences in gene and protein expression levels between the highly perfused 
perilesional skin and the distant uninvolved skin might indicate that several biological 
changes occur well before clinical changes become manifest. (Chapter 4.2)
Monitoring Antipsoriatic Treatments with Markers for Inflammation 
· Topical treatment with CBD ointment leads to normalization of the cell biological 
composition as compared to the unaffected skin, except for the amount of dermal 
CD31+ endothelium. This might indicate that clinical improvement outruns the 
endothelial normalization. (Chapter 5.1)
· Adalimumab treatment rapidly affects epidermal differentiation, proliferation and the 
innate immune system well before the changes in the adaptive immune system 
become apparent. (Chapter 5.2)
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Future Directions
Niches in Clinical Evidence
Considering the results of this thesis, it might be worthwhile investigating the cost-effec-
tiveness of introducing combinations of classical therapies in day care settings. When 
combining topicals lead towards a faster clinical improvement this might lead to a 
reduction in the time patients are in need for treatment in a day care setting and therefore 
in a reduction in the costs for the health care system. 
 The same might apply for the use of corticosteroids in combination with vitamin D 
analogues. It remains to be investigated whether the combination might be used earlier 
by general practitioners to enhance treatment compliance due to better clinical results. 
Moreover, the use of the two-compound formulation seems to be favourable for patients 
as only one daily application is acquired compared to the use of the separate formulations. 
However, the two-compound formation is more expensive and it was not proven that this 
assumption holds true in daily practice.
Niches in Pathomechanistic Insights
The pathogenesis of psoriasis is still not fully understood, but ongoing research keeps 
revealing new pieces of this complicated puzzle. The updates given on the LTB4 model 
and the tape strip model have shown that both in vivo models provide useful tools to 
further investigate inflammatory reactions of the skin. 
 Apart from immunohistochemical evaluation, the course of the development of new 
psoriatic lesions might be followed by investigating the perfusion intensity by means of 
the TOPCam. As changes in the dilatation and permeability of the dermal papillary 
capillaries seem to outrun clinical changes and disappear, and variations in the perfusion 
intensity correlate with disease severity it is attractive to speculate that an increased 
superficial perfusion within the unaffected skin may predict the development of newly 
formed psoriatic lesions. It would be interesting to study patients suffering from active 
eruptive disease to find an answer to this question. If this hypothesis holds true perfusion 
images might serve as a non-invasive tool to identify disease activity.
 Moreover, resulting from this thesis, the question remains whether prolonging the 
treatment duration with the combination of topical corticosteroids and vitamin D 
analogues would lead towards complete endothelial normalization and whether this 
would lead to a longer disease-free interval. In that case, general practitioners and 
dermatologists could better aim for the optimal treatment duration.
 Lastly, it would be interesting to investigate the cytokine composition in the lesional 
skin of patients having an insufficient response to adalimumab treatment. This might 
reveal biomarkers to predict the treatment response to biological agents. In our current 
health care system, were personalized medicine becomes more and more important, this 
might provide a reliable tool to decide which agent could be used best.
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Doelstelling
De belangrijkste doelstelling van dit proefschrift was om onderzoek te verrichten naar 
niches in klinisch bewijsmateriaal met betrekking tot topische behandelingen en naar 
niches in pathomechanistische inzichten die relevant zijn voor de huidige en toekomstige 
behandelopties voor psoriasis. In dit hoofdstuk zal een samenvatting van de belangrijkste 
bevindingen en conclusies worden gegeven met het oog op de gestelde doelen van dit 
proefschrift, zoals beschreven in hoofdstuk 1. 
 Er werd een uitgebreid systematisch literatuuronderzoek uitgevoerd om een evidence - 
based overzicht te geven van alle beschikbare combinaties van topische therapieën 
voor de behandeling van psoriasis. Om de resultaten te structureren, werden de topische 
anti-psoriatische behandelopties onderverdeeld in ‘klassieke’ topicale behandelingen; 
bestaande uit ditranol, koolteer en keratolytica (hoofdstuk 2.1), en de ‘eerstelijns’ topicals, 
bestaande uit lokale corticosteroïden, vitamine D analogen, retinoïden en calcineurine 
remmers (hoofdstuk 2.2). De belangrijkste conclusies betreffende de werkzaamheid en 
veiligheid van de topicale combinatie therapieën en de daaruit voortvloeiende aanbevelingen 
zijn van elke combinatie apart beschreven.
 Biologische modellen bieden de mogelijkheid om geïsoleerde gebeurtenissen of 
geïsoleerde celtypen in een vereenvoudigde omgeving te bestuderen. De multifactoriële 
pathogenese van immuungemedieerde huidziekten, zoals psoriasis, is erg complex. En bij 
de ontdekking van iedere nieuwe betrokken speler wordt het lastiger om de pathogenese 
goed te begrijpen. In deze complexe gevallen, kunnen vereenvoudigde modellen een 
belangrijke mogelijkheid bieden om onderzoek te doen. Gedurende de afgelopen 
decennia zijn twee in vivo modellen veelvuldig gebruikt om bij benadering een psoriasis-
achtige ontstekingsreactie te bestuderen. Er  zijn twee immunohistologische studies 
opgezet om het dynamische effect van de applicatie van leukotriene B4 (LTB4) op de huid 
(hoofdstuk 3.1) en de verwijdering van de hoornlaag door middel van tape stripping 
(hoofdstuk 3.2) te onderzoeken in het licht van onze huidige kennis aangaande belangrijke 
drijfveren in de pathogenese van psoriasis. In de onderzoeken, beschreven in dit proefschrift, 
hebben we gefocust op epidermale differentiatie en proliferatie als vertegenwoordigers van 
het epidermale compartiment; T helper 1 (Th1) cellen als vertegenwoordigers van het 
adaptieve immuunsysteem; neutrofielen als vertegenwoordigers van het aangeboren 
immuunsysteem; humaan β-defensine 2 (hBD-2) en elastase proteïnaseremmer als anti-
microbiële eiwitten; en het belangrijke cytokine interleukine 17 (IL_17). De belangrijkste 
conclusies zullen afzonderlijk worden samengevat en worden besproken.
 Zoals hierboven beschreven is psoriasis een multifactoriële ziekte en naast de rol van 
keratinocyten en alle belangrijke celtypen van het aangeboren en adaptieve immuunsysteem, 
wordt de verhoging van de cutane bloedstroom ook gezien als een belangrijk fenomeen in 
de ontwikkeling én instandhouding van psoriasis laesies. De pilot studie beschreven in 
hoofdstuk 4.1  is opgezet om de bruikbaarheid van de Twente Optische Perfusie Camera 
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(TOPCam), een nieuwe Laser Doppler Perfusie Imager (LDPI), in het onderzoek naar de 
oppervlakkige cutane perfusie intensiteit in psoriasis laesies te bestuderen. In hoofdstuk 4.2 
wordt een correlatie studie beschreven waarin onderzoek is verricht naar de relatie tussen 
de oppervlakkige cutane perfusie intensiteit, zoals gemeten met de TOPCam, en de 
expressie van belangrijke psoriasis gerelateerde genen en eitwitten.
 Om de effecten van de bovengenoemde vertegenwoordigers van betrokken systemen 
in de pathogenese van psoriasis verder te onderzoeken tijdens de behandeling met een 
combinatie van topische corticosteroïden en vitamine D analogen, is onderzoek uitgevoerd bij 
patiënten lijdende aan een milde tot matig ernstige psoriasis (hoofdstuk 5.1). De effecten van 
adalimumab, gericht tegen TNF-α, op deze vertegenwoordigers zijn bestudeerd bij 
patiënten met matig ernstige tot ernstige psoriasis (hoofdstuk 5.2).
Niches in Clinical Evidence
Doel 1:  Het verkrijgen van een overzicht van de effectiviteit en veiligheid van combinaties van 
topische behandelingen van psoriasis. 
Combinaties van Klassieke Topicale Therapieën
Keratolytica gecombineerd met topicale corticosteroïden: De combinatie van corticosteroïden 
en keratolytica wordt goed verdragen en blijkt effectiever te zijn dan monotherapie met 
een van beide componenten. 
Keratolytica en calcineurine remmers: Behandeling met een combinatie van tacrolimus en 
salicylzuur heeft de voorkeur boven salicylzuur monotherapie. De superioriteit van deze 
combinatie kon niet worden aangetoond boven tacrolimus monotherapie.
Keratolytica gecombineerd met koolteer: Met betrekking tot de combinatie van koolteer en 
salicylzuur kunnen geen aanbevelingen worden gedaan.
Koolteer in combinatie met topicale corticosteroïden: Deze combinatietherapie blijkt minder 
effectief te zijn dan de veel gebruikte topische behandeling met vitamine D monotherapie, 
terwijl er geen verschillen in de veiligheid worden aangetoond. Daarom kan de combinatie 
van koolteer en topicale corticosteroïden niet worden aanbevolen.
Koolteer in combinatie met ditranol: Combinatietherapie van koolteer en ditranol is minstens 
zo effectief als een van beide monotherapieën en zou de voorkeur kunnen krijgen boven 
koolteer monotherapie, terwijl monotherapie met ditranol lipogel een gunstiger profiel 
heeft met betrekking tot het optreden van huidirritatie en vlekken op huid.
Ditranol gecombineerd met topicale corticosteroïden: Combinatietherapie heeft de voorkeur 
wanneer gebruik wordt gemaakt van superpotente corticosteroïden, terwijl het toevoegen 
van topicale corticosteroïden met een lagere klasse de therapeutische werkzaamheid niet 
verbetert.
Ditranol gecombineerd met topicale vitamine D analogen: De combinatie van beide middelen 
207
NEDERLANDSE SAMENVATTING
7
verhoogt de therapeutische werkzaamheid van ditranol monotherapie in de eerste weken 
van de behandeling, zonder een negatief effect op het veiligheidsprofiel.
Combinaties van Huidige Eerstelijns Topicale Therapieën
Topicale corticosteroïden in combinatie met vitamine D analogen: De combinatie van 
behandelingen lijkt veilig en effectiever dan monotherapie met een van beide actieve 
componenten, zowel op korte als op lange termijn.
Calcineurine remmers in combinatie met topicale corticosteroïden: Combinatietherapie lijkt 
de werkzaamheid van calcineurine remmers te verbeteren, terwijl er geen voordeel lijkt te 
zijn in vergelijking met monotherapie met topicale corticosteroïden. Gegevens over de 
veiligheid en verdraagbaarheid van deze combinatie zijn niet beschikbaar. 
Topicale retinoïden in combinatie met topicale corticosteroïden: In vergelijking met mono - 
therapie met topicale retinoïden lijkt de combinatie met potente of superpotente topicale 
corticosteroïden effectiever te zijn met een lagere incidentie bijwerkingen. Wanneer de 
combinatie therapie vergeleken wordt met monotherapie met topicale corticosteroïden, 
kan de toegevoegde waarde van deze gecombineerde behandeling niet worden aangetoond.
Topicale retinoïden in combinatie met vitamine D analogen: Er kan geen toegevoegde waarde 
worden aangetoond voor de combinatie ten opzichte van monotherapie met topicale  cortico- 
steroïden.
Een overzicht van de hoeveelheid gevonden bewijs betreffende de werkzaamheid en 
veiligheid van de verschillende topicale combinatie therapieën is weergegeven in tabel 1. 
Uit deze tabel kan worden opgemaakt dat er een scheve balans is in de hoeveelheid 
beschikbaar bewijs tussen combinaties van klassieke topicals en combinaties van eerstelijns 
topicals. Het is opmerkelijk dat er slechts beperkt bewijs is voor het gebruik van combinaties 
van klassieke topicale behandelingen, terwijl deze al decennia lang gebruikt worden door 
dermatologen. In sommige gevallen is de uitvoering van dubbelblinde gerandomiseerde 
studies niet mogelijk door bepaalde karakteristieken van een behandeling. Zo wordt 
bijvoorbeeld de werkzaamheid van ditranol bereikt door de concentratie stapsgewijs 
op te bouwen totdat lichte irritatie van de huid ontstaat, en is de penetrante geur van 
koolteer therapie niet te maskeren. Daarnaast is het gebrek aan geïncludeerde studies 
over de klassieke topicals, in ieder geval gedeeltelijk, het gevolg van het ontbreken van 
gestandaardiseerde gebruiksmethoden. Het zou effectiever zijn als onderzoekers een 
consensus zouden bereiken over het gebruik van dezelfde applicatie methoden en de te 
onderzoeken variabelen, zodat de resultaten gemakkelijker met elkaar vergeleken kunnen 
worden. Voor referenties wordt terugverwezen naar hoofdstuk 2.
Conclusie: een overzicht van de beschikbare data over de werkzaamheid en 
veiligheid van combinaties van topicale anti-psoriasis therapieën is verkregen. 
De hoeveelheid bewijsmateriaal gevonden per combinatie is weergegeven in tabel 1.
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Doel 2:  Het formuleren van aanbevelingen voor het gebruik van topicale combinatietherapieën
Combinaties van Klassieke Topicale Therapieën
Volgens de in hoofdstuk 2.1 beschreven resultaten kunnen de volgende combinaties van 
klassieke topicale therapieën worden aanbevolen:
· Combinatietherapie met topicale corticosteroïden en keratolytica; omdat het gebruik van 
keratolytica, zoals salicylzuur, vooral nuttig lijkt te zijn wanneer er sprake is van psoriasis 
plaques bedekt met dikke schilfers, wordt deze combinatie vooral aangeraden voor deze 
groep. Bovendien zou deze combinatie overwogen kunnen worden wanneer monotherapie 
met topicale corticosteroïden onvoldoende werkzaam is.
Zoals hierboven al is beschreven, is er slechts weinig bewijs om het gebruik van combinaties van 
klassieke topicale therapieën te ondersteunen. Uit de beschikbare gegevens blijkt dat alleen de 
combinatie van ditranol met koolteer óf met superpotente topicale cortico steroïden, en 
de combinatie van ditranol met calcipotriol de voorkeur geniet boven monotherapie.
 Vanuit de dagelijkse klinische praktijk is bekend dat behandeling met klassieke topicals, 
met name de behandeling met ditranol, wordt gebruikt als interventie om klinische verbetering 
te bewerkstelligen bij patiënten met matige ernstige psoriasis die niet kunnen worden 
behandeld met systemische middelen. Deze topicals worden bij voorkeur gebruikt in 
Tabel 1  Overzicht van de hoeveelheid beschikbaar bewijs
Koolteer +
Ditranol * +
Corticosteroïden ++ + +
Vitamine D analogen – – + +++
Calcineurine remmers + – – + –
Topicale retinoïden – – – + + –
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– geen bewijs gevonden; + weinig bewijs gevonden; ++ matige hoeveelheid bewijs gevonden; +++ veel 
bewijs gevonden. 
* Keratolytica worden gebruikt als stabilisator voor ditranol om oxidatie te voorkomen, daarom is deze 
combinatie niet meegenomen in dit onderzoek.
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 gespecialiseerde dagbehandelcentra, waar patiënten worden begeleid door gespecialiseerd 
personeel. Vanwege deze reden kan het gebruik van combinaties van klassieke topicals in 
de dagelijkse praktijk worden uitgevoerd zónder dat patiënten worden belast met (meer) 
gecompliceerde behandeling patronen. Aangezien uit de literatuur blijkt dat bepaalde 
combinaties leiden tot een snellere klinische verbetering, wordt bij het gebruik van deze 
combinaties de ziekte sneller beheersbaar voor patiënten zelf, wat de behandelduur via 
een dagbehandelcentrum kan verkorten. Dit resulteert uiteindelijk in een afname van de 
kosten voor de gezondheidszorg en in een toename van de draagkracht voor deze 
behandeling onder de patiënten.
Combinaties van Eerstelijns Topicale Therapieën
Aan de hand van de resultaten beschreven in hoofdstuk 2.2 kunnen de volgende topicale 
eerstelijns combinatietherapieën worden aanbevolen: 
· Combinatie van topicale corticosteroïden en vitamine D analogen; deze combinatie is 
bewezen effectiever vergeleken met monotherapie met topicale corticosteroïden en 
vergeleken met monotherapie met vitamine D analogen, terwijl de combinatie van 
beide middelen een gunstig veiligheidsprofiel heeft.
Onder artsen is het bekend dat veel patiënten die te maken krijgen met het dagelijks 
gebruik van lokale behandelingen, dit als een last ervaren waardoor de therapietrouw in 
het geding kan komen. Vooral bij patiënten die behandeld worden met eerstelijns topicals 
kan dit een beperkende factor zijn voor het klinisch resultaat, omdat patiënten zelf verant-
woordelijk zijn voor de dagelijkse toepassing. Dagelijkse behandeling is tijdrovend en kan 
leiden tot cosmetische bezwaren, omdat sommige zalven vlekken veroorzaken in kleding 
of een glanzende film op de huid achterlaten. De therapeutische werkzaamheid van 
topische middelen is vooral afhankelijk van regelmatige toepassing; onregelmatig gebruik 
heeft slechts een beperkt therapeutisch effect wat vervolgens leidt tot ongemotiveerde 
patiënten. Om de therapietrouw te bevorderen, is het wenselijk dat patiënten worden 
beloond voor alle tijd die zij in een behandeling investeren met snelle verbetering van het 
klinisch beeld zónder het optreden van ernstige bijwerkingen. Op de lange termijn kan dit 
ertoe leiden dat een hoger percentage van de patiënten een bevredigend resultaat 
behaald met de behandeling van topicals alleen, waardoor het aantal patiënten dat 
behandeling met duurdere systemische geneesmiddelen nodig heeft, zal afnemen. Dit 
heeft een gunstig effect op de kosten voor de gezondheidzorg wat wenselijk is in onze 
huidige samenleving waar de kosten van de gezondheidszorg voortdurend ter discussie 
staan. 
 De meeste psoriasis patiënten lijden aan milde tot matige ernstige psoriasis en in de 
meeste gevallen is de ziekte beperkt tot de huid. In veel gevallen kunnen de cutane 
ziekte verschijnselen worden behandeld met effectieve topicale therapie en kan de 
behandeling door huisartsen worden uitgevoerd. Volgens de Nederlandse richtlijnen 
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voor huisartsen (NHG standaard), is de eerste stap in de behandeling van psoriasis de 
behandeling met potente topicale corticosteroïden.1 Alleen wanneer 4 weken behandeling 
met potente topicale corticosteroïden onvoldoende effect heeft, wordt de combinatie 
van topicale corticosteroïden met vitamine D analogen aanbevolen. Het is denkbaar dat 
wanneer 4 weken topische behandeling niet tot bevredigende therapeutische resultaten 
heeft geleid, patiënten minder gemotiveerd zijn wanneer ze daarna opnieuw een lokaal 
smeerschema krijgen. Daarom zou overwogen kunnen worden om de combinatie van 
een topicaal corticosteroïd en een vitamine D analoog al op een eerder moment in het be-
handeltraject te gebruiken.
 De combinatie van topicale corticosteroïden en vitamine D analogen is verkrijgbaar 
in één samengesteld preparaat. Dit samengestelde preparaat is duurder dan wanneer de 
afzonderlijke preparaten worden gecombineerd. Het voordeel van het duurdere preparaat 
is dat het slechts eenmaal daags aangebracht hoeft te worden en het daarmee bevorderlijk 
is voor de therapietrouw en dus voor het klinisch resultaat. Dit leidt vervolgens tot een 
betere en snellere afname van de klinische verschijnselen en tot een afname van het 
aantal patiënten met milde tot matig ernstige psoriasis welke behandeling van een 
dermatoloog behoeven, hetgeen een mindering van de kosten voor de gezondheidszorg 
met zich mee brengt.
 Het gebrek aan studies over de lange termijn effectiviteit en veiligheid van combinaties 
is opmerkelijk. Gegevens over het gebruik op lange termijn zijn zeer relevant, omdat 
psoriasis een chronische aandoening is waarbij patiënten vaak gebonden zijn aan een 
levenslange behandeling. Het zou interessant zijn om te onderzoeken of het langdurig 
gebruik van topicals nog steeds zo effectief is als op de korte termijn of dat het langdurige 
gebruik zou kunnen leiden tot een verminderde werkzaamheid, zoals dat ook gemeld 
wordt voor sommige biologicals.2, 3
  
Conclusie: hoewel het concept van het combineren van verschillende genees -
middelen veelbelovend is, is er slechts overtuigend bewijs om het gebruik van de 
combinatie van keratolytica en topicale corticosteroïden, en de combinatie van 
topicale corticosteroïden en vitamine D analogen, aan te bevelen. Gegevens over 
de werkzaamheid en veiligheid met betrekking tot de langdurige behandeling 
met topicals ontbreken.
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Niches in Pathomechanistic Insights
Doel 3:  Het verder ontrafelen van de dynamiek van de eerste en alle daaropvolgende stadia van 
een ontstekingsreactie in de huid in twee bekende in vivo modellen (te weten: na de applicatie 
van LTB4 op de huid en na het verwijderen van de hoornlaag door middel van tape stripping) 
met betrekking tot de nieuw ontdekte drijfveren in the pathogenese van psoriasis 
De Applicatie van Leukotriene B4
In hoofdstuk 3.1 zijn de resultaten beschreven van de immunohistochemische evaluatie 
vóór en tijdens de eerste 72 uur na het aanbrengen van LTB4 op de huid van gezonde 
vrijwilligers. Binnen 8 uur na het aanbrengen van LTB4 op de huid wordt de dermis 
geïnfiltreerd door neutrofielen. De piek accumulatie van IL-17 producerende cellen en 
neutrofielen is waargenomen binnen de eerste 24 tot 36 uur na aanbrengen en domineren 
de acute fase van de ontsteking, duidend op een belangrijke rol tijdens de instabiele fase 
van ontsteking. De Th1 cellen nemen pas vanaf 24 uur na aanbrengen geleidelijk toe in 
aantal en blijven vervolgens gedurende de rest van de observatieperiode in ongeveer 
dezelfde aantallen aanwezig. Dit zou een belangrijkere rol in de chronische fase van de 
ontsteking kunnen impliceren. Het epidermale compartiment wordt pas geactiveerd 48 
tot 72 uur na aanbrengen van LTB4. 
Tape Stripping
De resultaten van de immunohistochemische analyse van de regeneratieve huid, als 
gevolg van het verwijderen van de hoornlaag, zijn beschreven in hoofdstuk 3.2. De huid 
van gezonde vrijwilligers wordt geëvalueerd vóór en tijdens de eerste 72 uur na toe- 
brengen van gestandaardiseerd trauma aan de huid. Het verbreken van de huidbarrière 
met Sello tape leidt tot activatie van het epidermale compartiment binnen de eerste 16 uur, 
en blijft geactiveerd tot aan het einde van de observatieperiode. Het aantal prolifererende 
keratinocyten daalt significant na 16 en 24 uur ten opzichte van de uitgangswaarde, 
en laten daarna een toename in aantal zien. De acute fase wordt gedomineerd door 
neutrofielen en IL-17 producerende cellen, terwijl het aantal Th1 cellen geleidelijk toe 
neemt en verhoogd blijft tot 72 uur.
De onderzoeksresultaten tonen opnieuw aan dat beide in vivo modellen een goede re-
produceerbaarheid hebben, aangezien bekende histologische uitkomsten4-7 ook in ons 
onderzoek gevonden zijn (hoofdstuk 3). Een hoge reproduceerbaarheid is van wezenlijk 
belang om onderzoekmethoden in vervolgstudies te gebruiken. Aangezien dit voor beide 
modellen bij herhaling wordt aangetoond, kunnen de modellen beschouwd worden als 
betrouwbare ondersteunende instrumenten voor het bestuderen van de regeneratieve 
huid als ook voor de door neutrofielen gedomineerde ontstekingsreacties van de huid.
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In de onderzochte modellen worden twee verschillende triggers gebruikt om een ont-
stekingsreactie van de huid te induceren. De applicatie van LTB4 (hoofdstuk 3.1) wordt 
gebruikt, omdat bekend is dat er verhoogde hoeveelheden van LTB4 aanwezig zijn in 
psoriasis laesies, welke geproduceerd worden door geactiveerde cellen van het 
aangeboren immuun systeem.8-12 LTB4 is een arachidonzuur derivaat en kan direct de 
adhesie en activering van leukocyten induceren. Daarnaast kan het een uitgesproken ont-
stekingsreactie in de gezonde huid induceren door de vorming van reactieve zuurstof in 
de neutrofielen en door afgifte van lysosomale enzymen, welke op hun beurt het 
epidermale compartiment beïnvloeden.
 De mechanische verwijdering van de bovenste lagen van de epidermis (hoofdstuk 3.2) 
leidt tot een vergelijkbare ontsteking van de huid zoals waargenomen na aanbrengen van 
LTB4. Dit lijkt echter niet via dezelfde volgorde in de tijd te verlopen. Deze gegevens 
suggereren dat verschillende triggers kunnen leiden tot een soortgelijke cutane ont-
stekingsreactie. In psoriasis zijn meerdere uitlokkende factoren beschreven, zoals een 
streptokokkeninfectie of trauma toegebracht aan de huid, ook wel bekend als het Koebner 
fenomeen. Hoewel dit verschijnsel voor het eerst is beschreven bij psoriasis patiënten,13 
is het niet ziektespecifiek en blijkt ook bij andere huidziekten op te kunnen treden. In 
hoofdstuk 3.2 wordt aangetoond dat door het verstoren van de huidbarrière het epidermale 
compartiment wordt geactiveerd en er vervolgens een breed scala van epidermale en 
immunologische veranderingen optreden in de huid van gezonde vrijwilligers. In de normale 
huid dooft deze immuunrespons binnen enkele dagen na het onderbreken van de huid- 
barrière vanzelf weer uit. In het geval van Koebner positieve huidziekten blijft het immuun- 
systeem geactiveerd en wordt een aanhoudende ontsteking van de huid gevonden.
 De immunohistochemische veranderingen die worden waargenomen in boven- 
genoemde onderzoeken met beide modellen lijken, althans gedeeltelijk, op de veranderingen 
die ook worden gezien in psoriasis huid. Omdat deze veranderingen ook worden 
gevonden in de gezonde huid na aanbrengen van LTB4 als ook na verstoring van de 
huidbarrière, zijn ze niet ziekte specifiek. Inflammatoire veranderingen in de epidermale 
en dermale compartimenten in psoriasis gaan samen met vasculaire veranderingen. In de 
besproken studies wordt een snelle infiltratie van diverse immuuncellen waargenomen 
na activatie van de huid. Daarom is het aantrekkelijk te speculeren dat er tegelijkertijd ook 
een toename van de vascularisatie is ontstaan, welke de snelle influx van immuuncellen 
mogelijk heeft gemaakt. 
 De resultaten van beide studies suggereren dat neutrofielen en IL-17 producerende 
cellen een belangrijke rol spelen bij de acute ontstekingsreactie van de huid in de fase net 
nadat de gezonde huid wordt getriggerd. In beide modellen tonen beide celtypen 
eenzelfde beloop in de tijd, gekenmerkt door een snelle piek accumulatie en daling 
daarna. De Th1 cellen daarentegen tonen een veel geleidelijker verloop in de tijd. Er is 
gesuggereerd dat overexpressie van de IL-23 /  IL-17 as leidt tot actieve ziekte met de vorming 
van nieuwe psoriasis laesies,14 en dat dominantie van de Th1 cellen en overexpressie van 
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de IL-12 / interferon-Ύ as leidt tot chronische ziekte. Keijsers et al.15 heeft de rol van 
neutrofielen in deze modellen verder onderzocht en uit deze studie is gebleken dat in 
deze modellen neutrofielen waarschijnlijk verantwoordelijk zijn voor de productie van 
IL-17 in plaats van de CD4+ T helper cellen.15 Aangetoond wordt, dat naast het 
samenvallende verloop in de tijd, neutrofielen ook de transcriptiefactor voor het 
produceren van IL-17 hebben en dat ze ook in het bezit zijn van gespecialiseerde structuren 
om IL-17 te releasen.15 
Conclusie: het LTB4 model en het tape strip model, welke beide al decennia zijn 
gebruikt in diverse studies, kunnen óók worden gebruikt om de dynamiek van 
recent ontdekte drijfveren op het gebied van de pathogenese van psoriasis, zoals 
die van IL-17 producerende cellen en Th1 cellen, te bestuderen.
Doel 4:   Het exploreren van de bruikbaarheid van een nieuwe whole field Laser Doppler Perfusion 
Imager in het bestuderen van de oppervlakkige cutane perfusie in psoriasis laesies
Kennis over de vroege veranderingen in de perfusie intensiteit kan ons van belangrijke 
informatie voorzien over de (vroege) ontwikkeling van nieuwe psoriasis laesies. Daarom 
zijn er inmiddels verschillende studies uitgevoerd om de oppervlakkige perfusie van 
psoriasis laesies te onderzoeken. Het voordeel van de Twente Optical Perfusie Camera 
(TOPCam), een nieuwe Laser Doppler Perfusion Imager, is het vermogen om snel te 
scannen zodat er slechts sprake is van minimale bewegingsartefacten door (micro) 
bewegingen. En daarnaast is het apparaat in staat om in één meting een veld tot 15 x 15 
cm tegelijkertijd in beeld te brengen. Eerdere gebruikte technieken hadden een 
beperkende straal van slechts enkele millimeters of een trage scan snelheid waardoor 
bewegingsartefacten ontstonden.16-18
De in hoofdstuk 4.1 beschreven resultaten tonen aan dat de TOPCam gebruikt kan worden 
om de perfusie intensiteit in zowel de omringende huid (de perilaesionale huid) als ook in 
psoriasis laesies zelf te visualiseren, zowel voor als na behandeling. Het apparaat kan 
worden gebruikt om een  één keer een gebied te scannen tot 15 x 15 cm. Om dit oppervlak 
in een keer te meten, dient het apparaat verder van de huid geplaatst te worden, wat ten 
koste gaat van de scan scherpte. Daarom is in ons onderzoek het apparaat gebruikt op 
een afstand van 40 cm boven de huid, overeenkomend met een scan gebied van 7 x 7 
cm. Deze opstelling is al eerder gebruikt door een andere onderzoeksgroep om de 
perfusie in brandwonden te onderzoeken.19
 Een ander belangrijk voordeel van de TOPCam is de mogelijkheid om de invloed van 
de hartcyclus op de cutane perfusie te visualiseren. Logischerwijs bepalen de contracties 
van de ventrikels de perfusie intensiteit van het vasculaire systeem, inclusief de microcir-
culatie in de huid. Het in beeld brengen van de cutane perfusie intensiteit zou niet tot één 
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willekeurige meting in de tijd beperkt mogen blijven. Wanneer het tot één enkele meting 
beperkt blijft, kan niet gecorrigeerd worden voor de invloed van de hartcyclus en kunnen 
de perfusie beelden niet op een juiste manier met elkaar vergeleken worden in de tijd. 
Bijvoorbeeld, wanneer twee perfusie beelden die kort na elkaar worden gemaakt, het 
eerste beeld genomen tijdens de systole en het tweede beeld tijdens de diastole, een 
opvallend verschil in de perfusie intensiteit laten zien, weerspiegelt deze variatie geen 
verandering in de gemiddelde perfusie intensiteit en is derhalve niet bruikbaar om de 
perfusie intensiteit in een laesie in de tijd te vervolgen. Met de TOPCam kunnen gedurende 
7 opeenvolgende seconden 170 beelden worden gemaakt en kan de hartcyclus 
gevisualiseerd worden, zoals beschreven in hoofdstuk 4. Dit stelde ons in staat om perfusie 
beelden, genomen op vergelijkbare momenten in de hartcyclus, met elkaar te vergelijken. 
Omdat de systolische bloeddruk in grotere mate afhankelijk is van fysiologische 
veranderingen, zoals temperatuur en stress, hebben we ervoor gekozen de gemiddelde 
perfusie intensiteit tijdens de diastole te gebruiken. 
 Eerder onderzoek toonde aan dat de aanvoerende arteriolen in psoriasis laesies nog 
steeds in staat zijn om te reageren op veranderingen in de temperatuur.20 Om deze reden 
zijn alle perfusie metingen gecorrigeerd voor de “normale” perfusie intensiteit van de 
onaangetaste huid, welke berekend is aan de hand van de gemiddelde perfusie intensiteit 
van drie geselecteerde gebieden. Naast de correctie voor omgevingsfactoren en de 
fysiologische variatie, worden alle metingen uitgevoerd door dezelfde onderzoeker in 
dezelfde kamer met airconditioning als extra correctie voor externe variaties.
 Het onderzoek heeft aangetoond dat deze niet-invasieve techniek van grote waarde 
zou kunnen zijn voor toekomstige studies naar de perfusie intensiteit in psoriasis. Op dit 
moment is het apparaat nog niet bruikbaar in de dagelijkse praktijk en zijn er verschillende 
functies die kunnen worden verbeterd om het praktisch gebruik te verbeteren. Zo zou 
een draagbaar apparaat beter bruikbaar zijn binnen de patiëntenzorg. Daarnaast is het op 
dit moment (nog) niet mogelijk om op exact dezelfde plaats op de huid te meten zonder 
markers te gebruiken, en is er (nog) geen mogelijkheid om te corrigeren voor de hoek die 
de laser met de huid maakt, welke de metingen zouden kunnen beïnvloeden. Tot slot zou 
het gebruik van een snellere camera de laadtijd van de afbeeldingen kunnen verkorten, 
waardoor het ook mogelijk wordt om meerdere laesies te scannen in een kortere tijd.
 
Conclusie: de TOPCam is geschikt om op niet-invasieve manier de oppervlakkige 
cutane perfusie te visualiseren in en rondom psoriasis laesies met minimale 
 bewegingsartefacten. Met dit apparaat is het mogelijk om een groter gebied 
tegelijkertijd te scannen, om perfusie beelden te corrigeren voor de invloed van 
de hartcyclus en te corrigeren voor de achtergrond perfusie.
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Doel 5:  Het bestuderen van de relatie tussen de cutane perfusie intensiteit en de nieuw ontdekte 
drijfveren die van belang zijn in de pathogenese van psoriasis 
Bij het onderzoek naar de bruikbaarheid van de TOPCam worden opmerkelijke variaties 
gezien in de cutane perfusie intensiteit binnen een klinisch homogeen ogende psoriasis 
laesie. We definieerden gebieden met de hoogste perfusie intensiteit als hotspots en 
gebieden met de laagste perfusie intensiteit als coldspots (hoofdstuk 4.1). Daarnaast is een 
verhoogde perfusie intensiteit gevonden in de klinisch onaangetaste perilaesionale huid 
in vergelijking met de op grotere afstand gelegen huid. Omdat het onbekend is of de 
gevonden verschillen in de perfusie intensiteit van enige betekenis zijn en of de verschillen 
van invloed zijn op de samenstelling van belangrijke cytokines en cellulaire componenten 
van het aangeboren en adaptieve immuunsysteem, is het onderzoek, beschreven in 
hoofdstuk 4.2, opgezet.
 De lokalisaties van de hotspots in de psoriasis laesies worden gedurende 8 weken 
vervolgd. In deze periode worden slechts minimale verschuivingen in de locatie van de 
hotspots gevonden bij de geanalyseerde patiënten. Deze bevindingen geven aan dat de 
perfusie intensiteit in psoriasis laesies langzaam veranderd en het vinden van hotspots in 
een laesie niet zozeer op toeval berust, maar eerder op een structureel onderdeel van de 
homogeen ogende psoriasis laesie. Immunohistochemische evaluatie toont opmerkelijke 
verschillen op zowel genexpressie en eiwit niveau, inclusief de expressie van IL-17 en 
TBX21/T-Bet, tussen hotspots en coldspots en ook tussen de sterk doorbloede 
perilaesionale huid en de op grotere afstand gelegen onaangetaste huid. Bijna alle 
markers voor epidermale proliferatie en differentiatie, markers voor het aangeboren en 
adaptieve immuunsysteem, als ook de marker voor de hoeveelheid dermaal gelegen 
capillairen, laten een duidelijke stapsgewijze verhoging in de expressie zien met het 
laagste expressie niveau in de op afstand gelegen onaangetaste huid en het hoogste 
expressie niveau in hotspots. Deze bevindingen kunnen erop wijzen dat er een heterogene 
celbiologische samenstelling bestaat, zowel binnen klinisch homogeen ogende laesies, 
als ook in de klinisch onaangetast huid.
 Daarnaast zouden deze bevindingen kunnen impliceren dat psoriasis laesies een 
focale organisatie hebben met actieve en minder actieve plekken met betrokkenheid van 
het  endotheel, keratinocyten en immunologische aspecten.
 
Conclusie: de verschillen in de expressie niveaus van psoriasis gerelateerde genen 
en eiwitten, waaronder IL-17 en TBX21/T-Bet, zowel binnen homogeen ogende 
psoriasis laesies als binnen de ziektevrije huid, correleren met variaties in de 
cutane perfusie intensiteit zoals gemeten door de TOPCam.
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Doel 6:  Het verder bestuderen van de effecten van de behandeling van psoriasis met een combinatie-
behandeling van topicale corticosteroïden en vitamine D analogen en van anti-TNF-α 
behandeling op de nieuw ontdekte drijfveren in de pathogenese van psoriasis 
Calcipotriol – Betamethasondipropionaat Zalf 
In hoofdstuk 5.1 worden de resultaten van de immunohistochemische analyses van 
psoriasis laesies getoond na acht weken behandeling met calcipotriol - betamethasondi-
propionaat (CBD) zalf. Lokale behandeling met CBD zalf resulteert in een verbetering in 
klinische parameters bij alle patiënten. De patiënten worden op basis van de klinische 
respons ingedeeld in twee groepen. Wanneer aan het einde van de behandelperiode 
een klinische score van 0 of 1 wordt bereikt, wordt de patiënt als 'goede responder' 
 geclassificeerd. Wanneer de klinische score > 1, wordt de patiënt geclassificeerd als ‘matige 
responder’. De celbiologische samenstelling van de behandelde laesies van ‘goede 
responders’ is vergelijkbaar met de samenstelling gevonden in de gezonde huid, met 
uitzondering van de expressie van CD31+ dermaal endotheel. De expressie van CD31 in 
het dermale compartiment bleef significant verhoogd. Ondanks de blijvend verhoogde 
expressie van CD31, wordt een duidelijke vermindering van de cutane perfusie intensiteit 
gemeten met de TOPCam én in de klinische huid scores. Deze resultaten geven aan dat 
de klinische verbetering vooruitloopt op de endotheliale veranderingen.
De hoeveelheid endotheel (immunohistochemisch gemeten als de expressie van CD31) in 
de behandelde huid van de ‘goede responders’ blijft significant verhoogd vergeleken met 
de klinisch onaangetaste huid, terwijl de klinische scores terugvielen naar 0 of 1 en 
tegelijkertijd de perfusie intensiteit gemeten met de TOPCam aanzienlijk af nam. De perfusie 
intensiteit wordt door de TOPCam weergegeven als het product van de concentratie en 
de snelheid van bewegende erytrocyten21 en lijkt eerder een weerspiegeling te zijn van 
de bloedstroom in plaats van de hoeveelheid dermaal endotheel.
 De verhoogde expressie van CD31 suggereert dat de vasculaire modificaties mogelijk 
als een van de laatste pathologische veranderingen aanwezig blijven binnen genezende 
psoriasis laesies. Het is bekend dat psoriasis de neiging heeft te recidiveren als meerdere 
kleine foci op plaatsen waar voorheen ook psoriasis laesies gezeten hebben. Mogelijk dat 
deze foci samenvallen met de plekken in huid waar nog een verhoogde hoeveelheid 
dermaal endotheel aanwezig is. De vraag blijft of voortzetting van de behandeling zou 
leiden tot volledige normalisering van het dermale endotheel.
Anti - Tumor Necrose Factor-α
Adalimumab neutraliseert het oplosbare cytokine TNF-α doordat de interactie met de 
receptor op het celoppervlak geblokkeerd wordt.22 Dit resulteert in een snelle klinische 
verbetering van psoriasis. De vermindering van huidklachten wordt in de helft van de 
patiënten al binnen de eerste tien dagen na start van de behandeling waargenomen. De 
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expressie van de markers voor de aangeboren immuniteit, epidermale differentiatie en 
proliferatie tonen een snelle normalisatie op zowel mRNA als eiwit expressie niveau. 
Significante verschillen in expressie niveaus van deze markergenen worden al na tien 
dagen behandeling gezien. Opmerkelijk genoeg blijven de markers van het adaptieve 
immuunsysteem achter en tonen een vertraagde normalisatie tijdens de behandeling.
De snelle verbetering van de homeostase in het epidermale compartiment binnen de 
eerste tien dagen na start van de behandeling verliep samen met de verbetering van de 
klinische parameters. Tegelijkertijd daalde het aantal neutrofielen, belangrijke cellulaire 
componenten van het aangeboren immuunsysteem, in de dermis snel. Ophopingen van 
deze cellen in de hoornlaag als microabscesses van Munro of binnen het stratum Malpighi 
als spongiforme micropustules van Kogoj, zijn indicatief voor een actieve psoriasis. Er is 
toenemend bewijs dat deze cellen van het aangeboren immuunsysteem in staat zijn om 
IL-17 te produceren15, 23 en dat ze daarmee, vooral in geval van actieve ziekte,14 een cruciale 
rol spelen in de pathogenese van psoriasis. De patiënten die deelnamen aan onze studie 
hebben allen een lang bestaande chronische vorm van plaque psoriasis. Dit zou de relatief 
lage aantallen neutrofielen en IL-17 producerende cellen kunnen verklaren, welke we tijdens 
immunohistochemische evaluatie vonden in vergelijking met de hoge aantallen zoals we 
vonden in de acute fase van ontsteking na het aanbrengen van LTB4 en het verwijderen van 
het stratum corneum door middel van tape stripping (hoofdstuk 3). Tijdens de behandeling 
met adalimumab is slechts een niet-significante afname van het IL-23A mRNA gevonden. 
En de expressie van IL-17A mRNA toont slechts een significante daling na 16 weken 
behandeling, terwijl op eiwitniveau geen significante daling is gemeten. Deze bevindingen 
passen binnen de hypothese dat verschillen in de cytokine samenstelling indicatief kan zijn 
voor een acute ziekte dan wel een chronische ziekte. Maar uit recente studies die de 
werkzaamheid onderzoeken van de nieuw ontwikkelde biologics gericht tegen IL-17, blijkt 
dat deze medicijnen zeer effectief zijn in de behandeling van chronische plaque psoriasis.24, 25
Het adaptieve immuunsysteem toont een vertraagde normalisatie tijdens adalimumab 
behandeling in vergelijking met het aangeboren immuunsysteem en het epidermale 
compartiment. Het aantal T-cellen, belangrijke vertegenwoordigers van het adaptieve 
immuunsysteem, toont geen vermindering na tien dagen behandeling. Eerdere studies 
hebben aangetoond dat andere anti-psoriatische behandelingen, zoals potente topische 
corticosteroïden,26 in staat zijn om het aantal T-cellen al na 7 dagen behandeling te doen 
verminderen. De combinatie van deze behandelingen zou een superieure effectiviteit 
kunnen hebben met een sneller optredende klinische verbetering. Het gebruik van 
potente topische corticosteroïden zou daarom een plek kunnen hebben in de 
ondersteuning van adalimumab behandeling, omdat een synergistische aanpak kan 
helpen  voorkomen dat individuele componenten overmatig worden gebruikt en leiden 
tot bijwerkingen.
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 De TNF-α expressie in lesionale psoriatische huid veranderde niet significant tijdens 
behandeling met adalimumab, hetgeen in overeenstemming is met eerdere studies die 
hebben aangetoond dat TNF-α posttranscriptioneel wordt gereguleerd.27-29 Er is eerder 
aangetoond dat de vroege effecten van de behandeling met adalimumab worden 
gemedieerd door de verlaging van de p38 MAPK fosforylering en de daarop volgende 
afname van de p38 MAPK pathway, resulterend in een afname van de mRNA expressie van 
IL-1β, IL-8 en IL-20.28 De snelle afname van de expressie van IL-8  wordt in onze studie 
bevestigd en toont al een significante afname na tien dagen behandeling (hoofdstuk 5.2).
Conclusie: topische behandeling met CBD zalf geeft een verbetering van de 
klinische parameters en van belangrijke psoriasis gerelateerde eiwitten, met 
uitzondering het dermaal gelegen CD31+ endotheel. Systemische behandeling 
met adalimumab leidt tot een snelle normalisatie van de onderzochte vertegen-
woordigers van het aangeboren immuunsysteem, van epidermale differentiatie 
en proliferatie en van klinische parameters. In tegenstelling tonen de onderzochte 
 vertegenwoordigers van het adaptieve immuunsysteem een vertraagde normalisatie.
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De Belangrijkste Conclusies van dit Proefschrift
Overzicht van de Beschikbare Gegevens Betreffende het Gebruik van 
Combinaties van Topicals
• Het ontbreken van gestandaardiseerde behandelingsprotocollen voor klassieke topicale 
therapieën resulteren in een belemmering van de interpretatie van verschillende studie - 
resultaten en een juiste generalisatie. (Hoofdstuk 2.1)
• Evidence-based gegevens over de lange termijn effectiviteit en veiligheid op kwalitatief 
hoog niveau zijn beperkt. (Hoofdstuk 2.2) 
• De combinatie van topische corticosteroïden met keratolytica, of met vitamine D 
analogen kunnen worden aanbevolen boven het gebruik van de overeenkomstige 
monotherapieën. (Hoofdstuk 2)
 
Update van Twee In Vivo Modellen voor de Inductie van Cutane Ontsteking
• Het LTB4 model is zeer goed reproduceerbaar en kan daarom gebruikt worden voor 
verder onderzoek naar de dynamiek van een psoriasis-achtige ontsteking van nieuw 
ontdekte belangrijke betrokken onderdelen van het immuunsysteem. (Hoofdstuk 3.1)
• Het tape strip model maakt onderzoek mogelijk naar de volgorde van cruciale ontste-
kingsprocessen getriggerd door cutane verwondingen, die worden verondersteld een  rol 
te spelen in de pathogenese van immuungemedieerde Koebner positieve huidziekten. 
(Hoofdstuk 3.2)
• Neutrofielen en IL-17 producerende cellen overheersen de acute fase van een cutane 
inflammatoire reactie en lijken een belangrijkere rol te spelen tijdens de instabiele fase. 
Th1 cellen lijken juist een belangrijkere rol te spelen in de chronische fase van de 
ontsteking. (Hoofdstuk 3)
De Heterogeniteit van Ontsteking binnen een Psoriasis Laesie
• De TOPCam, een nieuwe Laser Doppler perfusie Imager, is in staat om op niet-invasieve 
wijze de oppervlakkige perfusie intensiteit binnen een psoriasis laesies te visualiseren. 
(Hoofdstuk 4.1)
• Er bestaat heterogeniteit in de, door de TOPCam in beeld gebrachte, perfusie intensiteit 
binnen psoriasis laesies met een homogeen uiterlijk. (Hoofdstuk 4) 
• Verschillen in de cutane perfusie intensiteit in psoriasis laesies tonen een correlatie met 
verschillen in expressie niveaus van diverse psoriasis gerelateerde genen en eiwitten. 
(Hoofdstuk 4.2)
• Verschillen in gen en eiwit expressie niveaus tussen de sterk doorbloede perilaesionale 
huid en de op afstand gelegen onaangetaste huid, zou erop kunnen wijzen dat een 
aantal biologische veranderingen al plaatsvinden ruim voordat klinische veranderingen 
zichtbaar worden. (Hoofdstuk 4.2)
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Het Monitoren van Anti-psoriatische Behandelingen met Markers  
voor Ontsteking 
• Topische behandeling met CBD zalf leidt tot normalisering van de celbiologische 
samenstelling in vergelijking met de gezonde huid, met uitzondering van de 
hoeveelheid dermaal gelegen CD31+ endotheel. Dit zou erop kunnen wijzen dat de 
klinische verbetering voorloopt op de endotheliale normalisering. (Hoofdstuk 5.1) 
• Epidermale differentiatie, proliferatie en het aangeboren immuunsysteem worden snel 
beïnvloed na start met adalimumab behandeling, terwijl het adaptieve immuunsysteem 
duidelijk achter blijft. (Hoofdstuk 5.2)
Toekomst Perspectief
Niches in Clinical Evidence 
Naar aanleiding van de resultaten van dit proefschrift, zou het de moeite waard kunnen 
zijn om onderzoek te doen naar de kosteneffectiviteit van het gebruik van combinaties 
van klassieke topicale therapieën binnen de dermatologische dagbehandeling. Het 
combineren van topicals kan leiden tot een snellere klinische verbetering en dus tot een 
vermindering van het aantal behandelingen die patiënten nodig hebben binnen een 
dagbehandeling, vervolgens leidend tot een verlaging van de kosten voor de gezond-
heidszorg.
 Hetzelfde zou kunnen gelden voor het gebruik van corticosteroïden in combinatie 
met vitamine D analogen. Er is nog niet onderzocht of het eerder inzetten van deze 
combinatie door huisartsen een positief effect heeft op de therapietrouw doordat sneller 
klinische resultaten worden bereikt. Het lijkt erop dat het gebruik van het samengestelde 
preparaat gunstiger is voor patiënten, omdat zij de behandeling in één keer aan kunnen 
brengen op de huid, terwijl het gebruik van de afzonderlijke preparaten vraagt om twee 
applicaties per dag. Het samengestelde preparaat is wel duurder dan de afzonderlijke 
preparaten samen en er is nog niet aangetoond of het gebruik hiervan in de praktijk 
inderdaad leidt tot een verbetering van de therapietrouw.
Niches in Pathomechanistic Insights
De pathogenese van psoriasis is nog steeds niet volledig opgehelderd, maar nieuwe 
onderzoeken onthullen steeds nieuwe stukjes van deze gecompliceerde puzzel. De update 
van het LTB4 model en het tape strip model hebben aangetoond dat beide in vivo 
modellen (nog steeds) bruikbare hulpmiddelen zijn om ontstekingsreacties van de huid 
verder te onderzoeken.
 Naast immunohistochemische evaluatie, zou ook het beloop van nieuwe psoriasis 
laesies gevolgd kunnen worden door de perfusie intensiteit te onderzoeken met de 
TOPCam. Omdat veranderingen in de dilatatie en permeabiliteit van de dermale papillaire 
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capillairen vooraf gaan aan klinische veranderingen, verdwijnen bij genezing en variaties 
in de perfusie intensiteit correleren met de ernst van de ziekte, is het aantrekkelijk om te 
speculeren dat een verhoogde oppervlakkige perfusie in de gezonde huid een 
voorspelling zou kunnen zijn van de ontwikkeling van een nieuwe psoriasis laesie. Het zou 
interessant zijn om patiënten met een actieve eruptieve ziekte te bestuderen met de 
TOPCam om een  antwoord te vinden op deze vraag. Wanneer deze hypothese blijkt te 
kloppen, zouden de perfusie beelden kunnen dienen als niet-invasief hulpmiddel om de 
ziekteactiviteit te identificeren. 
 Naar aanleiding van dit proefschrift blijft de vraag bestaan of het verlengen van de 
duur van de behandeling met de combinatie van lokale corticosteroïden en vitamine D 
analogen zou leiden tot een volledige normalisering van het endotheel en tot een langere 
ziektevrije periode. In dat geval zouden huisartsen en dermatologen een beter houvast 
hebben om de optimale behandelduur te bepalen.
 Ten slotte zou het interessant zijn om de cytokine samenstelling in de laesionale huid 
van patiënten met een onvoldoende respons op de behandeling met adalimumab te 
onderzoeken. Dit zou nieuwe biomarkers aan het licht kunnen brengen om de klinische 
respons op biologische agentia te voorspellen. In onze huidige gezondheidszorg, waarin 
gepersonaliseerde zorg steeds belangrijker wordt, zouden dergelijke biomarkers gebruikt 
kunnen worden als betrouwbaar hulpmiddel om per individu te beslissen welke 
behandeling de voorkeur geniet.
222
CHAPTER 7
Referenties
1. NHG-Standaard Psoriasis. Available from: URL: https://wwwnhgorg/standaarden/volledig/nhg-standaard- 
psoriasis Accessed March 2014. 
2. van den Reek JM, van Lumig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W et al. Determinants of 
drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.  Br J Dermatol 
2014;170:415-24.
3. Menting SP, van Lumig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM et al. Extent and 
Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis: One-Year Follow-up. 
JAMA 2014;150:130-6.
4. Rijzewijk JJ, Van Erp PE, Bauer FW. Two binding sites for Ki67 related to quiescent and cycling cells in human 
epidermis. Acta Derm Venereol 1989;69:512-5.
5. Gerritsen MJ, van Erp PE, van Vlijmen-Willems IM, Lenders LT, van de Kerkhof PC. Repeated tape stripping of 
normal skin: a histological assessment and comparison with events seen in psoriasis. Arch Dermatol Res 
1994;286:455-61.
6. de Jong EM, van Erp PE, van Vlijmen IM, van de Kerkhof PC. The inter-relation between inflammation and 
epidermal proliferation in normal skin following epicutaneous application of leukotriene-B4: an immuno-
histochemical study. Clin Exp Dermatol 1992;17:413-20.
7. Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM. Epicutaneous application of 
leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for 
psoriatic lesions. Arch Dermatol Res 1997;289:331-6.
8. Ziboh VA, Casebolt TL, Marcelo CL, Voorhees JJ. Biosynthesis of lipoxygenase products by enzyme preparations 
from normal and psoriatic skin. J Invest Dermatol 1984;83:426-30.
9. Ruzicka T, Simmet T, Peskar BA, Ring J. Skin levels of arachidonic acid-derived inflammatory mediators and 
histamine in atopic dermatitis and psoriasis. J Invest Dermatol 1986;86:105-8.
10. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 
2001;385:231-41.
11. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007;405:379-95.
12. Friedrich EB, Tager AM, Liu E, Pettersson A, Owman C, Munn L et al. Mechanisms of leukotriene B4--triggered 
monocyte adhesion. Arterioscler Thromb Vasc Biol 2003;23:1761-7.
13. Köbner H. Zur Aetiologie der Psoriasis. Vjschr Dermatol 1876;8:559-61.
14. Christophers E. Explaining phenotype heterogeneity in patients with psoriasis.  Br J Dermatol 2008;158:437-41.
15. Keijsers RR, Hendriks AG, van Erp PE, van Cranenbroek B, van de Kerkhof PC, Koenen HJ et al. In vivo induction 
of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing 
RORgammat and IL-17. J Invest Dermatol 2014;134:1276-84.
16. Hull SM, Goodfield M, Wood EJ, Cunliffe WJ. Active and inactive edges of psoriatic plaques: identification by 
tracing and investigation by laser--Doppler flowmetry and immunocytochemical techniques. J Invest 
Dermatol 1989;92:782-5.
17. Goodfield M, Hull SM, Holland D, Roberts G, Wood E, Reid S et al. Investigations of the ‘active’ edge of plaque 
psoriasis: vascular proliferation precedes changes in epidermal keratin.  Br J Dermatol 1994;131:808-13.
18. Davison SC, Ballsdon A, Allen MH, Barker JN. Early migration of cutaneous lymphocyte-associated antigen 
(CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol 2001;10:280-5.
19. Droog EJ, Steenbergen W, Sjoberg F. Measurement of depth of burns by laser Doppler perfusion imaging. 
Burns 2001;27:561-8.
20. Hern S, Stanton AW, Mellor R, Levick JR, Mortimer PS. Control of cutaneous blood vessels in psoriatic plaques. 
J Invest Dermatol 1999;113:127-32.
21. Draijer M, Hondebrink E, van Leeuwen T , Steenbergen W. Twente Optical Perfusion Camera: system overview 
and performance for video rate laser Doppler perfusion imaging. Opt Express 2009;17:3211-25.
22. Adalimumab [Summary of product characteristics] (2013) Queenborough, U.K.: Abbott Laboratories. Available 
from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/ 
000481/WC500050870.pdf. Accessed March 2013.
223
NEDERLANDSE SAMENVATTING
7
23. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S et al. Mast cells and neutrophils release IL-17 
through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500.
24. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E et al. Anti-interleukin-17 monoclonal 
antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
25. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G et al. Brodalumab, an anti-interleukin-17- 
receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
26. Bovenschen HJ, Vissers WH, Seyger MM, van de Kerkhof PC. Selective persistence of dermal CD8+ T cells in 
lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 2005;85:113-7.
27. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M et al. Protein expression of TNF-alpha in 
psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 
2006;176:1431-8.
28. Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L et al. Preferential inhibition of the 
mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti- 
TNFalpha therapy.  Br J Dermatol 2010;163:1194-204.
29. Soegaard-Madsen L, Johansen C, Iversen L, Kragballe K. Adalimumab therapy rapidly inhibits p38 mitogen- 
activated protein kinase activity in lesional psoriatic skin preceding clinical improvement.  Br J Dermatol 
2010;162:1216-23.

Chapter 8
List of Publications
Curriculum Vitae
Dankwoord

227
LIST OF PUBLICATIONS
8
List of Publications
Publications related to this thesis:
Hendriks AGM, Keijsers RRMC, de Jong EMGJ, Seyger MMB, van de Kerkhof PCM; 
Combinations of classical time-honoured topicals in plaque psoriasis: a systematic 
review. Journal of European Academy of Dermatology and Venereology. 2013 Apr; 27(4): 
399-410. Epub 2012 Jul 11.
Hendriks AGM, Keijsers RRMC, de Jong EMGJ, Seyger MMB, van de Kerkhof PCM; Efficacy 
and safety of combinations of first-line topical treatments in chronic plaque psoriasis: 
a systematic literature review. Journal of European Academy of Dermatology and 
Venereology. 2013 Aug; 27(8): 931-51. Epub 2012 Dec 20.
Hendriks AGM, Steenbergen W, Hondebrink E, van Hespen JC, van de Kerkhof PCM, 
Seyger MMB; Whole field laser Doppler imaging of the microcirculation in psoriasis 
and clinically unaffected skin. Journal of Dermatological Treatment. 2014 Feb; 25(1): 
18-21. Epub 2013 May 21.
Hendriks AGM, Keijsers RRMC, Seyger MMB, van de Kerkhof PCM, van Erp PEJ; Cutaneous 
application of Leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: 
An immunohistological study. Skin Pharmacology and Physiology. 2014; 27(3): 120-6. 
Epub 2014 Jan 4.
Hendriks AGM, Keijsers RRMC, Seyger MMB, van Erp PEJ, van de Kerkhof PCM; To what 
extent are characteristics of immune mediated skin disorders expressed in normal 
skin regenerating from standardized surface injury? Dermatology 2014; 228(3): 255-60. 
Epub 2014 Mar 6.
Hendriks AGM, van der Velden HMJ, Wolberink EAW, Seyger MMB, Schalkwijk J, Zeeuwen 
PLJM, de Jong EMGJ, Pasch MC, van Erp PEJ, van de Kerkhof PCM; The effect of 
adalimumab on key drivers in the pathogenesis of psoriasis. British Journal of 
Dermatology 2014;170(3):571-80. Epub 2014 Mar 20.
Hendriks AGM, Steenbergen W, Zeeuwen PLJM, Schalkwijk J, Hondebrink E, Klitsie MA, 
Schreurs R,  van de Kerkhof PCM, Seyger MMB; Perfusion intensity correlates with 
expression levels of psoriasis-related genes and proteins. Submitted to Skin Pharmacology 
and Physiology.
Hendriks AGM, van de Kerkhof PCM, de Jonge CS, Lucas M, Steenbergen W, Seyger MMB; 
Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts 
remaining elevation of dermal expression levels of CD31. Submitted to Skin Research 
and Technology.
228
CHAPTER 8
Publications not related to this thesis:
Hendriks AGM, Voermans NC, Schalkwijk J, Hamel BC, van Rossum MM; Well defined 
clinical presentation of Ehlers-Danlos Syndrome in patients with tenascin-X deficiency: 
a report of four cases. Clinical Dysmorphology. 2012 Jan; 21(1): 15-8. Epub 2011 Oct 1. 
Keijsers RRMC, Hendriks AGM, van Erp PEJ, van Cranenbroek B, van de Kerkhof PCM, 
Koenen HJ, Joosten I; In vivo induction of cutaneous inflammation results in the 
accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17. 
Journal of Investigative Dermatology. 2014 May;134(5):1276-84. Epub 2013 Dec 6.
Keijsers RRMC, Joosten I, Hendriks AGM, Koenen HJ, van Erp PE, van de Kerkhof PCM; 
Balance of Treg versus T-helper cells during systemic treatment with adalimumab and 
topical treatment with calcipotriol-betamethasone dipropionate ointment. Submitted 
to Experimental Dermatology.
229
CURRICULUM VITAE
Curriculum Vitae
Anke Gertruda Martina Hendriks werd geboren op 12 januari 1985 in Venray. In 2003 
behaalde zij haar VWO diploma aan het Elzendaal College te Boxmeer. Na haar middelbare 
school periode startte zij haar studie Biomedische Wetenschappen aan de Radboud 
Universiteit Nijmegen. Gedurende deze studie werd haar interesse voor de studie 
Geneeskunde gewekt. Na het behalen van haar propedeuse in 2004 en haar Bachelor 
diploma in 2006 is zij overgestapt naar de studie Geneeskunde aan dezelfde universiteit. 
Tijdens de coschappen en het senior coschap Dermatologie groeide haar interesse voor 
dit vak. Na het behalen van haar artsexamen in 2011 startte Anke op 1 april 2011 met 
haar promotieonderzoek op de afdeling Dermatologie van het Universitair Medisch Centrum 
St. Radboud te Nijmegen onder begeleiding van prof. dr. dr. P.C.M. van de Kerkhof, 
dr. M.M.B. Seyger en dr. P.E.J. van Erp. Vanaf 1 december 2013 is Anke in opleiding tot 
dermatoloog in het Radboudumc. Anke is sinds 6 juni 2014 getrouwd met Laurens van Daal.
Foto door: M. Reelick.

231
DANKWOORD
Dankwoord
‘Data, data, data! I cannot make bricks without clay!’
Sherlock Holmes
Na drie mooie jaren van onderzoek is mijn proefschrift zo goed als klaar en is het nu tijd 
het laatste, meest gelezen en misschien wel het belangrijkste hoofdstuk op papier te 
zetten. Want zonder alle hulp en ondersteuning die ik de afgelopen jaren heb gekregen, 
was dit proefschrift er niet geweest. Zo zeer als ik ernaar uitgekeken heb om iedereen te 
bedanken, zo moeilijk vind ik het nu om het in woorden op papier te zetten. Om niemand 
te vergeten wil ik graag iedereen, die op enige wijze bijgedragen heeft aan de 
totstandkoming van dit proefschrift, via deze weg bedanken. Maar natuurlijk zijn er een 
aantal mensen die een speciaal bedankje hebben verdiend! 
Allereerst wil ik alle patiënten en vrijwilligers bedanken die hebben meegewerkt aan de 
verschillende studies. Want, zoals het citaat uit mijn favoriete film hierboven al beschrijft, 
zonder hen en zonder data was dit proefschrift er niet geweest. 
Prof. dr. dr. P.C.M. van de Kerkhof. Beste professor, ik kan me ons eerste gesprek nog goed 
herinneren. Toen ik aan het einde van mijn senior coschap op de afdeling Dermatologie 
eenmaal besefte dat ik me hier helemaal op mijn plek voelde, was ik maar wat blij dat ik bij 
u op gesprek mocht komen. Toen ik vervolgens 3 maanden later werd aangenomen voor 
een promotietraject onder uw directe supervisie, kon ik mijn geluk niet op! Uw onuitput-
telijke energie en enthousiasme werken altijd even aanstekelijk en ook al zat het ook wel 
eens tegen, na elk van onze wekelijkse overleggen kon ik vol goede moed en 
zelfvertrouwen weer verder met mijn onderzoek. Er was altijd ruimte voor mijn eigen 
inbreng. Ondanks dat u ontzettend druk bent, stond de deur toch altijd open als u er was, 
of waren er wel een paar minuutjes vrij voor overleg of een gezellige babbel aan de 
koffieautomaat. Bedankt voor uw fijne begeleiding.
Dr. M.M.B. Seyger. Beste Marieke, samen zijn we begonnen aan het onderzoek met de 
TOPCam in samenwerking met de universiteit van Twente en hebben we de studies van 
A tot Z zelf bedacht en opgezet. Ik kon altijd even bij je binnen lopen en tijdens onze altijd 
gezellige, bijna wekelijkse ‘TOPCam-overleggen’, heb ik heel veel van je geleerd en maakte 
je, ondanks je drukke agenda en chronisch verstopte mailbox, toch altijd tijd vrij om 
eventjes te vragen hoe het met mij ging. Door jouw positiviteit, gedrevenheid en kritische 
blik is het erg fijn om met je samen te werken. Ik heb geleerd om de dingen kritisch(er) te 
bekijken en mijn manuscripten steeds weer te verbeteren. En ook van de gezamenlijke 
begeleiding van ‘onze’ technische geneeskunde studenten heb ik veel geleerd. Bedankt!
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Dr. P.E.J. van Erp. Beste Piet, voordat ik begon wist ik niet zoveel van het werk in het 
laboratorium. Bedankt voor alles wat je mij hebt geleerd en voor het feit dat je altijd tijd 
maakte om te pas en te onpas even te overleggen samen. Je hebt vanaf mijn eerste dag 
als promovenda geroepen; ‘Geniet van je tijd als onderzoeker Anke! Want voordat je 
het weet is het voorbij!’ Ik kon me daar in het begin niet zoveel bij voorstellen, maar nu 
mijn onderzoekstijd ten einde loopt, kan ik niet anders dan je gelijk geven. Het is voorbij 
gevlogen en, ondanks dat het erg leuk is om weer in de kliniek te zijn begonnen, vind ik 
het toch ontzettend jammer om deze geweldige tijd af te sluiten!
Prof. J. Schalkwijk en Dr. P.L.J.M. Zeeuwen. Beste Joost en Patrick, bedankt voor alle hulp en 
ondersteuning in het laboratorium, bij de interpretatie van de qPCR data en over de te 
gebruiken statistiek. Mede dankzij jullie heb ik mijn weg gevonden in het verkrijgen en 
gebruiken van de genexpressie data. Bedankt daarvoor!
Prof. W. Steenbergen en ir. E. Hondebrink. Beste Wiendelt en Erwin, bedankt voor de prettige 
samenwerking en jullie betrokkenheid bij het TOPCam project. Ondanks de grote afstand, 
hebben jullie toch meerdere malen onze afdeling bezocht om onze manier van onderzoek 
te bekijken of wanneer het apparaat haperde en we er via de mail en telefoon niet uit 
kwamen. Samen met Marieke wordt het project nu verder voortgezet en blijf ik op de 
achtergrond graag betrokken bij de ontwikkelingen.
Dr. M.M. van Rossum. Beste Michelle, bedankt dat je me tijdens mijn coschappen de 
mogelijkheid hebt gegeven om een artikel te schrijven over het Ehlers-Danlos syndroom. 
Je hebt me begeleid tijdens de eerste stapjes de onderzoekswereld in en me geleerd hoe 
ik een wetenschappelijk artikel moest schrijven. Het duurde langer dan gepland om het 
op papier te zetten, maar het is uiteindelijk een mooi case report geworden. Bedankt voor 
je kritische feedback en fijne begeleiding!
Annet, Juul, Karlijn, Margit en Romy. Een speciaal bedankje voor jullie! We zijn ongeveer 
gelijk begonnen aan onze promoties en al snel bleek dat we het ook buiten het werk erg 
goed met elkaar konden vinden, zelfs onze mannen en ook kleine Merel. We hebben al 
vaak tegen elkaar gezegd dat het zó bijzonder is dat we als collegaatjes ook naast ons werk 
al zoveel samen hebben meegemaakt! Bedankt voor al die keren dat we samen konden 
lachen en tot in de kleine uurtjes op de dansvloer stonden, zomaar spontaan, tijdens een 
vrijgezellenfeestje of een trouwerij! Maar vooral ook voor alle keren dat we samen een 
traantje hebben weggepinkt omdat het bij een van ons even tegen zat! Wat een geluk 
dat ik ook de komende jaren samen met jullie mag werken! Ik vul het dankwoord van 
Karlijn graag aan. Two down… four to go!
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Arts-onderzoekers. Anne, Renée, Lisa, Malou, Jeffrey, Jorre, Maartje, Denise en Sabine. 
Bedankt voor alle gezelligheid op het werk, voor alles wat we van elkaar hebben geleerd 
en voor alle momenten waarop we onze frustraties met elkaar konden bespreken. Jullie 
hebben er mede voor gezorgd dat ik een geweldige onderzoekstijd heb gehad! Heel veel 
succes bij het afronden van jullie projecten. Hopelijk houden we de vrijdagmiddagborrels 
er zo nu en dan in! 
Marisol. Lief Solleke! Bedankt voor alle hulp bij de vele trials die we samen hebben gedaan, 
ons bijzonder tripje naar Madrid en voor het feit dat ik altijd op je kon rekenen. Nu je jouw 
onderzoekshart hebt gevolgd naar de Dermatologie, hoop ik dat jouw proefschrift ook 
snel vorm gaat krijgen. Ik ga onze gezellige samenwerking missen!
Lab collega’s. Bedankt voor de fijne samenwerking de afgelopen jaren en natuurlijk voor 
alle gezelligheid in de koffiekamer, tijdens de wekelijkse Journal clubs, LOTTO besprekingen 
en alles daaromheen, zoals de jaarlijkse Paaslunch. Een extra bedankje voor Hanna, Ivonne, 
Diana en Roelie voor al jullie hulp in het laboratorium en onuitputtelijke geduld!
Alle arts-assistenten en stafleden, bedankt voor jullie collegialiteit en gezelligheid op de 
werkvloer! Ik voel me ontzettend welkom en ik kijk uit naar de komende jaren op de 
afdeling Dermatologie.
Studenten technische geneeskunde. Beste Sofieke, Ruud, Marit en Michiel, bedankt voor 
jullie hulp bij het onderzoek met de TOPCam en voor de ontwikkeling van het programma 
om de gegevens te analyseren. Aangezien mijn technische kant niet al te ver ontwikkeld 
is, was dit mij zonder jullie hulp niet gelukt. Ik wens jullie allemaal veel succes met jullie 
verdere studie en carrière.
Medisch fotografen. Beste Jan en Anja, bedankt voor het maken van de foto's van alle 
patiënten die hebben meegewerkt aan mijn studies.
Alle medewerkers van de afdeling Dermatologie, bedankt voor de fijne samenwerking en 
plezierige werksfeer. 
Lieve vrienden en familie. De afgelopen jaren is er heel wat veranderd. Helaas zien we elkaar 
niet meer zo vaak als vroeger en is het door alle steeds drukker wordende agenda's steeds 
weer een uitdaging om af te spreken. Maar áls we elkaar dan zien, tijdens een borrel, de 
jaarlijkse weekendjes weg of een heerlijk etentje is het weer als vanouds gezellig! Bedankt 
voor alle afleiding in de weekenden en de interesse die jullie de afgelopen jaren hebben 
getoond! Hopelijk houden we alle gezelligheid er in tot we allemaal grijs en gerimpeld zijn! 
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Karlijn (paranimf). Lieve Karly, je bent een voorbeeld voor alle onderzoekers! Het doorzet-
tingsvermogen en de discipline waarmee jij kunt werken, is echt ongekend. Wat is het fijn 
om iemand dichtbij me te hebben die alles zo nuchter kan bekijken en kan relativeren, 
vooral omdat het mij daar soms een beetje aan ontbreekt. Bedankt voor alle keren dat je 
naar mijn frustraties hebt geluisterd, voor de hele fijne en gezellige tijd die we samen 
hebben doorgebracht in de bieb, maar vooral ook daarbuiten! Jij hebt je promotie 
inmiddels op een geweldige manier afgerond en ik hoop dat het mij net zo goed af zal 
gaan. Super dat je op deze belangrijke dag naast mij staat en samen met Romy mijn 
Watson wilt zijn!
Romy (paranimf). Lieve Roompje, toen ik je leerde kennen was ik senior-co op de afdeling 
Dermatologie en werkte jij daar als arts-assistent. Jij vertelde me dat er een onderzoeks-
project van start zou gaan dat deels gerelateerd was aan dat van jou, en dat ik daar maar 
eens naar moest informeren. En kijk waar ik nu sta! Ik kan je niet genoeg bedanken dat 
je mij die ‘gouden tip’ gegeven hebt! We hebben als onderzoeks-maatjes veel samen 
gewerkt in het lab en hebben heel wat afgestript en geLTB4t! Bedankt voor de 
onvergetelijke tijd in de bieb, in het lab en daarbuiten! Met jou erbij is het altijd 
even gezellig en is het echt een feestje om met je samen te mogen werken! Maar ook 
op de moeilijke momenten ben je er en sta je voor iedereen klaar. Super dat je op 
deze belangrijke dag naast mij staat en samen met Karlijn mijn Watson wilt zijn! 
Op naar jouw promotie!
Lieve opi en omi. Wat ontzettend speciaal dat ik dit boekje ook aan jullie kan geven en 
ik tot nu toe álle bijzondere momenten in mijn leven met jullie heb mogen delen! 
Bedankt dat jullie er altijd voor ons zijn, de deur in Vortum altijd openstaat en voor al 
jullie interesse in mij.
Lieve Tim, Bart en Lotte, lieve broertjes en zusje, bedankt voor alle gezelligheid, voor alle 
borrels, alle avondjes spellen, alle bijzondere uitstapjes en voor het feit dat jullie altijd voor 
ons klaar staan. Heel speciaal dat we altijd zoveel leuke dingen zijn blijven doen met het 
hele gezin. Jullie zijn me alle 3 zo ontzettend dierbaar! Maar ook mijn lieve schoonzusjes 
en schoonbroers, Zoë, Elise, Gijs, Hanneke, Martijn, Irma, Jeroen en mijn lieve kleine nichtjes 
Fem en ons speciale nichtje op komst, Elise, Julia en Katie natuurlijk bedankt hiervoor!
Lieve Jac en Nelly, ik had mij geen fijnere schoonouders kunnen wensen. Bedankt voor 
jullie interesse in mij en in mijn werk de afgelopen jaren. Maar vooral ook voor alle pittige 
discussies, heerlijke etentjes en gezellige vakanties. We zijn altijd welkom in Cuijk en het 
voelt bij jullie dan ook echt als een 2e thuis. 
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Lieve papsi en mamsi, bedankt dat jullie altijd achter me hebben gestaan en mij altijd 
hebben gestimuleerd om het allerbeste uit mezelf te halen. Maar bovenal voor dat fijne 
warme thuis wat jullie ons gegeven hebben en waar ik nog steeds maar al te graag ben! 
De deur staat altijd open om een hapje mee te eten, voor een spelletje of een borrel en 
jullie staan altijd voor ons klaar! Door jullie ben ik geworden wie ik nu ben. Dit boekje is 
voor jullie!
En tot slot, op de belangrijkste plaats, mijn beste maatje en liefste vriend, Laurens, lieffie, 
bedankt dat je er de afgelopen 12.5 jaar altijd voor me bent geweest! Je hebt me altijd 
gemotiveerd en gestimuleerd om er alles uit te halen wat er in zit. Je stond achter me toen 
ik Biomedische Wetenschappen ging studeren, toen ik na 3 jaar studie besloot dat het 
toch Geneeskunde moest worden en ook tijdens dit promotietraject heb je altijd achter 
me gestaan en me alle ruimte gegeven die ik nodig had. Zo trots als je op me was als er 
een artikel geaccepteerd werd, zo gemakkelijk toverde je weer een glimlach op mijn 
gezicht als het even tegenzat. Wat hebben we het fijn samen en wat was en is dit een 
bijzonder jaar voor ons! Ook komend jaar beloofd weer heel speciaal te worden en hoop 
ik samen met jou te gaan genieten van kleine Puk. Ik kijk uit naar alles wat de toekomst ons 
samen gaat brengen! Jij en ik! 

